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1 Introduction 
Diabetes mellitus is a major public health problem characterized by high blood 
glucose levels due to defects in insulin secretion and/or insulin action (ADA 
2010). There are two major types of diabetes. Type 1 diabetes mellitus, 
previously called insulin dependent diabetes mellitus (IDDM) or juvenile-onset 
diabetes develops due to immunogenic destruction of pancreatic ?-cells 
resulting in a deficient insulin production. Around 90% of diabetes affected 
people suffer from type 2 diabetes mellitus, previously called non insulin 
dependent diabetes mellitus (NIDDM) or adult-onset diabetes. Defects on 
insulin secretion, insulin resistance and a reduction of ?-cell mass characterize 
this diabetes type (ADA 2010; Butler et al. 2003; Sakuraba et al. 2002). The 
world prevalence of diabetes among adults (aged 20 to 79 years) is 6.4% in the 
year 2010, i.e. 285 million people are affected (Shaw et al. 2010). In 2030, an 
increase to 7.7% and 439 million adults, respectively, is expected (Shaw et al. 
2010). Furthermore, diabetes appeared to be a considerable cause of 
premature mortility as 6.8% of global mortility are due to diabetes (Roglic et al. 
2010). Therefore diabetes is not only a problem of the individual suffering from 
severe secondary lesions but also of the society due to high expenses. Health 
expenditure for diabetes only for the European region is expected to correspond 
to 105.5 billion USD in the year 2010 and 124.6 billion USD in the year 2030 
(IDF 2009). North America represents the region with the highest costs as 214.2 
billion USD are budgeted for 2010 and 288.7 billion USD for 2030 (IDF 2009). 
Changed living circumstances related to overly nutrition and lack of physical 
activity promote the development of diabetes (Leahy 2005). The number of 
adults with diabetes will increase among others in developing countries 
indicating a growing burden of diabetes in the world (Shaw et al. 2010). 
However, the reasons for diabetes are still not completely clarified, whereby a 
great effort on research is going on. Animal models are needed to get insight in 
different aspects of this disease with techniques that are not applicable in 
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humans whereas one single animal model is not sufficient to cover all aspects 
of this multifactorial disease (Larsen 2009). 
One aspect of diabetes is linked to the incretin hormones glucose-dependent 
insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) which 
potentiate insulin secretion after nutrient ingestion mediating the so-called 
“incretin effect” (Elrick et al. 1964; McIntyre et al. 1964). Patients with type 2 
diabetes mellitus exhibited an impaired incretin effect whereby the insulinotropic 
action of GIP is reduced to almost absent while this of GLP-1 is preserved 
(Nauck et al. 1993b). 
Young adult GIPRdn transgenic pigs, generated by lentiviral gene transfer, 
showed parallels to type 2 diabetes patients as they exhibited a significantly 
reduced ?-cell mass and disturbed glucose tolerance compared to controls 
(Renner 2008). The aim of this work was to further characterize GIPRdn 
transgenic pigs physiologically and morphologically at different age stages to 
find out more about the role of the GIP/GIPR axis in the pathogenesis of type 2 
diabetes mellitus. 
2 Review of the literature 
2.1 The incretin hormone system 
At the beginning of the 20th century a substance called “secretin” released from 
the duodenum was found to be responsible for the stimulation of pancreatic 
cells provoking a secretion of the pancreatic juice (Bayliss et al. 1902). The term 
“incretin” was coined by La Barre in 1932 to denote this substance as a 
glucose-lowering and intestinal-derived factor (La Barre 1932). When in 1960 
the radioimmunoassay was developed, leading to the possibility to determine 
serum insulin levels, an important progress on the incretin concept was made. 
By radioimmunoassay proof was furnished, that an oral glucose load mediated 
a higher insulin secretion compared to an intravenous glucose load (Elrick et al. 
1964; McIntyre et al. 1964). The first incretin hormone was identified at the end 
of the 1960`s (Brown et al. 1969). Based on its ability to inhibit gastric acid 
secretion in dogs, it was named gastric inhibitory polypeptide (GIP) (Brown et 
al. 1971; Brown 1971; Brown et al. 1975). However, further investigations were 
performed and GIP was also characterized as insulin-stimulating factor (Dupre 
et al. 1973). As this characteristic was not only detectable after pharmacological 
doses like inhibition of gastric acid secretion but also at physiological levels, 
GIP was renamed glucose-dependent insulinotropic polypeptide, thus 
maintaining the original acronym. Cloning and sequencing of mammalian 
proglucagon genes and complementary DNAs revealed a second incretin 
hormone, glucagon-like peptide-1 (GLP-1), with potent insulinotropic properties 
(Schmidt et al. 1985). These two hormones, GIP and GLP-1, work in an additive 
manner and mediate the so-called incretin effect which describes the 
phenomenon, that glucose given orally causes a higher insulin response 
compared to an isoglycemic intravenous glucose infusion (Nauck et al. 1993a). 
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2.2 Glucose-dependent insulinotropic polypeptide (GIP) 
2.2.1 Synthesis, secretion and degradation of GIP 
The bioactive 42-amino acid peptide form of GIP derives from a proGIP protein 
precursor (Takeda et al. 1987). Secretin, glucagon, growth-hormone releasing 
factor and vasoactive intestinal peptide are structurally related hormones to GIP 
(Sherwood et al. 2000). Moody et al. showed that the sequence or porcine GIP 
differs from that of human GIP only by two single base changes at the DNA 
level, demonstrating a high sequence identity between the two species (Moody 
et al. 1984). Synthesis and secretion of GIP take place in the K-cells, which 
were mainly identified in the duodenum and the proximal jejunum (Buchan et al. 
1978). Throughout the entire small intestine also a small number of cells 
producing both GIP and GLP-1 were detected revealing colocalization of both 
hormones (Mortensen et al. 2003). The enzyme dipeptidyl peptidase-4 (DPP-4) 
is responsible for the degradation of GIP. In humans, the half-life of biologically 
active GIP was determined being between 5 and 7 minutes using a N-terminal 
directed radioimmunoassay to distinguish between the biological active form 
GIP-(1-42) and the predominantly existing non-insulinotropic metabolite 
GIP-(3-42) (Deacon et al. 2000).  
2.2.2 GIP receptor and signal transduction 
Nutrient ingestion stimulates GIP secretion from the intestinal K-cells, whereas 
fat is the most potent GIP stimulator in humans in contrast to carbohydrates in 
pigs (Baggio et al. 2007; Rijkelijkhuizen et al. 2009). After binding to its specific 
GIP receptor (GIPR), GIP can execute its insulinotropic ability. The GIPR is a 
member of the seven transmembrane-spanning, heterotrimetric G-protein-
coupled receptor superfamily (Usdin et al. 1993). The N-terminal extracellular 
domain of the GIPR and the first extracellular loop act as regions of the highest 
binding affinity for GIP, whereas the first transmembrane domain is essential for 
receptor activation (Gelling et al. 1997). The carboxyl-terminal tail (CT) seemed 
not to play an important role in intracellular signal transduction, but receptor 
expression depends on a minimum chain length of approximately 405 amino 
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acids and specific serine residues in the CT are required for plasma membrane 
insertion (Wheeler et al. 1999). Glucose represents the primary stimulation 
factor for insulin secretion (Malaisse et al. 1979) . When glucose is metabolized 
in the ?-cell the ATP/ADP ratio increases resulting in closure of ATP sensitive 
K+ channels, membrane depolarization, activation of voltage gated 
Ca2+ channels followed by an increase in intracellular Ca2+ levels and 
insulin-granule exocytosis (Ashcroft et al. 2004). GIP mediates increases in 
intracellular Ca2+ levels and additionally shows direct effects on insulin 
exocytosis mechanisms (Ding et al. 1997; Holst et al. 2004; MacDonald et al. 
2002; Wahl et al. 1992). Binding of GIP to the GIPR leads to G-Protein coupling 
at the third intracellular loop of the GIPR followed by increases in cAMP levels 
(Cypess et al. 1999; Hallbrink et al. 2001; Harmar 2001; Salapatek et al. 1999; 
Takhar et al. 1996; Wheeler et al. 1993). Elevated cAMP levels induce both 
protein kinase A (PKA)-dependent (Ding et al. 1997) and -independent 
pathways (Seino et al. 2005). PKA stimulates several intracellular events like 
rising of intracellular Ca2+ levels, which cause, in the case of pancreatic ?-cells, 
enhanced exocytosis of insulin-containing granules (Ding et al. 1997). Mitogen-
activated protein kinase (MAPK), phosphatidylinositol-3 kinase (PI3K)/protein 
kinase B (PKB) and phospholipase A2 (PLA2) pathways contribute to direct 
PKA-independent effects of GIP on insulin secretion (Ehses et al. 2001; Kubota 
et al. 1997; Straub et al. 1996). 
2.2.3 Biological actions of GIP 
Originally, GIP was identified based on its ability to inhibit gastric acid secretion 
in dogs (Brown et al. 1975). Over the years the insulinotropic action of GIP and 
the other metabolic effects were considered important, although the effects of 
GIP are not restricted to the endocrine pancreas. GIP is also involved in a wide 
range of physiological actions in the adipose tissue, the bone metabolism and 
the nervous system (Baggio et al. 2007). Several studies in GIPR knockout 
(GIPR-/-) mice (Miyawaki et al. 1999), double incretin receptor knockout 
(DIRKO) mice (Hansotia et al. 2004) and GIPRdn mice (Herbach et al. 2005) 
accounted for the elucidation of the various physiological roles of GIP. In the 
2  Review of the literature 6 
following the biological actions of GIP in the endocrine pancreas and 
extrapancreatic tissues are introduced. 
2.2.3.1 The endocrine pancreas 
After food intake GIP is secreted from the intestinal K-cells and binds to its 
specific receptor initiating a potentiation of insulin secretion (Dupre et al. 1973). 
Hypo-, eu- and hyperglycemic clamp studies in combination with GIP infusion 
confirmed the hypothesis that the insulinotropic effect of GIP is glucose-
dependent (Elahi et al. 1979; Kreymann et al. 1987; Nauck et al. 1993a). GIP 
seemed not to be effective under fasting conditions in humans indicating that 
there is a glucose threshold for its insulinotropic action (Elahi et al. 1979). While 
GLP-1 was detected to be involved in the regulation of fasting glycemia (Baggio 
et al. 2000), GIP appeared to act only as a potentiator of glucose-induced 
insulin secretion (Lewis et al. 2000). Nevertheless, there are also studies 
suggesting GIP being capable to influence insulin secretion under fasting 
conditions in humans (Amland et al. 1985a). Furthermore, the overall incretin 
effect mediated to 50-70% by GIP was detected by immunoneutralization 
studies with intravenous administration of GIPR antagonists or antibodies for 
the GIPR (Gault et al. 2002b; Lewis et al. 2000; Tseng et al. 1996; Tseng et al. 
1999). The pro-proliferative and anti-apoptotic effects of GIP play an important 
role in the remodeling of the pancreas (see 2.2.3.2). Moreover, GIP stimulates 
insulin gene transcription and protein synthesis in the ?-cell (Fehmann et al. 
1995; Wang et al. 1996) as well as it mediates an up-regulation of glucose-
sensing elements (Wang et al. 1996). Not only insulin but also the other islet 
hormones glucagon, somatostatin and pancreatic polypeptide are regulated by 
GIP (Adrian et al. 1978; Amland et al. 1985b; Ipp et al. 1977). The influence of 
GIP on glucagon secretion is discussed controversially as on the one hand GIP 
was incapable to effect glucagon secretion in normal humans (Elahi et al. 1979; 
Nauck et al. 1993b) and on the other hand a glucagon-enhancing action of GIP 
under fasting conditions was detected (Meier et al. 2003). Whether the 
contribution of GIP on the regulation of somatostatin and pancreatic polypeptide 
in humans is important remains unclear (McIntosh et al. 2009). 
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2.2.3.2 Pro-proliferative and anti-apoptotic effects of GIP on ?-cells 
As in type 2 diabetes patients ?-cell mass is reduced by at least 65 % (Butler et 
al. 2003) and the insulinotropic effect of GIP is impaired, the influence of GIP on 
proliferation and differentiation of ?-cells is an interesting aspect for diabetes 
research. The GIPR is highly expressed on ?-cells (Moens et al. 1996) and 
there are several indications that GIP acts as a growth and metabolic factor for 
?-cells. Mitogenic signaling modules, like mitogen-activated protein kinase 
(MAPK) and phosphatidylinositol-3 kinase (PI3K), are activated by GIP, 
indicating that this incretin hormone is a pro-proliferative factor (Trumper et al. 
2002). Several signal cascade studies were performed to investigate the 
influence of GIP on ?-cell fate. Using the well-differentiated ?-cell line, INS-1, 
growth factor properties of GIP were examined (Trumper et al. 2001). Detection 
of 5-bromo-deoxyuridine (BrdU) incorporation in GIP and glucose stimulated 
INS-1 cells using an ELISA revealed increases in the rate of DNA synthesis in 
INS-1 cells compared to cells stimulated with glucose only confirming mitogenic 
effects of GIP. Furthermore, activation of the major mitogenic signaling modules 
PKA/CREB, p44/p42 MAPK and PI3K/PKB by GIP were detected (Ehses et al. 
2002). MAPK signaling modules are defined as cellular regulators of processes 
like differentiation and proliferation. The ERK1/2 is belonging to these signaling 
modules. GIP was shown to regulate all known kinases of the ERK1/2 module 
using two different ?-cell lines for this experiment, the GIP transfected CHO-K1 
cell line and the INS-1 cell line (Ehses et al. 2002). The identification of the 
cAMP-PKA-Rap1-ERK pathway demonstrated an important influence of GIP on 
cellular proliferation/differentiation and/or gene transcription events in 
pancreatic ?-cells (Ehses et al. 2002). In another study (D-Ala2)-GIP, a potent 
DPP-4 resistant GIP agonist, was utilized to examine effects on proliferation 
and apoptosis (Maida et al. 2009). Treatment of C57BL/6 mice with 
(D-Ala2)-GIP before and concomitant with streptozotocin (STZ) administration 
tended to promote ?-cell survival. Reduction of islet apoptosis was distinctly 
visible. Therefore it was concluded that GIPR activation is able to couple to 
proliferative and anti-apoptotic pathways in murine ?-cells (Maida et al. 2009). A 
detailed analysis of the DPP-4 resistant GIP analog D-GIP1-30 revealed 
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markedly beneficial effects on ?-cells (Widenmaier et al. 2010). The 
experiments to examine the effects of D-GIP1-30 were carried out in in vitro 
studies with INS-1 cells and in in vivo studies using different rodent models 
including STZ treated rats, Vancouver diabetic fatty (VDF) rats and obese 
Zucker diabetic fatty (ZDF) rats. The onset of cell death in Staurosporine (STS; 
an activator of the mitochondria-derived apoptotic pathways) treated INS-1 cells 
was significantly suppressed by D-GIP1-30 compared to the natural occurring 
form of GIP, GIP1-42. All in vivo studies showed improvement of glucose 
tolerance and insulin response when the rodents were treated with D-GIP1-30. 
Histological analyses revealed a significantly larger ?-cell area due to reduced 
apoptosis and maintenance of structural islet integrity (Widenmaier et al. 2010). 
Additionally, other anti-apoptotic actions of GIP were found. In one study 
caspase-3 activity was demonstrated to be reversed by GIP in INS-1 cells by 
inhibition of the cell death-associated p38 MAPK pathway after treatment with 
wortmannin, an inhibitor of the PI3K/PKB signal cascade (Ehses et al. 2003). 
GIP appeared to be able to regulate both cell growth and cell death via dynamic 
control of the p38 MAPK module. Another experiment showed that GIP 
decreases nuclear Foxo1 interaction with the Foxo1 response element in INS-1 
?-cells, a process resulting in downregulation of the bax gene during 
glucolipotoxicity-induced apoptosis (Kim et al. 2005). These results could also 
be confirmed by in vivo experiments in VDF rats. Likewise, it was shown that 
the anti-apoptotic effects of GIP in ?-cells are partially mediated through 
transcriptional regulation of Bcl-2, an apoptosis regulating gene product that 
facilitates cell survival (Kim et al. 2008). Widenmeier et al. examined how GIP is 
involved in the interactions between cytoplasmic Bcl-2 family members and the 
mitochondria in INS-1 cells during apoptosis. After treating the cells with STS, 
an activator of the mitochondria-derived apoptotic pathways, a significantly 
reduced stimulation of these pathways was observed following GIP application. 
Pro-survival responses to GIP during STS treatment could be explained by GIP 
provided ?-cell survival via Akt-dependent suppression of p38 MAPK and JNK 
(Widenmaier et al. 2009). 
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However, studies of pro-proliferative and anti-apoptotic effects of GIP in vivo are 
very limited. Findings of increased relative ?-cell volume in GIPR-/- mice (Pamir 
et al. 2003) and no apparent differences in islet size and number of DIRKO 
mice (Hansotia et al. 2004) are inconsistent with previous results in ?-cell lines 
or rodent models treated with an GIP analog. Thus further in vivo investigations 
are needed to define the role of GIP for ?-cell fate. 
2.2.3.3 Adipose tissue 
Expression of functional GIPRs on rat adipocytes and 3T3-L1 cells 
(preadipocyte cell line) (Yip et al. 1998) as well as the occurrence of GIPR 
mRNA in adipose tissue (Usdin et al. 1993) suggested a function of GIP in fat 
metabolism. Also, fat ingestion is a potent stimulator of GIP secretion in humans 
(Falko et al. 1975), wherefore the anabolic effects of GIP related to fat 
metabolism were examined. Dose-dependent enhancement of lipoprotein lipase 
activity by GIP (Eckel et al. 1979) as well as prevention of obesity due to 
inhibited GIPR signaling indicate that GIP is a potent factor for lipogenesis 
(Isken et al. 2008; Miyawaki et al. 2002). Interestingly, lipolytic effects of GIP 
were discovered, too (McIntosh et al. 1999; Yip et al. 1998). A different role of 
GIP under fasting conditions and in the presence of circulating nutrients might 
explain these contrary actions (McIntosh et al. 2009). 
2.2.3.4 Bone 
The presence of GIPR mRNA and protein in normal bone and osteoclast-like 
cell lines (SaSo2 and MG63) offered an indication of the regulatory effects of 
GIP on bone metabolism (Bollag et al. 2000; Bollag et al. 2001; Zhong et al. 
2007). Stimulation of osteoblast-like cells (SaOS2) with GIP revealed anabolic 
effects of presumptive osteoblasts (Bollag et al. 2000). Zhong et al. analyzed 
the effect of GIP on osteoclast function and detected its role as a mediator in 
postprandial suppression of skeletal resorption (Zhong et al. 2007). In vivo 
studies confirmed the physiological relevance of GIP related to bone 
metabolism. Altered bone microarchitecture as well as reduced bone mass and 
size in GIPR-/- mice were detected (Tsukiyama et al. 2006; Xie et al. 2005) 
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Correspondingly, repressive effects on bone resorption and stimulative effects 
on bone formation were shown in GIP transgenic mice (Xie et al. 2007). 
2.2.3.5 Nervous system 
In the central nervous system GIPR expression was substantiated in the 
cerebral cortex, hippocampus and olfactory bulb (Usdin et al. 1993). 
Interestingly, GIP mRNA could not be detected in the brain by in situ 
hybridization and PCR indicating the presence of a novel peptide in the brain 
(Usdin et al. 1993). Subsequent studies revealed stimulating effects of GIP on 
proliferation of hippocampal progenitor cells (Nyberg et al. 2005). Furthermore, 
GIPR-/- mice exhibited lower numbers of newborn cells in the dentate gyrus 
regions of the hippocampus (Nyberg et al. 2005) indicating a regulatory function 
of GIP in the central nervous system. Expression analyses of GIPR and GIP in 
the peripheral nervous system and the spinal cord revealed a widespread 
neuronal GIP expression (Buhren et al. 2009). An impaired peripheral axonal 
regeneration in GIPR-/- mice pointed towards beneficial effects of GIP/GIPR 
signaling with respect to nerve regeneration (Buhren et al. 2009). 
2.3 Glucagon-like peptide-1 (GLP-1) 
2.3.1 Secretion, synthesis and degradation 
Mammalian proglucagon genes encode not only glucagon but also two other 
peptides named glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 
(GLP-2), based on 50% sequence homology to glucagon (Bell et al. 1983). An 
insulinotropic action was detected for GLP-1 but not for GLP-2 (Schmidt et al. 
1985). GLP-1 exists in two biological active forms, GLP-1 (7-36) and (7-37), 
whereby the (7-36)-amide is the mainly circulating form (Orskov et al. 1994). 
GLP-1 is a tissue-specific posttranslational proteolytic product of the 
proglucagon gene that is derived from the intestinal endocrine L-cells in the 
distal ileum and colon (Eissele et al. 1992; Mojsov et al. 1986). Various 
stimulators like nutrients, neural and endocrine factors mediate GLP-1 
secretion. Carbohydrates and fat are the mainly stimulators for GLP-1 release 
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(Brubaker 2006). The half-life of GLP-1 is less than 2 minutes due to a fast 
degradation by the enzyme DPP-4 (Deacon et al. 1995). 
2.3.2 GLP-1 receptor and signal transduction 
Effects mediated by GLP-1 occur after binding to its specific receptor, the 
GLP-1 receptor (GLP-1R). This receptor is like the GIPR a member of the 
seven transmembrane-spanning, heterotrimeric G-protein-coupled receptor 
family (Mayo et al. 2003). GLP-1R expression was identified in several organs 
including the ?-cells in the islets of Langerhans within the pancreas (Tornehave 
et al. 2008) as well as lung, heart, kidney, stomach, intestine, pituitary, skin, 
nodose ganglion neurons of the vagus nerve and several regions of the CNS 
(Baggio et al. 2007). After binding to the N-terminal extracellular region efficient 
coupling to G-proteins is mediated by distinct domains in the third intracellular 
loop. Increases of intracellular Ca2+, activation of adenylate cyclase and 
phospholipase C and activation of PKA, PKC, PI3K, Epac2 and MAPK signal 
transduction pathways relay further signal transduction (Drucker et al. 1987; 
Holz et al. 1995; Thorens 1992; Wheeler et al. 1993). 
2.3.3 Biological actions of GLP-1 
Insulin secretion as well as insulin transcription and biosynthesis are stimulated 
via GLP-1 binding to its specific receptor (Baggio et al. 2007). An inhibitory 
effect of GLP-1 on glucagon secretion was observed (Creutzfeldt et al. 1996). 
Pro-proliferative and anti-apoptotic effects of GLP-1 on ?-cells were 
demonstrated in several studies (Farilla et al. 2002; Farilla et al. 2003; Li et al. 
2003; Maida et al. 2009), whereas GLP-1 revealed stronger influence on ?-cell 
survival than GIP (Maida et al. 2009). Moreover, functions in other tissues were 
discovered. GLP-1 enhances cardiac function and mediates cardioprotection as 
well as neuroprotection and glucose uptake and storage in muscles (Drucker 
2006; Nauck 2009). Reduction of glucose production in the liver, and gastric 
emptying as well as the effect of an appetite regulator could be added to the 
functions of GLP-1 (Nauck 2009). 
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Figure 2.1 Biological actions of GIP and GLP-1 (figure modified from Baggio 
et al. 2007 and Drucker 2007) 
2.4 The contribution of GIP and GLP-1 to type 2 diabetes 
mellitus 
It has been shown that an oral glucose load resulted in higher insulin levels and 
thereby faster decline of blood glucose levels compared to an isoglycemic 
intravenous glucose load (Elrick et al. 1964; McIntyre et al. 1964). The incretin 
hormones GIP and GLP-1 were found to be responsible for this process. Thus 
the term “incretin effect” was coined for this observation. Approximately 60% of 
the total insulin secretion after food intake is mediated by the incretin hormones 
(Nauck et al. 1986a). Patients with type 2 diabetes mellitus exhibited no 
significant differences in C-peptide levels after oral and intravenous glucose 
administration, indicating a reduced incretin effect (Nauck et al. 1986b). Further 
investigations showed differences in secretion and insulinotropic action of GIP 
and GLP-1 in type 2 diabetic patients compared to healthy control subjects. 
Studies on GIP secretion in type 2 diabetic patients demonstrated normal 
secretion in most cases, but hypersecretion in some individuals (Ross et al. 
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1977; Vilsboll et al. 2001). While former studies showed a reduced GLP-1 
secretion (Toft-Nielsen et al. 2001; Vilsboll et al. 2001), more recent studies 
disproved this finding showing normosecretion of GLP-1 in diabetic subjects 
(Vollmer et al. 2008). Studies on the insulinotropic action of both incretins 
revealed that the insulinotropic action of GIP was markedly impaired, while this 
of GLP-1 was preserved in type 2 diabetic patients (Nauck et al. 1993b). In the 
past it was hypothesized that due to changes in the level or defects in GIPR 
expression, the insulinotropic action of GIP is impaired in type 2 diabetic 
patients (Holst et al. 1997). Findings of a blunted insulin response to GIP in first-
degree relatives of type 2 diabetes patients promoted the assumption of a 
defect GIPR in these subjects (Meier et al. 2001). Lynn et al. showed reduced 
GIPR mRNA expression in the pancreatic islets of ZDF rats (Lynn et al. 2001). 
Hyperglycemic partially pancreatectomized rats exhibited downregulated GLP-1 
and GIPR expression providing a possible explanation for the impaired incretin 
effect in type 2 diabetes mellitus affected peoples (Xu et al. 2007). A meta-
analysis of nine genome wide association studies revealed that GIPR variants 
influence glucose and insulin responses to an oral glucose challenge supporting 
the hypothesis that changes in GIPR play a role in the pathogenesis of type 2 
diabetes mellitus (Nauck et al. 2004a; Saxena et al. 2010). 
2.5 Incretins in diabetes research 
To examine the role of the incretin hormones in general and their role in diabetic 
metabolism, several genetically modified rodent models have been established. 
In the following section these animal models are reviewed as well as further 
investigations on prolonging the action of GIP and/or GLP-1 as a therapeutic 
approach are summarized. 
2.5.1 GIP receptor knockout mice (GIPR-/-) 
In 1999 Miyawaki et al. generated mice with a targeted mutation of the GIPR 
gene in order to investigate effects of the GIP/GIPR axis on glucose 
metabolism. The complete loss of GIPR function was controlled by stimulating 
isolated pancreatic islets of GIPR-/- mice with GIP. The isolated islets of 
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homozygous GIPR-/- mice showed no insulinotropic action following stimulation 
with glucose and GIP compared to controls (Miyawaki et al. 1999; Pamir et al. 
2003). Histological abnormalities were found neither in the pancreas nor in the 
gastrointestinal tract or the adrenal gland (Miyawaki et al. 1999). In contrast, 
another study revealed an increased ?-cell area (referred to total pancreatic 
area) of 45% and reduced staining intensity for insulin in 
immunohistochemically stained pancreatic sections of GIPR-/- mice (Pamir et al. 
2003). Fasting glucose levels and blood glucose levels after intraperitoneal 
glucose injection were unaltered compared to controls, while blood glucose and 
plasma insulin levels after an oral glucose tolerance test were significantly 
elevated and reduced, respectively. (Miyawaki et al. 1999). The disruption of the 
GIP/GIPR axis led to reduced insulin gene transcription and protein 
biosynthesis and increased islet sensitivity to GLP-1 (Pamir et al. 2003).  
Furthermore, GIPR-/- mice were protected from obesity compared to wild-type 
mice when fed a high-fat diet from 7 to 50 weeks of age and did not develop 
insulin resistance like obese control animals (Miyawaki et al. 2002). Also, diet-
induced obesity was attenuated in GIPR-/- mice crossbred with a genetically 
obese mouse model (Lepob/Lepob mice) compared to single-homozygous 
Lepob/Lepob mice confirming that the protecting effects of GIP even occur in the 
absence of leptin, an adipokine that stimulates fat oxidation in peripheral tissues 
for body weight control (Miyawaki et al. 2002). Adiponectin presents another 
major adipokine. Three weeks of high-fat (HF) diet feeding in GIPR-/- mice 
caused significantly increased fat oxidation in skeletal muscles and significantly 
elevated adiponectin levels and GIPR-/- mice did not put on body weight 
compared to wild-type mice fed the HF diet (Naitoh et al. 2008). In contrast, 
GIPR-/- mice exhibited no differences in plasma adiponectin levels after 20 
weeks of HF diet compared to GIPR-/- mice fed a control diet (Hansotia et al. 
2007) concluding that GIPR signal interruption modulates adiponectin levels in 
the early stage of obesity induced by a HF diet (Naitoh et al. 2008). Recently, 
GIPR-/- mice were used to study whether the effects of GIP and estrogen on 
body weight and fat mass could be linked (Isken et al. 2008). Ovariectomized 
(OVX) GIPR-/- mice and wild-type mice were compared with respect to body 
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composition, energy metabolism and hypothalamic neurocircuitry. OVX GIPR-/- 
were protected from obesity going along with reduced cumulative food intake 
while OVX wild-type mice exhibited a significant higher body weight gain 
compared to OVX GIPR-/- and sham OVX mice. Interestingly, previous studies 
detected no influence of GIP on food intake behavior (Miyawaki et al. 2002) 
suggesting that the GIP/GIPR axis might be relevant to mediate feeding under 
changed physiological conditions like estrogen decline (Isken et al. 2008). 
Furthermore, GIP appeared to have age-associated effects on body 
composition. GIPR-/- mice showed improved insulin sensitivity and physical 
activity concomitantly to reduced fat mass compared to wild-type mice (Yamada 
et al. 2007). Low and high glycemic index (GI) diets were fed to GIPR-/- mice to 
evaluate the influence of GIP and age to body composition (Isken et al. 2009). 
Male wild-type (C57BL/6J) and GIPR-/- mice were fed the high-carbohydrate diet 
which differed only in its GI over 20 to 26 weeks starting at the age of 16 weeks 
(young-adult) and 44 weeks (aged). GIPR-/- genotype could not be linked to 
differences in body weight gain, body fat and hepatic triacylglycerol content. An 
increased cumulative energy intake was only observed in aged wild-type mice 
on high-GI diet while GIPR-/- mice were protected from this effect. GIPR 
deficiency improved insulin sensitivity in aged mice fed a high-GI diet. In 
agreement to this observation aged GIPR-/- mice on high-GI diet exhibited 
improved carbohydrate oxidation. Furthermore, an increased locomotor activity 
during the dark phase was referred to the aged GIPR-/- genotype in combination 
with the high-GI diet. These observations suggested that a blockage of GIPR 
signaling might be advantageous for aged humans consuming high-GI diets 
(Isken et al. 2009). 
Effects of GIP on bone remodeling were examined using GIPR-/- mice. Lower 
bone mass and alterations in bone architecture in the knockout mice compared 
to wild-type animals indicated an anabolic effect of GIP on bone mass and 
quality (Xie et al. 2005). In this context, mice with a disruptive GIPR signaling 
were examined to evaluate the role of GIP on calcium deposition in the bone 
(Tsukiyama et al. 2006). After nutrient ingestion GIPR-/- showed significantly 
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elevated plasma calcium levels compared to controls concluding effects of GIP 
on the efficient storage of ingested calcium (Tsukiyama et al. 2006). 
2.5.2 GLP-1 receptor knockout mice (GLP-1R-/-) 
GLP-1R-/- mice were generated to examine the physiological importance of 
GLP-1 for regulation of satiety and blood glucose (Scrocchi et al. 1996). 
GLP-1R-/- mice exhibited only mild fasting hyperglycemia but impaired glucose 
tolerance and reduced insulin secretion after an oral glucose challenge 
(Hansotia et al. 2004; Preitner et al. 2004; Scrocchi et al. 1996). In contrast to 
GIPR-/- mice, abnormal glycemic excursions were visible during an 
intraperitoneal glucose tolerance test (Scrocchi et al. 1996) as well as 
significantly reduced peak insulin levels compared to wild-type mice (Preitner et 
al. 2004). Defective glucose-induced insulin secretion and reduced proinsulin 
gene expression indicated multiple ?-cell abnormalities (Pederson et al. 1998). 
However, total ?-cell volume was unaltered in GLP-1R-/- mice while the 
distribution of the endocrine fraction was markedly changed. ?-Cells were 
located more centrally and more medium-sized islets were detected in 
GLP-1R-/- mice indicating an influence of GLP-1 on islet topography (Ling et al. 
2001). Body weight and food intake did not differ from controls, although GLP-1 
is evidentially a potent inhibitor of food intake (Scrocchi et al. 1996). Enhanced 
glucose-stimulated GIP levels in GLP-1R-/- mice and increased GIP stimulated 
insulin release from the perfused pancreas or isolated islets of GLP-1R-/- mice 
revealed compensatory mechanisms in the enteroinsular axis (Flamez et al. 
1999; Pederson et al. 1998). Additionally, the importance of endogenous GLP-1 
for the control of bone metabolism was examined using GLP-1R-/- mice 
(Yamada et al. 2008). A diminished cortical bone mass and reduce bone 
stability in the tibia of GLP-1R-/- mice was detected. Increases of osteoclast 
numbers and bone resorption were stimulated indirectly through a modulation of 
the calcitonin expression by GLP-1. Thus, an essential role of GLP-1 for the 
regulation of bone resorption was substantiated (Yamada et al. 2008). 
Hyperinsulinemia and exercise are metabolic perturbations regulating the 
glucose flux insulin-dependently and insulin–independently, respectively. The 
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different glucoregulatory abilities of GLP-1 were examined using the GLP-1R-/- 
mouse model (Ayala et al. 2009). A hyperinsulinemic-euglycemic clamp 
experiment suggested an essential role for GLP-1 during the postabsorptive 
phase regulating glucose homeostasis insulin-dependently. However, GLP-1R-/- 
mice became hyperglycemic during exercise due to a failing suppression of 
hepatic endogenous glucose production and hepatic glycogen accumulation, 
concluding that GLP-1 regulates muscle glucose uptake and hepatic glucose 
flux also independent of its role as an incretin (Ayala et al. 2009). 
2.5.3 Double incretin receptor knockout mice (DIRKO) 
Mice lacking both GIPR and GLP-1R allowed to study physiological 
consequences of a complete loss of GIP and GLP-1 action on glucose 
homeostasis (Hansotia et al. 2004). Glucose tolerance following an oral glucose 
challenge was significantly more impaired compared to single incretin knockout 
(SIRKO) mice. Also, insulin levels were decreased after an oral glucose 
challenge and glycemic excursion following intraperitoneal glucose 
administration was abnormal while fasting glucose levels were not significantly 
elevated in DIRKO mice compared to controls. Histological analyses revealed 
no difference in the number and size of DIRKO versus wild-type islets. The 
administration of DPP-4 inhibitors confirmed GIPR and GLP-1R as principal 
targets for glucose-lowering actions of the inhibitors. Despite the absence of 
both incretin receptors DIRKO mice developed only a mild phenotype of 
glucose intolerance and reduced insulin secretion (Hansotia et al. 2004; 
Preitner et al. 2004).  
Diet studies in DIRKO mice elucidated the influence of the lack of incretin 
signaling on insulin action (Ayala et al. 2008). DIRKO mice and control animals 
were fed a regular chow or high-fat (HF) diet for 12 weeks starting at 3 weeks of 
age. DIRKO mice exhibited decreased body weight gain and reduced muscle 
mass after being fed the chow diet. While control animals fed a HF diet showed 
increased body weight gain, this diet did not affect the weight gain of DIRKO 
mice. Furthermore, DIRKO mice showed increased energy expenditure and 
activity. Insulin action of both groups was evaluated by a hyperinsulinemic 
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euglycemic clamp study discovering enhanced whole-body insulin action in 
DIRKO mice and protection from HF diet induced insulin resistance. Also, 
glucose uptake in cardiac and muscle tissues was enhanced in DIRKO mice. 
These observations pointed towards the importance of incretins in regulating 
glucose homeostastis beyond the pancreas (Ayala et al. 2008). 
2.5.4 Mice expressing a dominant-negative GIPR  
(GIPRdn transgenic mice) 
GIPRdn transgenic mice represent another mouse model to examine the role of 
the GIP/GIPR axis. In contrast to models with a complete loss of GIP action, the 
reduction of GIPR signaling in GIPRdn transgenic mice led to a severe diabetic 
phenotype just before weaning (Herbach et al. 2005). Severe glucosuria, 
elevated serum glucose concentrations, reduced insulin levels and increased 
glucagon levels characterized the diabetic phenotype of GIPRdn transgenic 
mice. Additionally, marked changes in islet morphology were detected. Islet 
profiles were much smaller in size and number and revealed an altered 
composition. Total ?-cell volume as well as total volume of isolated ?-cells (a 
marker for islet neogenesis) were markedly reduced while the total volume of 
non-?-cells was increased indicating GIP as an important factor for postnatal 
islet and ?-cell development (Herbach et al. 2005). 
As special diets are discussed to improve glucose metabolism in diabetic 
patients, GIPRdn transgenic mice were fed a high-fiber/low-disaccharide diet to 
mimic new diet set ups (Herbach et al. 2008). GIPRdn transgenic mice fed a 
high-fiber diet showed reduced non-fasting blood glucose levels and a tendency 
towards declined fasting blood glucose levels compared to transgenic mice fed 
a regular diet. Also, ?-cell function and insulin sensitivity were significantly 
improved. High-fiber diet positively affected survival rates of GIPRdn transgenic 
mice. Notably, improved ?-cell function and glucose tolerance indicated a 
beneficial effect of high-fiber/low-disaccharide diet in GIPRdn transgenic mice 
(Herbach et al. 2008).  
Nephropathy is one of the most common epiphenomena of diabetes. Age-
related kidney lesions associated with a diabetic phenotype were examined in 
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GIPRdn transgenic mice at the age of 3, 8, 20 and 28 weeks (Herbach et al. 
2009). Early renal changes like podocyte hypertrophy, reduced numerical 
volume density of podocytes in glomeruli and homogenous thickening of the 
glomerular basement membrane were detected by qualitative and quantitative 
morphological analyses. GIPRdn transgenic mice showed further renal and 
glomerular hypertrophy as well as mesangial expansion and matrix 
accumulation. At 28 weeks of age advanced glomerulosclerosis going along 
with tubointerstital lesions and proteinuria were observed. Hyperglycemia and 
renal alterations correlated obviously in GIPRdn transgenic mice indicating these 
mice as an appropriate model to study mechanisms involved in the onset and 
progression of diabetic nephropathy (Herbach et al. 2009). 
2.5.5 GIP transgenic mice 
The role of GIP as an anabolic factor for bone metabolism was already 
analyzed in GIPR-/- mice (Xie et al. 2005). Generating mice overexpressing GIP 
allowed to confirm previous results of GIPR-/- mice and to further define the 
impact of GIP on the skeleton. Data on bone density and histomorphometry 
were collected as well as bone markers for formation and resorption were 
determined concluding that an increased GIP signaling induces gain in bone 
mass (Xie et al. 2007) and prevents age-induced bone loss (Ding et al. 2008).  
As GIP synthesis was detected in the hippocampal dentate gyrus GIP 
transgenic mice were utilized to study the effects of GIP on behavior (Ding et al. 
2006). A number of behavioral tests were performed and GIP appeared to 
modulate the regulation of locomotor activity and exploration (Ding et al. 2006).  
2.5.6 Prolonging the action of GIP, GLP-1 or both 
The half-live of native GLP-1 and GIP is very short due to their fast degradation 
by the enzyme DPP-4 (Deacon et al. 1995; Deacon et al. 2000) Therefore 
strategies to prolong incretin hormone action were developed in order to use 
their beneficial effects on  ?-cell function for therapeutic purposes. In general, 
there are three different strategies to prolong incretin action: 
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1. N-terminal modification of GIP/GLP-1 to convey DPP-4 resistance 
2. C-terminal modification of GIP/GLP to circumvent renal filtration 
3. DPP-4 inhibition 
To establish DPP-4 resistant analogs amino acid substitutions were induced. 
Although the most modifications including amino acid substitution generate 
DPP-4 resistance, the biological activity and receptor stimulation can differ 
markedly (Green et al. 2007). Several GIP analogs with modifications at Tyr1 
and Ala2 were developed (Gault et al. 2002a; Gault et al. 2003a; Hinke et al. 
2002; Irwin et al. 2009b; O'Harte et al. 1999; O'Harte et al. 2002). Comparing 
the activity of the analogs with the native GIP hormone, Tyr1-modified forms 
were completely DPP-4 resistant and showed enhanced biological activity while 
Ala2-modified analogs were only partially DPP-4 resistant and less efficient 
(Irwin et al. 2009a). Amino acid substitution within the GLP-1 sequence at Ala8 
seemed to be superior to modifications at His7 (Green et al. 2006; Green et al. 
2007; O'Harte et al. 2000). Weak agonists or even receptor antagonists were 
established by amino acid substitutions at Glu9 for GLP-1 and Glu3 for GIP, 
respectively (Gault et al. 2007; Green et al. 2004; O'Harte et al. 2007). Even if 
DPP-4 resistance is an important approach to prolong the action of the 
incretins, renal filtration is not prohibited by N-terminal modifications meaning 
that the effective period is limited to four hours due to rapid kidney elimination 
(Green et al. 2007). 
C-terminal modification of GIP and GLP-1 demonstrated a functional strategy to 
circumvent renal filtration. Fatty acid acylation and PEGylation (attachment of 
polyethylene glycol chains) are used to promote binding to plasma proteins to 
delay renal elemination. Several C-terminal modifications for both GIP (Gault et 
al. 2008; Irwin et al. 2005a; Irwin et al. 2005b; Irwin et al. 2006; Kerr et al. 2009) 
and GLP-1 (Chou et al. 1997; Lee et al. 2006; Rolin et al. 2002) were generated 
and tested in preclinical studies. Dual modification by N-terminal acylation and 
C-terminal PEGylation of GIP generated a DPP-4 resistant long-acting GIP 
analog with a comparable efficiency to native GIP (Salhanick et al. 2005). 
Accordingly, Liraglutide represents a long-acting GLP-1 analog generated by 
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dual modification which has already been tested in type 2 diabetes patients 
(Nauck et al. 2006; Vilsboll et al. 2007). 
Degradation of GIP and GLP-1 by DPP-4 leads to formation of metabolites 
without insulinotropic potential. Thus, a blockage of the enzyme DPP-4 provides 
an attractive method to prolong the action of GIP and GLP-1. To test the 
efficiency of various DPP-4 inhibitors several preclinical studies with animal 
models for type 2 diabetes mellitus were carried out (Ahren et al. 2000; Balkan 
et al. 1999; Deacon et al. 2002; Duez et al. 2009; Liu et al. 2009). Studies in 
humans could confirm the beneficial effects of DPP-4 inhibitors on glucose 
metabolism (Ahren et al. 2002). Vildagliptin, Sitagliptin and Saxagliptin are only 
three examples of the numerous existing DPP-4 inhibitors (Ahren 2007a, 
2007b, 2009). 
Exendin-4 represents a naturally existing GLP-1 mimetic. It was isolated from 
the salivary gland of the Gila Monster lizard Heloderma suspectum 
demonstrating approximately 53% sequence homology to GLP-1 (Eng et al. 
1992; Goke et al. 1993). In addition, it is not a substrate for DPP-4 making it 
interesting for therapeutic use (Keating 2005; Nielsen et al. 2003). A synthetic 
derived form of exendin-4, the so called exenatide (Byetta®), was the first 
incretin-based pharmaceutical reaching the market (Green et al. 2007). 
Recently, long-term effects of elevated steady-state exendin-4 levels were 
examined using gene therapy. A helper-dependent adenovirus (HDAd) served 
as a vector for expressing the exendin-4 peptide (Samson et al. 2008). After 8 
weeks of high-fat diet feeding mice were treated with the HDAd. Glucose 
homeostasis was positively influenced, while insulin levels did not increase. 
Additional changes on insulin sensitivity, adipokine levels, hepatic steatosis and 
energy expenditure gave impetus towards further investigations (Samson et al. 
2008).  
2.6 The pig as an animal model in research 
Although rodent models are predominantly used in research, pigs provide great 
advantages for the translation of data to humans, due to many physiological 
and anatomical similarities. Skin and subcutaneous tissues only differ slightly 
2  Review of the literature 22 
from that of humans, allowing comparison of kinetics and dynamics after 
injection of drugs (Meyer 1996). Sparse body hair, similar dermal-epidermal 
thickness ratio as well as similar size, orientation and distribution of blood 
vessels are only some analogies (Meyer 1996; Sullivan et al. 2001). Sullivan et 
al. compared studies about wound healing in various animal models leading to 
the conclusion that the pig correlates well to human (Sullivan et al. 2001). 
Investigations of intestinal absorption and nutrient requirements are also 
interesting for many fields of research. Therefore it is advantageous that pigs 
are omnivorous and the digestive effectiveness is comparable to humans (Miller 
et al. 1987). Constant training of pigs allows to perform most experimental 
procedures in conscious and unstressed animals (Larsen et al. 2004). Another 
advantage of pigs is the possibility to obtain larger amounts of blood or tissue 
samples compared to rodents. Placement of central venous catheters either 
temporary or permanent (Moritz et al. 1989; Smith et al. 1991) allows 
circumvention of repeated stressful blood sampling. 
There are different opportunities to generate an adequate model for human 
diseases. Induction of random gene mutations by chemicals, treatment with 
drugs for targeted reduction of organ functions and generation of genetically 
modified animals can be discriminated. Also, spontaneous onset of diseases in 
pigs similar to humans is used as a basis for comparison. 
2.6.1 Genetically modified pigs for translational research 
The translation of scientific outcomes into clinical applicable strategies plays an 
important role in today’s research and coined the term “translational medicine” 
(Wehling 2008). Appropriate animal models are needed to elucidate 
pathogenesis and pharmacological strategies in human diseases. Genetic 
modification is a useful method to generate animal models for a specific 
disease. Different methods available for genetic modification in pigs may lead to 
overexpression, impairment or loss of function of a gene allowing to evaluate 
the effects on the organism. In the following some highlights of genetically 
modified pigs for common diseases are presented. 
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2.6.1.1 Cardiovascular disease 
Heart diseases are a worldwide common problem. Nitric oxide plays an 
important role in multiple pathways among other things in cardiac development, 
angiogenesis and wound healing. The endothelial nitric oxide synthase (eNOS) 
was identified regulating vascular function, vascular structure and blood 
pressure. To receive information on its function transferable to humans 
transgenic pigs overexpressing eNOS were generated by somatic cell nuclear 
transfer (SCNT). Yucatan minipigs served as models for this study and 
appeared to be useful to clarify the role of eNOS for atherosclerosis, 
hypertension and wound healing (Hao et al. 2006). 
2.6.1.2 Cerebral diseases 
Huntington disease (HD) is caused by a dominant mutation in a gene called 
Huntingtin. HD presents an autosomal inheritable progressive neuro-
degenerative disorder, whereby both homozygous as well as heterozygous 
phenotypes lead to an onset of this disease commonly in the middle age. 
Involuntary, jerky movements as well as cognitive and psychiatric symptoms are 
typical disturbances of the affected peoples. As the endogenous mouse HD 
gene appeared to be not as pathogenic as in humans, pigs provided an 
attractive alternative. Characterization of the porcine HD gene revealed more 
similarity to human HD genes than those of rodents indicating pigs as a 
valuable model for physiological and pharmacotherapeutical studies of 
Huntington disease (Matsuyama et al. 2000).  
Another neurodegenerative process in the brain is responsible for the onset of 
Alzheimer disease (AD). Although AD is delineated as multifactorial 
disturbance, AD onset is also elicited by an autosomal dominant mutation 
disorder. Mutations of the amyloid precursor protein (APP) gene and the 
presinilin genes (PSEN) resulted in higher production levels of the APP, 
whereby increases in APP expression cause neuritic plaques and formation of 
neurofibillary tangles. Discrepancies in disease development of mice compared 
to humans postulated a more homologous model. Göttingen minipigs 
expressing a specific splice variant of human APP, that carries an AD-causing 
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dominant mutation (Swedish mutation) were generated by so called handmade 
cloning (Kragh et al. 2009). 
2.6.1.3 Ophthalmic disease 
In 1997 Petters et al. designed a pig model for retinitis pigmentosa (RP) 
representing pioneers in generation of transgenic pigs. RP is an incurable 
degenerative disease. Although various mutations in RP patients were 
identified, a common pattern of loosing eyesight was recognized. An early 
development of night vision loss caused by rod photoreceptor degeneration 
associated with a progressive loss of cone photoreceptors finally leads to 
blindness. As the mutation Pro374Leu is characterized causing severe rod 
degeneration it was chosen for generating a transgenic pig model. Pronuclear 
microinjection served as method for producing transgenic pigs. Pigs exhibited a 
rapid severe loss of rod photoreceptors in combination with moderate early 
cone photoreceptor degeneration deteriorating over time (Petters et al. 1997). 
2.6.1.4 Motor neuron disease 
Spinal muscle atrophy (SMA) occurs in three different severity grades and is the 
most common inherited motor neuron disease. Degeneration of anterior horn 
cells of the spinal cord resulting in muscle atrophy distinguishes this autosomal 
recessive disorder. The loss of function of survival motor neuron-1 (SMN-1) was 
identified to be responsible for SMA onset. Identification and cloning of the 
porcine SMN-1 gene was carried out. Notably, the absence of the SMN-1 
protein in primary fibroblasts of a SMA type 1 patient was compensated by 
transfection with porcine SMN-1. Human and porcine SMN are consistent in 
sequence, localization and expression indicating that a transgenic swine model 
is feasible for further investigations of SMA (Lorson et al. 2008). 
2.6.1.5 Cystic fibrosis 
Cystic fibrosis (CF) is a common autosomal recessive disease, which affects 
wide parts of the organism including intestine, lung, liver, gallbladder and male 
genital tract. The mutated cystic fibrosis transmembrane conductance regulator 
(CFTR) gene was discovered to be the trigger for degenerations. To obtain a 
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pig model for cystic fibrosis, the CFTR gene was disrupted by homologous 
recombination in porcine fibroblasts and transferred by somatic cell nuclear 
transfer (SCNT). Meconium ileus and pancreatic destruction occurred first in 
CFTR-/- piglets similar to human neonates as well as additional alterations of 
gallbladder and bile ducts. Lung and vas deferens of the testis exhibited no 
abnormalities similar to humans at a comparable age (Rogers et al. 2008). 
2.6.1.6 Diabetes 
Genetic mutation of the hepatocyte nuclear factor (HNF)-1? was discovered to 
be responsible for the development of type 3 maturity-onset diabetes of the 
young (MODY3), an autosomal dominant inherited disease. Umeyama et al. 
generated transgenic pigs expressing the human HNF-1? mutant gene imitating 
pathophysiological characteristics of MODY3 in humans. Intracytoplasmic 
sperm injection (ICSI) combined with somatic cell nuclear transfer (SCNT) 
served as method for transgenic pig production. Piglets exhibited markedly 
elevated non-fasting blood glucose levels and a disturbed oral glucose 
tolerance. Altered morphology of glomerular structures and of islets of 
Langerhans in the pancreas were demonstrated in immunohistochemically 
stained sections. However, high mortality rate and early death during the 
neonatal period of the transgenic-cloned pigs require further studies to improve 
postnatal survival (Umeyama et al. 2009). 
2.6.2 Pigs as models in type 2 diabetes mellitus research 
Currently, the use of pigs in biomedical research is relatively small compared to 
the fraction of rodentiae (mice, rats) and lagomorphae (rabbits) (BMELV 2009). 
However, similarities to humans related to cardiovascular system and pancreas 
make them an excellent tool for diabetes research. Size, shape and position of 
the pig pancreas are very similar to that of humans as well as blood supply of 
endocrine and exocrine tissues (Murakami et al. 1997). Although the islet 
structure of young pigs is more diffuse than in adult humans, changes in islet 
structure with increasing age make them more comparable to adult humans 
(Jay et al. 1999; Ulrichs et al. 1995; van Deijnen et al. 1992; Wieczorek et al. 
1998). ?-Cells were predominantly detected in the dorsal pancreas both in the 
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core and in the periphery of the islets while pancreatic polypeptide (pp) 
containing cells were found almost exclusively in the ventral pancreas. This cell 
dispersion is true for both humans and pigs (Jay et al. 1999; Orci et al. 1979; 
Rahier et al. 1981; Stefan et al. 1983; Wieczorek et al. 1998). ?-Cells represent 
the major part of endocrine cells in the ventral and dorsal pancreas of the pig 
whereas in humans pp-cells were shown to be the major endocrine fraction in 
the ventral pancreas (Jay et al. 1999; Orci et al. 1979; Rahier et al. 1981; Stefan 
et al. 1983; Wieczorek et al. 1998). Nevertheless, the ?-cell content of the 
porcine endocrine tissue ranges between 60 to 80%, therefore resembling the 
human ?-cell content (Larsen et al. 2004). Another similarity between humans 
and pigs is the main expression of islet amyloid polypeptide (IAPP) in ?-cells 
(Lukinius et al. 1996). However, a dissimilarity between the human and pig 
IAPP sequence is present and only humans are prone to the formation of 
pancreatic amyloid (Larsen et al. 2004). Porcine insulin and GIP sequence are 
very similar to this of humans allowing their use in treatment and studies 
(Bromberg et al. 2006; Jornvall et al. 1981; Moody et al. 1984). 
Some pig strains commonly used as models for type 2 diabetes mellitus are 
listed below. Minipigs are often preferred due to smaller size and less expenses 
in housing. 
2.6.2.1 Yucatan Minipigs 
Two lines of Yucatan minipigs with either impaired glucose tolerance (so-called 
“low K”) or enhanced glucose tolerance (so-called “high K”) were produced by 
selective breeding (Phillips et al. 1979; Phillips et al. 1982). Minipigs with an 
impaired glucose tolerance showed reduced serum insulin levels, although 
storage and synthesis of insulin were intact. An altered pancreatic receptor 
response seemed to be responsible for glucose intolerance. However, fhe F7 
generation of the low-K line exhibited no more glucose intolerance and 
therefore these pigs are currently not available anymore. 
Furthermore, chemicals were used to generate diabetic Yucatan miniature pigs. 
Treatment with alloxan led to impaired glucose tolerance caused by partial 
?-cell damage, whereby feeding of a high-fat/high-cholesterol diet was used to 
provoke dyslipidemia. Increased atherosclerosis was discovered in diabetic 
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dyslipidemic minipigs. Atorvastatin, a potent drug for the treatment of 
hypercholesterinemia protected diabetic minipigs from atherosclerosis (Dixon et 
al. 2002).  
Alloxan induced diabetic Yucatan minipigs were furthermore used to examine 
microangiopathies associated with diabetes like diabetic retinopathy. As in 
former studies dyslipidemia induced by a high-fat diet caused macrovascular 
disorders in Yucatan minipigs, it should be clarified whether microvascular 
changes are also associated with diabetes. Retinal capillary basement 
membrane thickening was detected making this model interesting for early 
intervention and treatment studies for diabetic retinopathy (Hainsworth et al. 
2002). 
Overfeeding of Yucatan minipigs led to obesity and was associated with lower 
insulin sensitivity compared to control-fed pigs (Sebert et al. 2005). 
Administration of a high-calorie diet before sexual maturation should give 
information about cellular and metabolic modifications and about IGF-1 levels 
and insulin sensitivity related to childhood obesity (Sebert et al. 2005). 
2.6.2.2 Sinclair minipigs 
This pig strain served as a model for diabetes associated with dyslipidemia. 
Alloxan treatment was utilized to destroy insulin producing ?-cells implicating 
diabetes. In addition to alloxan application feeding of a high-fat and high-
cholesterol diet caused dyslipidemia in these diabetic minipigs and allowed to 
study peripheral vascular and coronary artery diseases. Diabetic minipigs 
exhibited enhanced contractile tension oscillations in coronary arteries and 
impaired endothelium-dependent relaxation compared to controls. Fatty streak 
formation in diabetic minipigs was markedly increased (Dixon et al. 1999). 
2.6.2.3 Göttingen minipigs 
The metabolic syndrome describes risk factors associated with the development 
of type 2 diabetes. Decreased insulin sensitivity, enhanced insulin secretion as 
well as hypertension, dyslipidemia and microvascular complications 
characterize the metabolic syndrome, a typical prediabetic period. Female 
Göttingen minipigs fed a high-fat/high-energy diet exhibited some of the 
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metabolic disturbances observed in obese patients like elevated triglyceride 
levels and significantly higher area under the insulin curve after an intravenous 
glucose tolerance test (Johansen et al. 2001). Male Göttingen minipigs fed with 
a high-fat/high-energy diet for 3 months also developed slight hyperglycemia 
and compensatory hyperinsulinemia. Experiments related to insulin resistance 
in type 2 diabetic patients could be performed in this animal model (Larsen et al. 
2002b). 
As insulin secretion and action are impaired in type 2 diabetic patients and 
pulsatile insulin secretion was found to be important for insulin effects in the 
liver, muscle and adipose tissue, Göttingen minipigs were also used to study 
pulsatile insulin action to gain insight into the pathogenesis of type 2 diabetes 
mellitus. Larsen et al. evaluated the minipigs being a good model for further 
studies related to insulin pulsatility due to their similarities of insulin kinetics to 
humans and advantages in sampling compared to other species (Larsen et al. 
2002a). After the treatment with nicotinamide (NIA) in combination with 
streptozotocin (STZ) Göttingen minipigs developed mild diabetes characterized 
by a reduction of ?-cell mass as observed in type 2 diabetic patients. Insulin 
pulsatility studies were carried out to obtain information, whether disturbed 
pulsatile insulin secretion in type 2 diabetes patients is linked to reduced ?-cell 
mass. Diabetic Göttingen minipigs exhibited normal insulin pulsatility concluding 
other mechanisms to be responsible causing the impaired insulin pulsatility 
seen in human type 2 diabetes patients (Larsen et al. 2003a). 
Obese and obese-STZ treated Göttingen minipigs were used to investigate 
whether impaired insulin pulsatility as an early marker of ?-cell dysfunction is 
only detectable when obesity and reduced ?-cell mass are present 
concomitantly. Glucose-entrained insulin secretion was significantly reduced in 
obese-STZ minipigs while obese minipigs without STZ treatment showed no 
marked differences compared to controls. Accordingly, the coexistence of 
obesity and reduced ?-cell mass in the Göttingen minipig caused further 
deterioration in ?-cell function demonstrated by changes in insulin pulsatility. 
Due to this fact it was suggested that abnormalities in insulin pulsatility are a 
sensitive marker for ?-cell dysfunction (Larsen et al. 2005). 
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The NIA-STZ treated Göttingen minipig presented also a feasible model for 
therapy studies. Effects of dipepitdyl peptidase-4 (DPP-4) inhibitors that protect 
the incretins GLP-1 and GIP from fast degradation by the enzyme DPP-4, and 
NN221, a long-acting GLP-1 derivate, on glucose metabolism of these pigs 
were evaluated (Larsen et al. 2003b; Ribel et al. 2002). 
2.6.2.4 Yorkshire strains 
Yorkshire pigs are normal sized domestic pigs commonly used for 
atherosclerosis research. It was discovered, that Yorkshire pigs with induced 
diabetes by STZ treatment, fed a special diet high in fat and cholesterol 
exhibited accelerated atherosclerosis (Gerrity et al. 2001). Increases in 
triglyceride levels, blood glucose as well as accumulation and proliferation of 
arterial smooth muscle cells emerged in this animal model. Further 
investigations of this pig model were performed studying the mechanisms of 
smooth muscle cell proliferation. Insulin-like growth factor-1 (IGF-1) levels were 
increased and growth-enhancing effects of IGF-1 on smooth muscle cells were 
potentiated by long-chain fatty acids. Thus, enhanced IGF-1 and triglyceride 
levels in type 2 diabetic patients appeared to be responsible for the accelerated 
SMC proliferation and lesion progression in the vascular system (Askari et al. 
2002). 
Furthermore, wound healing investigations were carried out in Yucatan pigs as 
diabetic patients often suffer from wound healing problems. The diabetic state 
was reached by treatment with STZ. Several 1.5 x 1.5 squares were outlined on 
the dorsal skin to create wounds. Adhesive polyurethane chambers were placed 
around the wounds and served for standardized conditions during wound 
healing in a liquid environment. Diabetic pigs exhibited delayed 
reepithelialization and reduced IGF-1 levels in the wounds. This model is 
feasible for investigations of pathophysiological wound healing procedures and 
experiments of new therapies (Velander et al. 2008). 
Recently, the correlation between type 2 diabetic patients and obesity traits in 
Yorkshire pigs was investigated. Pig genes associated with fat deposition were 
analyzed. Mapping of genes associated with human type 2 diabetes mellitus 
revealed that only the TCF7L2 was related with five fat traits of the pig. 
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Functional gene candidate analyses are needed to find out more about the 
function of these genes and to establish the pig as a useful model for obesity 
and type 2 diabetes mellitus (Du et al. 2009). 
2.6.2.5 Chinese Guizhou minipig 
High-fat diet is known to induce insulin resistance and increases in triglyceride 
levels in pigs. Atherosclerotic fatty streaks were observed in rats and rabbits 
after being fed a high-sucrose diet. A high-fat/high-sucrose diet was fed to 
Chinese Guizhou minipigs to provoke both altered glucose and lipid metabolism 
as well as abnormalities in the vascular system. The diabetic phenotype of the 
pigs was characterized by reduced insulin sensitivity, glucose intolerance and a 
decrease of pancreatic ?-cells. Furthermore, pigs showed an altered lipid 
metabolism and aortic lipid accumulations. Establishment of this new animal 
model might offer the possibility to study whether dietary and diabetogenic 
factors influence the onset of atherosclerosis (Xi et al. 2004). 
In the pathophysiology of human atherosclerosis inflammatory factors like 
TNF-?, ILK-1? and ILK-6 are increased. STZ treatment induced diabetes in 
Chinese Guizhou minipigs. Fasting blood glucose levels were controlled 
regularly to initiate insulin therapy at glucose levels over 10 mmol/L. 
Measurement of inflammatory factors TNF-?, ILK-1? and ILK-6 in the aortic 
intima by Western blot and RT-PCR showed distinct increases indicating 
diabetes as a potent risk factor for atherosclerosis (Lu et al. 2007).  
2.7 GIPRdn transgenic pigs 
Although a great research effort is carried out on diabetes, the pathogenesis of 
type 2 diabetes is still not completely clarified. Pigs utilized in type 2 diabetes 
research up to now primarily served as models for cardiovascular diseases and 
dyslipidemia, phenomena associated with diabetes. As spontaneous onset of 
diabetes has not yet been reported in pigs, chemical induction of diabetes 
served as the method of choice, whereby physiological processes during 
development of type 2 diabetes mellitus are disregarded. Pigs expressing a 
dominant-negative GIPR imitate the situation of an impaired insulinotropic effect 
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of GIP observed not only in type 2 diabetic patients but also in ~50% of their 
first degree relatives (Nauck et al. 2004b). This first genetically modified pig 
model for type 2 diabetes mellitus provides the possibility to investigate the 
effects of an impaired insulinotropic action of GIP and to define its role in the 
pathogenesis of type 2 diabetes mellitus. Generation and initial physiological 
and morphological characterization of GIPRdn transgenic pigs was carried out 
previously (Renner 2008). In the following generation of and previous results on 
GIPRdn transgenic pigs are summarized. 
2.7.1 Generation of GIPRdn transgenic pigs 
The GIPR is a seven transmembrane domain heterotrimeric G-protein coupled 
receptor including three extracellular loops, three intracellular loops, an amino-
terminal extracellular domain as well as an intracellular carboxyl terminus. The 
GIPRdn differs from the endogenous GIPR by an eight amino-acid deletion 
(amino acid position 319-326/nucleotide position 955-978) and two additional 
point mutations (amino acid position 340/nucleotide position 1018-1020) 
causing and amino acid exchange from alanine to glutamate (Ala ? Glu) in the 
third intracellular loop which is known to be essential for signal transduction 
(Cypess et al. 1999; Hallbrink et al. 2001; Harmar 2001; Salapatek et al. 1999; 
Takhar et al. 1996). The binding affinity of the ligand GIP to the GIPRdn is 
almost equal compared to the endogenous GIPR. However, binding of GIP to 
the GIPRdn does not lead to any further signal transduction (Herbach et al. 
2005; Volz 1997). 
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Figure 2.2 Amino acid sequence of the human GIPRdn with marked mutations 
Targeted mutations of the GIPRdn are indicated in green (eight amino acid deletion) 
and red (amino acid shift (Ala ? Glu)) (Renner 2008). 
 
GIPRdn transgenic pigs were generated by lentiviral gene transfer. The lentiviral 
vector consisted of the cDNA of the human GIPRdn under the control of the rat 
insulin 2 (Ins 2) gene promoter (RIPII). Lentiviral vectors were injected into the 
perivitelline space of pig zygotes. Subsequently, the embryos were transferred 
laparoscopically to cycle synchronized recipient gilts. Two founder boars were 
selected to establish two transgenic lines by mating them to non-transgenic 
females. Genotyping of founder boars and their offspring was carried out by 
PCR and Southern blot analyses. GIPRdn mRNA expression was evaluated in 
isolated islets of Langerhans by RT-PCR. All transgenic animals showed 
GIPRdn expression in the islets of Langerhans, while in the islets of non-
transgenic pigs no expression was detected. 
2.7.2 Physiological characterization 
To investigate the influence of GIPRdn expression on glucose metabolism blood 
glucose as well as serum fructosamine levels were evaluated. Additionally, oral 
and intravenous glucose tolerance tests were performed in GIPRdn transgenic 
pigs and controls. GIPRdn transgenic pigs exhibited no changes in fasting blood 
glucose levels from the age of 35 days up to 210 days. Non-fasted piglets 
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before weaning also showed normal blood glucose levels compared to controls. 
Furthermore, serum fructosamine levels, an intermediate-term marker of 
glucose tolerance, did not differ between GIPRdn transgenic pigs and controls at 
any time point. 
         
0 25 50 75 100 125 150 175 200 225
0
25
50
75
100
125
150
175
200
 tg (n = 5)
 wt (n = 5)
Age (days)
G
lu
c
o
s
e
 
(m
g/
dl
)
20 41 62 84 210
0
50
100
150
200
250
300
 wt (n=5)
 tg (n=5)
Age (days)
Fr
u
c
to
s
a
m
in
e
 
(µ
m
o
l/l
)
A
B
G
lu
c
o
s
e
 
(m
g/
dl
)
Fr
u
c
to
s
a
m
in
e
 
(µ
m
o
l/l
)
 
Figure 2.3 Normal blood glucose and serum fructosamine levels in GIPRdn 
transgenic pigs (tg) compared to controls (wt)  
(A) Blood glucose levels; (B) serum fructosamine levels; n: number of animals 
investigated. Data are means ± SEM (Renner 2008). 
2  Review of the literature 34 
An oral glucose tolerance test was performed in 5-month-old GIPRdn transgenic 
pigs and controls. Serum glucose levels of GIPRdn transgenic pigs were 
markedly elevated and the AUC glucose was significantly larger by 26% 
compared to their littermate controls. Furthermore, insulin levels were 
decreased and the AUC insulin demonstrated a significant reduction of 49% in 
transgenic pigs compared to control animals. 
 
Figure 2.4 Disturbed oral glucose tolerance and reduced insulin secretion in 
5-month-old GIPRdn transgenic pigs (tg) compared to controls (wt). 
(A) Serum insulin levels and area under the insulin curve (AUC insulin); (B) serum 
glucose levels and AUC glucose; n: number of animals investigated. Data are means ± 
SEM; *: p<0.05, **: p<0.01 vs. control (Renner 2008). 
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The same collective of animals used for the OGTT was utilized to perform an 
intravenous glucose tolerance test at the age of 11 months. Significantly 
elevated blood glucose levels with a markedly increased AUC glucose by 10% 
as well as markedly reduced insulin levels and a significantly diminished AUC 
insulin by 52% furnished proof for a disturbed intravenous glucose tolerance 
going along with decreased insulin secretion in 11-month-old GIPRdn transgenic 
pigs compared to controls. 
 
Figure 2.5 Disturbed intravenous glucose tolerance and reduced insulin 
secretion in 11-month-old GIPRdn transgenic pigs (tg) compared to 
controls (wt). 
(A) Serum insulin levels and area under the insulin curve (AUC insulin); (B) serum 
glucose levels and AUC glucose; n: number of animals investigated. Data are means ± 
SEM; *: p<0.05 vs. control (Renner 2008). 
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2.7.3 Morphological characterization 
In order to clarify the underlying reasons for disturbed oral and intravenous 
glucose tolerance and reduced insulin secretion quantitative stereological 
analyses of the pancreas and quantitative islet isolation were performed in 12 to 
13-month-old GIPRdn transgenic pigs and control animals. While the left 
pancreatic lobe was used for islet isolation, the remnant pancreas served for 
quantitative stereological analyses. 
The total number of islet equivalents (islets with a diameter of ~150 µm) was 
significantly reduced in GIPRdn transgenic pigs compared to littermate controls 
(p<0.05). Islet purity and vitality were identical in both groups. 
Table 2.1 Islet isolation results using the left pancreatic lobes of non-transgenic 
(wt) and GIPRdn transgenic pigs (tg) (n=3 in each group) 
808573.85 ± 11.795.439 ± 696mean ± SEM
808589.146,240tg #3
808581.766,026tg #2
808550.664,053tg #1
85 ± 5.088.3 ± 3.331176.23 ± 18478,197 ±
6,038
mean ± SEM
80851119.6671,658wt #3
80851519.5390,260wt #2
9595889.7172,673wt #1
Islet
Vitality (%)*
Islet
Purity (%)*
Total IEQ/
g Organ
Total IEQ
PurifiedType
of Pig
 
IEQ: islet equivalent (islet of 150 µm in size); * estimation by two independent 
individuals after microscopic inspection (Renner 2008). 
 
Quantitative stereological analyses revealed that the total volume of ?-cells 
(V (?-cell, Pan)) and the volume density of ?-cells (Vv (?-cell/Pan)) in the pancreas 
were significantly reduced in GIPRdn transgenic pigs compared to controls by 
71% (Figure 2.6 A/B). The total volume of ?-cells in the islets (V (?-cell, Islet)) 
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showed a marked reduction of 75%, whereas volume density of ?-cells in the 
islets (Vv (?-cell/Islet)) was diminished by 11% (Figure 2.6 C/D). A clear difference 
between transgenic and wild-type animals was also observed in total islet 
volume (Vv (Islet, Pan)) and volume density of islets (Vv (Islet/Pan)) in the pancreas 
(Figure 2.6 E/F). A reduction of 72% for both parameters was determined. Total 
volume of isolated ?-cells and volume density of isolated ?-cells in the pancreas 
as marker for islet neogenesis did not differ between the two groups indicating 
other mechanisms (proliferation, apoptosis) being responsible for the reduction. 
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Figure 2.6 Reduced total islet and ?-cell volume in GIPRdn transgenic pigs (tg) 
compared to controls (wt). 
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(A/B) Total volume (V(islet, Pan)) and volume density (Vv(islet/Pan)) of islets in the pancreas; 
(C/D) total volume (V(?-cell, islet)) and volume density (Vv(?-cell/islet)) of ?-cells in the islets; 
(E/F) total volume (V(?-cell, Pan)) and volume density (Vv(?-cell/Pan)) of ?-cells in the 
pancreas; data are means ± SEM; n: number of animals investigated; *:p<0.05 vs. 
control (Renner 2008).  
3 Animals, Materials and Methods 
3.1 Pigs 
Pigs investigated in this study were hemizygous male and female transgenic 
and non-transgenic littermate or age-matched control animals. Stables were 
planar fixed and covered with straw. Once daily, animals were fed a commercial 
diet. Water was offered ad libitum. During all study procedures, animals were 
housed in single pens under controlled conditions. To prepare the pigs for the 
metabolic studies all experimental procedures were trained carefully prior to the 
tests. All animal experiments were carried out according to the German Animal 
Protection Law (209.1/211-2531-54/02). 
Table 3.1 Diet composition 
 
Deuka primo care  
(piglets up to 25 kg) 
Deuka porfina U  
(growing and adult pigs) 
MJ ME/kg 14.0 12.6 
Crude protein % 16.0 17.0 
Crude fat %   4.3   3.0 
Crude fiber %   5.0   6.5 
Crude ash %   4.6   5.5 
Lysin %   1.35   0.9 
Calcium %   0.65   0.85 
Phosphorus %   0.55   0.55 
Sodium %   0.2   0.25 
ME: metabolizable energy 
3.2 Materials 
3.2.1 Apparatuses 
Accu-jet® pro pipette controller  Brand, Wertheim 
Agarose gel electrophoresis chamber  MWG-Biotech, Ebersberg 
Analytical balance Sartorius, Göttingen 
AU 400 autoanalyzer  Olympus, Hamburg 
Benchtop 96 tube working rack Stratagene, La Jolla, USA 
Gel documentation system  Bio Rad, Munich 
3  Animals, Materials and Methods 40 
GeneQuant pro Amersham Bioscience, Freiburg 
Glass case for glass rack Roth, Karlsruhe 
Heating plate with magnetic stirrer IKA process equipment, Staufen 
HM 315 microtome  Microm, Walldorf 
Hybridization oven  H. Saur, Reutlingen 
LB 2111 ?-counter Berthold, Bad Wildbad 
Leitz Wetzlar Microscope  Leica Microsystems, Wetzlar 
Microwave Siemens, Munich 
MS1 Minishaker  IKA process equipment, Staufen 
Multipette® plus Eppendorf, Hamburg 
pH-meter WTW, Weilheim 
Phosphorimager Storm 860  GE Healthcare, Munich 
Power Pac 300 Bio Rad, Munich 
Precision® XceedTM Glucometer  Abbott, Wiesbaden 
Scintillation counter LS6500  Beckman, Palo Alto, USA 
Staining box according to Schiefferdecker  Roth, Karlsruhe 
Storage phosphor screen Bio Rad, Munich 
Thermomixer 5436  Eppendorf, Hamburg 
UV-Crosslinker Biometra, Göttingen 
Videoplan® image analysis system  Zeiss-Kontron, Eching 
 
Thermocycler: 
Biometra Uno Thermoblock  Biometra, Göttingen 
Biometra TProfessional Biometra, Göttingen 
Mastercycler® gradient  Eppendorf, Hamburg 
 
Centrifuges: 
Heraeus Megafuge 1.0R Heraeus, Munich 
Table centrifuge with cooling (5417R)  Eppendorf, Hamburg 
3.2.2 Consumables 
Cavafix® Certo® central venous catheter B. Braun, Melsungen 
Centrifuge tubes (15 ml, 50 ml) Falcon®, Becton Dickinson, 
 Heidelberg 
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Cover slips 24x40 mm Engelbrecht, Edermünde 
Disposable plastic pipettes Falcon®, Becton Dickinson,
 Heidlberg 
Disposable syringes (2, 5, 10, 20 ml) Codan Medical ApS, Roedby,
 Denmark 
Disposable tubes for ?-counter Sarstedt, Nümbrecht 
Hybond-N+ Nylon membrane GE Healthcare, Munich 
Microscope slides Star Frost® Engelbrecht, Edermünde 
MicroSpinTM S-300 HR Columns GE Healthcare, Munich 
Microwave Tender Cooker 2.5 Quart Nordic Ware, Minneapolis, USA 
MillexTM-GP syringe driven filter unit® Millipore, Billerica, USA 
(0.22 µm)  
Monovette® blood collection system Sarstedt, Nümbrecht 
(Serum, EDTA)  
OP-Cover (60 x 90 cm) A. Albrecht, Aulendorf 
Parafilm® M American Can Company, 
 Greenwich, USA 
PCR reaction tubes (0.2 ml) Braun, Wertheim 
Perfusor® cable (50 cm) B. Braun, Melsungen 
Precision XtraTM Plus blood glucose Abbott, Wiesbaden 
stripes 
Safe-Lock reaction tubes (1.5 ml, 2 ml) Eppendorf, Hamburg 
Skin adhesive spray A. Albrecht, Aulendorf 
Sterican® cannulas (18 G, 20 G) B. Braun, Melsungen 
3-way-Stopcock Fresenius Kabi, Bad Homburg 
Uni-Link embedding cassettes Engelbrecht, Edermünde 
Vasco® OP Protect gloves B. Braun, Melsungen 
Vascocan® indwelling venous catheter B. Braun, Melsungen 
Vicryl (2-0) suture material Ethicon, Norderstedt 
3.2.3 Chemicals 
Comment: unless otherwise noted, all chemicals were used in p.a. quality 
Acetic acid (glacial acetic acid)  Roth, Karlsruhe 
Agarose Invitrogen, Karlsruhe 
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BCIP/NBT (5-bromo-4-chloro-3-indolyl- Vector Laboratories, 
phosphate/nitroblue tetrazolium) Burlingame, USA 
Bromophenolblue Serva, Heidelberg 
Chloroform  Merck, Darmstadt 
Citric acid Merck, Darmstadt 
D-(+)-glucose Sigma-Aldrich, Deisenhofen 
3,3´ diaminobenzidine tetrahydrochloride KemEnTec, Copenhagen,
 Denmark  
Disodiumhydrogenphosphate Merck, Darmstadt 
EDTA  Sigma-Aldrich, Deisenhofen 
Eosin Roth, Karlsruhe 
Ethanol  Roth, Karlsruhe 
Ethidiumbromide (1 mg/ml)  Merck, Darmstadt 
Formaldehyde solution, 37% Sigma-Aldrich, Deisenhofen 
Fuchsin + Substrate-Chromogen Dako Cytomation, Hamburg 
Glucose 50% solution B. Braun, Melsungen 
Glycerine Roth, Karlsruhe 
Hydrochloric acid (1 N) Merck, Darmstadt 
Hydrochloric acid (25%) Merck, Darmstadt 
Hydrogen peroxide (35%) Roth, Karlsruhe 
Isoamylalcohol (3-methyl-1-butanol) Roth, Karlsruhe 
Kalium chloride  Merck, Darmstadt 
Kaliumdihydrogenphosphate  Merck, Darmstadt 
Magnesium chloride (25 mM) Qiagen, Hilden 
Mayer`s Hemalaun Applichem, Germany 
0.9% NaCl solution B. Braun, Melsungen 
Nuclear Fast Red Roth, Karlsruhe 
Phenol Roth, Karlsruhe 
2-Propanol  Merck, Darmstadt 
Sodiumacetate-trihydrate Merck, Darmstadt 
Sodium chloride Merck, Darmstadt  
Sodiumdodecylsulphate Merck, Darmstadt 
Sodium hydroxide (2 N) Roth, Karlsruhe  
Spermidine  Sigma, Deisenhofen 
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Tris-(hydroxymethyl)-aminomethane Roth, Karlsruhe 
Vectashield Mounting Medium with DAPI Vector Laboratories, Burlingame,
 USA 
Xylene SAV LP, Flintsbach a. Inn 
3.2.4 Antibodies, drugs, enzymes and other reagents 
3.2.4.1 Antibodies 
3.2.4.1.1 Primary antibodies 
Monoclonal mouse anti-human Ki67  Dako Cytomation, Hamburg 
Polyclonal guinea pig anti-porcine insulin Dako Cytomation, Hamburg 
Polyclonal rabbit anti-human cleaved  Cell Signaling, Danvers, 
USA 
caspase-3 
Polyclonal rabbit anti-human GIPR  Acris, Herford 
Polyclonal rabbit anti-human GLP-1R  Acris, Herford 
Polyclonal rabbit anti-human glucagon  Dako Cytomation, Hamburg 
Polyclonal rabbit anti-human somatostatin  Dako Cytomation, Hamburg 
Polyclonal rabbit anti-human pancreatic  Dako Cytomation, Hamburg 
polypeptide 
3.2.4.1.2 Secondary antibodies 
AP-conjugated donkey anti-rabbit IgG  Dianova, Hamburg 
AP-conjugated goat anti-guinea pig IgG Southern Biotech, Birmingham, 
 USA 
Biotinylated goat anti-rabbit IgG Vector Laboratories, Burlingame,
 USA 
Biotinylated goat anti-mouse IgG  Dako Cytomation, Hamburg 
Cy 3-conjugated donkey anti-guinea pig IgG Jackson Immunoresearch 
 Laboratories, Baltimore, USA 
FITC-conjugated donkey anti-mouse IgG Jackson Immunoresearch 
 Laboratories, Baltimore, USA 
HRP-conjugated donkey anti-guinea pig IgG Dianova, Hamburg 
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HRP-conjugated pig anti-rabbit IgG  Dako Cytomation, Hamburg 
HRP-conjugated rabbit anti-guinea pig IgG Dako Cytomation, Hamburg 
3.2.4.2 Drugs 
Azaperon (Stresnil®) Janssen Pharmaceutica,
 Beerse, Belgium 
Cefquinom (Cobactan®) Intervet, Unterschleißheim 
Heparin-Sodium (25.000 IE/5 ml) B. Braun, Melsungen 
Ketamine hydrochloride (Ursotamin®) Serumwerk Bernburg, Bernburg 
Metamizol-Sodium (Vetalgin®) Intervet, Unterschleißheim 
Meloxicam (Metacam®) Boehringer Ingelheim, Ingelheim 
Xylazine (Xylazin 2%) WDT, Garbsen 
3.2.4.3 Enzymes 
Herculase® enhanced DNA Polymerase Stratagene, La Jolla, USA 
Proteinase K (20 mg/ml)  Roche, Mannheim 
Restriction enzymes and -buffers MBI Fermentas, St. Leon Roth 
Ribonuclease A (RNase-A) (0.2 U/µl) Roche, Mannheim 
Taq Polymerase (5 U/ml) Agrobiogen, Hilgerstshausen 
3.2.4.4 Other reagents 
?-[32P]-dCTP GE Healthcare, Munich 
Blood & Cell Culture DNA Midi Kit Qiagen, Hilden 
dNTPs (dATP, dCTP, dGTP, dTTP)  MBI Fermentas, St. Leon Roth 
5 x first strand buffer Invitrogen, Karlsruhe 
Gel blotting paper (GB002) (Whatman-paper) Schleicher & Schüll, Dassel 
Goat serum MP Biomedicals, Illkirch, France 
Horse serum MP Biomedicals, Illkirch, France 
Jetquick Gel extraction Spin Kit Genomed, Löhne 
10 x PCR buffer Agrobiogen, Hilgertshausen 
Porcine Insulin RIA Kit Millipore, Billerica, USA 
Porcine serum MP Biomedicals, Illkirch, France 
Porcine serum albumin Sigma-Aldrich, Taufkirchen 
Rabbit serum MP Biomedicals, Illkirch, France 
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Rapid-Hyb buffer  GE Healthcare, Munich 
Roti® Histokitt II Roth, Karlsruhe 
Synthetic porcine GIP Bachem, Weil am Rhein 
Synthetic Exendin-4 Bachem, Weil am Rhein 
Vectastain Elite ABC Kit Vector Laboratories, Burlingam,
 USA 
Vet-Sept® solution (10%) A. Albrecht, Aulendorf 
3.2.5 Buffers, media and solutions 
Comment: unless otherwise noted, in a Millipore machine (EASYpure® II, pure 
Aqua, Schnaitsee) de-ionized water was used as solvent which is termed aqua 
bidest. 
3.2.5.1 Chloroform-isoamylalcohol (CiA) 
96 ml chloroform 
4 ml isoamylalcohol 
Storage at 4°C protected from light 
3.2.5.2 Citrate buffer (pH 6.0) 
4.2 g citrate monohydrate 
ad 2000 ml aqua bidest. 
3.2.5.3 Citrate buffer for cleaved caspase-3 IHC (pH 6.0) 
Stock solution A: 19.2 g citric acid in 1000 ml aqua bidest. 
Stock solution B: 29.4 g trisodium citrate-dihydrate in 1000 ml aqua bidest. 
working solution: 27 ml solution A + 123 ml solution B + 1.5 ml Tween 20  
 ad 1500 ml aqua bidest. 
3.2.5.4 Phenol-chloroform-isoamylalcohol (PCiA) 
25 ml  phenol 
25 ml  CiA 
Storage at 4°C protected from light 
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3.2.5.5 dNTP-mix 
100 µl of each dNTP (2M) 
ad 4.6 ml aqua bidest. 
Aliquoted; storage at -20°C 
3.2.5.6 PBS buffer 
137 mM NaCl 
10 mM Na2HPO4 
2.7 mM KCl 
2 mM KH2PO4 
3.2.5.7 Proteinase-K solution 
20 mg Proteinase K 
1 ml  Aqua bidest. 
Aliquoted; storage at -20°C 
3.2.5.8 TBS buffer (10x) (pH7.6) 
90 g NaCl 
60.5 g Tris 
ad 1000 ml aqua bidest. 
3.2.5.9 TE buffer 
10 mM  Tris/HCl (pH 8.0) 
1 mM  EDTA (pH 8.0) 
3.2.5.10 Buffers for agarose gels 
3.2.5.10.1 TAE buffer (50x) 
242 g Tris (2 M) 
57.1 ml glacial acetic acid 
100 ml  EDTA 0.5 M (pH 8.0) 
ad 1000 ml aqua bidest. 
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3.2.5.10.2 TAE running buffer (1x) 
20 ml 50 x TAE buffer 
ad 1000 ml  aqua bidest. 
3.2.5.10.3 Loading buffer for DNA (6x) 
3 ml glycerine 
7 ml aqua bidest. 
1 point of a 
 spatula bromophenolblue 
Aliquoted; storage at 4°C 
3.2.5.11 Solutions for Southern blot 
3.2.5.11.1 Denaturation solution 
0.5 M NaOH 
1.5 M NaCl 
3.2.5.11.2 Neutralization solution 
1 M  NaCl 
0.5 M Tris/HCl (pH 8.0) 
3.2.5.11.3 SSC buffer (20x) (pH 7.0) 
3 M  NaCl 
0.3 M  Sodiumacetate-trihydrate  
3.2.5.11.4 Washing solution I 
2 x  SSC 
0.1% SDS 
3.2.5.11.5 Washing solution II 
1 x SSC 
0.1% SDS 
3.2.6 Oligonucleotides 
RIP2 (sense): 5’-TAGTCGACCCCCAACCACTCCAAGTGGAG-3’ 
RIP2 (antisense): 5’-CAGCCCTAACTCTAGACTCGAGGGATCCTA-3’ 
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Actin (sense): 5`-GCCAACCGTGAGAAGATGAC-3` 
Actin (antisense): 5`-GGTCTCGAACATGATCTGG-3` 
3.2.7 DNA molecular weight markers 
Gene RulerTM (1 kb DNA Ladder)  MBI Fermentas, St. Leon Roth 
Lambda DNA/EcoRI + HindIII-Marker MBI Fermentas, St. Leon Roth 
pUC Mix Marker 8  MBI Fermentas, St. Leon Roth 
3.3 Methods 
3.3.1 Identification of GIPRdn transgenic pigs 
The identification of GIPRdn transgenic pigs was accomplished by PCR as well 
as by Southern blot analysis. Southern blot analysis furnished proof not only for 
discrimination of transgenic pigs from wild-type animals, but also for 
determination of the number of integration sites of the transgene. 
3.3.1.1 Polymerase chain reaction (PCR)  
3.3.1.1.1 DNA isolation from ear punches 
Ear punches were obtained from 2-day-old piglets and stored at –20°C until 
further processing. Tissue digestion from ear samples (0.5 cm2) was performed 
using 30 µl Proteinase K (20 mg/ml) and 400 µl lysis buffer as follows: 
 
Composition of 5 ml lysis buffer: 
500 µl 160 mM saccharose 
800 µl 80 mM EDTA pH 8.0 
500 µl 100 mM Tris/HCl pH 8.0 
125 µl 0.5% SDS 
3.175 ml aqua bidest. 
 
Tissue samples and Proteinase K were added to the lysis buffer, mixed well and 
incubated overnight at 60°C. The next day, undigested components were 
separated by centrifugation (5 min, 13000 x g) and the supernatant was 
transferred into a new sterile reaction tube. Sodium chloride (400 µl, 4.5 M) and 
phenol-chloroform-isoamylalcohol (PCiA; 300 µl) were added and samples were 
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pivoted about 10 minutes for a thorough through-mixing of the components. To 
achieve phase separation samples were centrifuged (5 min, 13000 x g). The 
lower two phases containing lipids, RNA, carbohydrates and proteins were left 
in the reaction tube while the upper aqueous phase containing DNA was 
pipetted into a new sterile reaction tube. Then samples were washed with PCiA, 
pivoted and centrifuged at least three times until no more residua were visible 
between the lower and the upper phase. Afterwards the addition of 550 µl 
(0.7 x volume of the aqueous phase containing DNA) isopropanol induced DNA 
precipitation. The precipitated DNA could be transferred into a reaction tube 
containing 70% ethanol. This step was repeated once and DNA was kept in 
ethanol for several hours. Then ethanol was discarded and DNA was air-dried 
at room temperature for 6 minutes and resuspended with 55 µl Tris/HCl solution 
(10 mM). To ensure complete DNA resolution, samples were stored at 4°C 
overnight. The next day, DNA concentration was measured at 260 nm using a 
GeneQuant pro spectrophotometer (Amersham Bioscience, Freiburg). For PCR 
use, DNA concentration was adjusted to 100 ng/µl. 
3.3.1.1.2 PCR conditions 
Transgene-specific primers were used to identify GIPRdn transgenic pigs: 
RIP2 (sense): 5’-TAGTCGACCCCCAACCACTCCAAGTGGAG-3’ 
RIP2 (antisense): 5’-CAGCCCTAACTCTAGACTCGAGGGATCCTA-3’ 
 
To verify integrity of the genomic DNA a so-called house-keeping gene was 
amplified additionally. In this case ?-actin was used which is expressed 
independently of cell type, cell cycle or external influences. 
The following ?-actin specific primers were used: 
?-actin (sense):  5`-GCCAACCGTGAGAAGATGAC-3` 
?-actin (antisense): 5`-GGTCTCGAACATGATCTGG-3` 
The PCR reactions with a total volume of 25 µl were prepared on ice in 0.2 ml 
reaction tubes as follows: 
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Table 3.2 Reaction batch for RIP2-hGIPRdn/?-actin PCR 
RIP2-hGIPRdn/?-actin 
10 x PCR buffer 2.5 µl 
MgCl2 (25 mM) 1.5 µl 
dNTPs (2 mM) 2.5 µl 
Sense Primer (25 µM) 0.5 µl 
Antisense Primer (25 µM) 0.5 µl 
Taq DNA Polymerase (5 U/µl) 0.2 µl 
Aqua bidest. 16.3 µl 
Template (100 ng/µl) 1 µl 
Total volume 25 µl 
 
 
PCR conditions are listed below: 
Table 3.3 Reaction conditions RIP2-hGIPRdn/?-actin PCR 
 RIP2-hGIPRdn/?-actin 
Denaturation 95°C    2 min  
Denaturation 95°C   30 s  
Annealing 60°C   30 s 31 x 
Elongation 72°C   1 min  
Final elongation 72°C 10 min  
 
3.3.1.1.3 Agarose gel electrophoresis 
Agarose gel electrophoresis served as a method for separating DNA strands 
according to their size. Thereto a 2% TAE-agarose solution was prepared. After 
boiling up the mixture in a microwave, ethidiumbromide (0 5 µg/ml) was added. 
Due to intercalation of the dye ethidiumbromide between the bases of nucleic 
acids DNA can be visualized and documented under UV-light. When the gel 
was cured running buffer was dumped into the chamber. The PCR products and 
a DNA molecular weight standard were loaded into the gel slots after addition of 
application of a 6 x loading dye to monitor the electrophoresis progress.  
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3.3.1.2 Southern Blot 
3.3.1.2.1 Genomic DNA islolation from EDTA blood 
For Southern blot analysis, genomic DNA extracted from EDTA blood (5 ml) 
using the Blood and Cell Culture DNA Midi kit® (Qiagen, Hilden, Germany) 
according to the manufacturer`s instructions was applied. 
3.3.1.2.2 Restriction digest 
Genomic DNA strands were cut into smaller fragments using a restriction 
enzyme. Besides of the DNA (8 µg) the reaction batch with a total volume of 
30 µl contained 30 U of the restriction enzyme ApaI, its appropriate buffer as 
well as Spermidine (0.1 M). After an overnight digestion at 37°C another 10 U of 
the restriction enzyme were added to each sample followed by an incubation 
step of one hour. Prior to the use of the samples for gel electrophoresis 6 x 
loading dye was pipetted to each sample for a better monitoring of the gel 
electrophoresis process.  
3.3.1.2.3 Gel electrophoresis and transfer of genomic DNA 
DNA fragments were loaded into the gel slots of a 0.9% TAE agarose gel to 
separate them by size. A 1 kb ladder served as DNA molecular weight 
standard. When the samples, visualized by the bromophenol blue containing 6 x 
loading dye, reached the end of the gel, the gel electrophoresis could be 
stopped. The electrophoresis result was documented under UV-light using a gel 
documentation system. Prior to the blotting process, the gel was pivoted in 
0.25 M hydrochloric acid for about 20 minutes depending on the color shift of 
the blue bands to yellow. After washing the gel for several minutes with aqua 
bidest. it was gently shook in denaturation solution until the color of the bands 
turned back to blue (around 45 minutes). Subsequently, the DNA was blotted 
onto a positive loaded nitrocellulose membrane by capillary transfer. Thereto 
the gel was placed upside-down on a plastic surface. Two layers of Whatman 
paper followed by multiple layers of absorbent paper were placed on the gel 
and weighed down by a weight of ca. 800 g to improve capillary transfer. The 
transfer was carried out overnight for 18-24 hours. The next day, the membrane 
was pivoted in neutralization solution for 5 minutes followed by 15 minutes of 
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air-drying. Cross linking of the transferred DNA with the membrane was 
accomplished under UV-light (120 J/cm2) before the membrane was stored at 
room temperature until further processing. 
3.3.1.2.4 Probe establishment 
The primers RIP2-sense and RIP2-antisense (see 3.3.1.1.2) were used to 
create a 720-bp probe. Plasmid DNA containing the RIP2-hGIPRdn construct in 
a concentration of 7 ng/µl served as template for the PCR. 
Table 3.4 Reaction batch probe Southern blot PCR 
 Probe Southern blot 
10 x Herculase buffer 10 µl 
dNTPs (10 mM) 2 µl 
Sense primer (100 µM) 0.5 µl 
Antisense primer (100 µM) 0.5 µl 
Aqua bidest. 83.5 µl 
Herculase Taq Polymerase 0.5 µl 
Template 3 µl 
Total volume 100 µl 
 
Table 3.5 PCR conditions probe Southern blot PCR 
 Probe Southern blot  
Denaturation 94°C 4 min  
Denaturation 94°C 1 min  
Annealing 62°C 1 min 34 x 
Elongation 72°C 3.03 min  
Final elongation 72°C 10 min  
 
The amplified PCR product was separated in a 1% TAE-agarose gel after 
addition of 20 µl 6x loading dye. Then, the designated band was excised using 
a scalpel blade and DNA was extracted from the gel using the Jetquick Gel 
Extraction Spin Kit according to the manufacturer’s instructions. Subsequently, 
2 µl of each extracted DNA sample as well as of the molecular weight standard 
Lambda/HindIII + EcoRI were loaded on a 1% TAE agarose gel. DNA 
concentration of the amplificates was estimated by comparison of the respective 
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band intensity with the intensity of the bands of the concentration standard 
Lambda/HindIII + EcoRI. 
3.3.1.2.5 Radioactive labeling of the probe 
The Rediprime II Random Prime Labeling System® was used to label 50-70 ng 
of the probe radioactively with 50 µCi ?-[32P]-dCTP (GE Healthcare) according 
to the manufacturer’s instructions. Random priming is a method to label DNA. 
Oligonucleotides of accidential sequence are added to denatured single strand 
DNA for hybridization. The so called Klenow enzyme, a fragment of the DNA 
Polymerase I of E. coli, synthesizes the opposite strand using the 
oligonucleotides as primers. DNA is labeled by integration of radioactive 
nucleotides. A MicroSpinTM S-300 HR column was used for removing all not 
incorporated nucleotides. Nuclear radiation per minute (cpm: counts per minute) 
was measured by a scintillation counter using 5 µl of a 1:100 dilution of the 
labeled probe. To calculate the cpm value per µl of the labeled probe the 
following formula, where Cerenkov is a correction factor for the calculation 
without scintillation liquid, was utilized: 
cpm/µl = cpm * 20 (dilution) * 1.55 (Cerenkov) 
3.3.1.2.6 Hybridization, washing and signal detection 
Prehybridization of the nylon membrane preceded the hybridization step. 
Therefore the nylon membrane was incubated in Rapid-Hyb buffer® for two 
hours at 65°C in a hybridization oven. For hybridization, the labeled probe was 
used in a concentration of 2 x 106 cpm per µl Rapid-Hyb buffer®. After 
denaturation of the adequate amount of probe for five minutes at 95°C and 
chilling on ice, the sample was added to the prehybridization solution and 
incubated overnight at 65°C. The next day, nonspecific bound radioactivity was 
removed by three washing steps: 1 x washing solution I for 20 minutes (RT); 
2 x washing solution II for 20 minutes (65°C). Blots were exposed in a 
Phosphor-Imager cassette and visualized with a Phosphor-Imager (Storm 860). 
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3.3.2 Physiological characterization of GIPRdn transgenic pigs 
3.3.2.1 Surgical implantation of central venous catheters 
For accomplishment of the glucose tolerance tests and GIP/Exendin-4 
stimulation tests, two central venous catheters (Cavafix® Certo®, B.Braun) were 
surgically inserted into the external jugular vein under general anesthesia using 
a modified method of Moritz et al. (1989). After an intramuscular injection of 
2 ml per 10 kg body weight (BW) Ketamin (Ursotamin®, Serumwerk Bernburg) 
and 0.5 ml per 10 kg BW Azaperon (Stresnil®, Janssen Pharmaceutica, 
Belgium) pigs could be prepared for surgery. The hair was extensively shaved 
around the neck and an indwelling catheter was placed into one of the ear 
veins. Surgical tolerance was reached and general anesthesia was maintained 
by an intravenous injection of Ketamin (Ursotamin®, Serumwerk Bernburg; 
dosage: 2 ml per 10 kg BW) and Xylazine (Xylazin®, 2%, WDT; dosage: 0.5 ml 
per 10 kg BW) as required. Metamizol (1 ml per 10 kg BW, Vetalgin®, Intervet) 
and Meloxicam (2 ml per 100 kg BW, Metacam®, Boehringer Ingelheim) were 
given intramuscularly for peri- and post-surgical analgesia. During surgery the 
inter digital reflex, nasal septum reflex and breathing pattern were controlled 
regularly. Following aseptic preparation of the surgical field a skin incision, five 
centimeters in length, was made followed by the exposure of the external 
jugular vein (Figure 3.1 A). Proximal and distal of the exposed vein a holding 
suture was placed to facilitate preparation of the intended site for vein 
cannulation (Figure 3.1 B). A venotomy was made and the catheters were 
inserted 10 to 15 cm into the vein depending on pig size (Figure 3.1 C). The 
objective was to position the catheters near the heart base (Figure 3.2). A 
proximal ligature was placed to stop blood reflux while a distal ligature was 
needed to fix the catheters (Figure 3.1 D). The incision was closed in two 
layers. External fixation of the catheters was carried out by a single suture to 
the skin (Figure 3.1 E). Further, the catheters were covered with sterile gauze 
and adhesive tape up to the withers level where they were coiled in a pouch to 
provide easy access (Figure 3.1F). An antibiotic (Cobactan® 2.5%, Intervet) was 
administered for three days (0.5 ml/10 kg BW) after catheter placement. The 
catheters were flushed with 250 IU Heparin/ml 0.9% isotonic NaCl solution 
(Heparin-Natrium, B. Braun, 0.9% NaCl, B. Braun) once daily. At the start of the 
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study period, all animals had fully recovered from the surgical procedure as 
evaluated by normal behavior and food intake. 
A
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Figure 3.1 Placement of two central venous catheters:  
(A) Exposition of the external jugular vein; (B) vein advanced by a proximal and distal 
holding suture; (C) placement of the first central venous catheter following venotomy; 
(D) placement of the second central venous catheter and distal fixation; (E) skin suture 
and external fixation of the central venous catheter; (F) pouch for easy access covered 
with adhesive tape. 
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Figure 3.2 Latero-lateral thoracic radiograph for determination of catheter 
placement (arrow marks the end of the catheter near the heart 
base) 
3.3.2.2 Oral glucose tolerance test (OGTT) 
The OGTT was performed in 11-week-old non-restrained, freely moving 
animals. After an 18-h overnight fast, animals were fed 2 g glucose/kg body 
weight (BW) mixed with 50 g commercial pig fodder (Deuka primo care; Deuka, 
Düsseldorf, Germany). The meal was eaten from a bowl under supervision. 
Blood samples were obtained from the jugular vein catheter at -10, 0, 15, 30, 
45, 60, 90 and 120 minutes relative to the glucose load. Serum glucose levels 
were determined using an AU 400 autoanalyzer (Olympus, Hamburg, Germany) 
while serum insulin levels were measured in duplicate using a porcine insulin 
radioimmunoassay (RIA) kit (Millipore, Billerica, USA) as described in 3.3.2.6. 
3.3.2.3 Intavenous glucose tolerance test (IVGTT) 
The IVGTT was performed in 11-week-old and 5-month-old pigs (22.5 ± 1.5 
weeks). After an 18-h overnight fast, a bolus injection of concentrated 50% 
glucose solution (0.5 g glucose/kg BW) was administered through one marked 
central venous catheter. Blood was collected at -10, 0, 1, 3, 5, 10, 20, 30, 40, 60 
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and 90 minutes relative to the glucose load in 11-week-old pigs and at -10, 0, 1, 
3, 5, 7, 10, 15, 20, 30, 40, 50, 60 and 90 minutes relative to the glucose load in 
5-month-old pigs. For blood sampling the second catheter was used to avoid a 
contamination with the applied glucose. Serum glucose and serum insulin levels 
were determined as described above (see 3.3.2.2). 
3.3.2.4 GIP/Exendin-4 concentration test 
To determine the amount of GIP or Exendin-4 administrated in combination with 
glucose leading to a distinct higher insulin secretion compared to glucose 
administration only a GIP/Exendin-4 concentration test was performed in 11-
week-old non-transgenic pigs. Three different concentrations of synthetic 
porcine GIP (40, 80 or 160 pmol/kg BW; Bachem, Weil am Rhein, Germany) 
and synthetic Exendin-4 (20, 40 and 60 pmol/kg BW; Bachem) were tested. 
Animals were studied on three occasions separated by at least 24 hours. After 
an 18-h fasting period a bolus of concentrated 50% glucose solution (0.5 g 
glucose/kg BW) was administered intravenously through one marked central 
venous catheter. Immediately after glucose administration, synthetic porcine 
GIP (40, 80 or 160 pmol/kg BW) or synthetic Exendin-4 (20, 40 and 60 pmol/kg 
BW) mixed with 1% of porcine serum albumin (Sigma-Aldrich, Taufkirchen, 
Germany) was applied intravenously. Blood samples were collected at -10, 0, 1, 
3, 5, 7, 10, 15, 20, 30, 40, 50 and 60 minutes relative to the glucose load 
through the second catheter. Serum glucose levels and serum insulin levels 
were measured as described above (see 3.3.2.2). 
3.3.2.5 GIP/Exendin-4 stimulation test 
The GIP/Exendin-4 stimulation test was performed in 11-week-old GIPRdn 
transgenic and control animals. Following an 18-h fasting period, 0.5 g 
glucose/kg BW were administered intravenously as a bolus of concentrated 
50% glucose solution through the central venous catheter. Immediately after 
glucose administration, 80 pmol/kg BW of synthetic porcine GIP (Bachem) or 
40 pmol/kg BW of synthetic Exendin-4 (Bachem) mixed with 1% of porcine 
serum albumin (Sigma-Aldrich) were administered intravenously. Blood 
samples were collected at -10, 0, 1, 3, 5, 7, 10, 15, 20, 30, 40, 50 and 60 
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minutes relative to the glucose load. Serum glucose levels and serum insulin 
levels were measured as described above (see 3.3.2.2). 
3.3.2.6 Determination of serum insulin levels by radioimmunoassay (RIA) 
A porcine insulin RIA kit (Millipore, Billerica, USA) was used to analyze serum 
insulin levels during an OGTT, IVGTT and GIP/Exendin-4 concentration and 
stimulation test according to the manufacturer’s instructions. In this RIA, a fixed 
concentration of labeled tracer antigen (125I labeled insulin) was incubated with 
a constant dilution of anti-porcine insulin antiserum such that the concentration 
of antigen binding sites on the antibody was limited. The addition of unlabeled 
insulin in the form of a serum sample resulted in competition between labeled 
tracer and unlabeled insulin for the limited and constant number of binding sites 
on the antibody. Thus, the amount of tracer bound to antibody decreased as the 
concentration of unlabeled antigen increased. This was measured after 
separating antibody-bound from free tracer and counting the antibody-bound 
fraction in a ?-counter. A calibration or standard curve was set up with 
increasing concentrations of standard unlabeled insulin and from this curve the 
amount of insulin in unknown samples was calculated. All samples were 
measured in duplicate. Only duplicates with a coefficient of variance (CV) less 
than 10% were accepted. 
Table 3.6 Assay flow chart of the RIA 
Step 1 Add assay buffer 
Step 2-3 Add insulin standard/ QC or sample of unknown IC 
Step 4 Add 125I-Insulin Tracer 
Step 5 Add porcine insulin antibody 
DAY 1 
Step 6 Vortex, cover and incubate 20-24 h at 4°C 
Step 7 Add precipitating reagent 
Step 8 Vortex and incubate 20 min at 4°C 
DAY 2 
Step 9-11 Centrifuge at 4°C for 20 min, decant and count pellets 
using a ?-counter 
QC: quality control, IC: insulin concentration 
3  Animals, Materials and Methods 59 
3.3.3 Morphological characterization of GIPRdn transgenic pigs 
3.3.3.1 Pancreas preparation  
Immediately after slaughter the whole pancreas was rapidly prepared. To avoid 
damage of pancreatic tissue due to autolysis the organ was immediately stored 
on ice for final dissection of fat, blood vessels and connective tissue. Then the 
pancreas was weighed. Prefixation in formalin preceded further manipulations 
of the organ to avoid damaging of the tissue. Subsequently, the pancreas was 
cut into 1 cm thick slices. To perform an area-weighted subsampling of 
pancreas tissue for quantitative stereological analyses slices were turned to 
their left side and covered by a 1 cm2 point-counting grid. This procedure 
represented volume-weighted subsampling as pancreas slices were of the 
same thickness. All points hitting pancreas tissue were counted. One tenth of 
the total number of points hitting pancreas yielded the total sample number. A 
random number (X) between one and the quotient of total hitting points and total 
sample number (Y) were defined for determination of the sites of sample 
collection. Pieces with a volume of 0.5 cm3 were taken at the sites X+Y; X+2*Y; 
X+3*Y … Selected samples were placed in an embedding cassette with the 
right cut surface facing downwards, fixed in 4% neutral buffered formalin at 
room temperature overnight, routinely processed and embedded in paraffin. A 
series of sections of approximately 4 µm thickness was cut with a HM 315 
microtome (Microm) from half of the paraffin embedded samples. Sections were 
mounted on 3-aminopropyltriethoxy-silane-treated glass slides for 
immunohistochemistry. For determination of pancreas area, all insulin stained 
sections as well as a sheet of millimeter paper for calibration purposes were 
photocopied at a final magnification of 400% on a commercial photocopier 
showing the complete cut surface of all pancreas slices. 
3.3.4 Quantitative stereological analyses 
Morphometric evaluation was carried out on a Videoplan® image analysis 
system (Zeiss-Kontron, Eching, Germany) attached to a microscope by a color 
video camera. Photocopies of the cut surfaces of pancreas samples served for 
planimetric determination of the cross-sectional area of the pancreas. 
Planimetric measurements of ?-, ?-, ?- and pp-cell areas were carried out on 
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immunohistochemically stained sections by circling their outlines with a cursor 
on a digitizing tablet of the image analysis system. A color monitor displayed 
images of stained cells at an 850 x final magnification. Quantitative stereological 
analyses were performed in 11-week-old and 5-month-old animals using the 
whole pancreas and in young adult (1-1.4-year-old) animals using the pancreas 
without the left pancreatic lobe, which was used for islet isolation in former 
studies. The volume of the pancreas (V (Pan)) was calculated by the quotient of 
the pancreas weight and the specific weight of the pig pancreas (1.07 g/cm3). 
The specific weight was determined by the submersion method (Scherle 1970). 
Several morphometric parameters were defined. The volume densities of ?-, ?-, 
?- and pp-cells in the islets (Vv (?-cell/Islet), Vv (?-cell/Islet), Vv (?-cell/Islet), Vv (pp-cell/Islet)) 
were obtained by dividing the total area of ?-, ?-, ?- and pp-cells in the islets by 
the total islet area (A (Islet/Pan)). The total volumes of ?-, ?-, ?- and pp-cells in the 
islets (V (?-cell, Islet), V (?-cell, Islet), V (?-cell, Islet), V (pp-cell, Islet)) were determined as a 
product of the volume densities of ?-, ?-, ?- and pp-cells (Vv (?-cell/Islet), 
Vv (?-cell/Islet), Vv (?-cell/Islet), Vv (pp-cell/Islet)) and V (Islet, Pan). V (Islet, Pan) was calculated 
as the product of Vv (Islet/Pan) and V (Pan). Volume densities of the various 
endocrine cell types in the islets refer to the volume fraction of the particular 
endocrine cell type in relation to the cumulative volume of the various endocrine 
islet cells, thus excluding capillaries and other interstitial tissues in the islets. 
Further, the product of the volume density of ?-cells in the pancreas (referring to 
?-cells in the islets and isolated ?-cells in the pancreas; Vv (?-cell, Pan)) and V (Pan) 
resulted in the total volume of ?-cells in the pancreas (V (?-cell, Pan)). To obtain the 
volume density of isolated ?-cells (insulin positive single cells and small clusters 
of insulin positive cells not belonging to established islets) in the pancreas, the 
total profile areas of isolated ?-cells were divided by A (Pan). The total volume of 
isolated ?-cells in the pancreas (V (iso?-cell, Pan)), a parameter indicative of islet 
neogenesis, was determined as the product of Vv (iso?-cell, Pan) and V (Pan). 
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Table 3.7 Parameters determined by quantitative stereological analyses 
A (Pan) = determined planimetrically by circling cut surfaces of photocopied 
    pancreas samples 
A (cell) = determined planimetrically by circling immunohistochemically stained 
    cells 
V (Pan) = pancreas weight / specific weight of the pig pancreas (1.07 g/cm3) 
Vv (cell/Pan) = A (cell) / A (Pan) 
V (cell, Pan) = Vv (cell/Pan) x V (Pan) 
Vv (cell/Islet) = A (cell) / A (Islet) 
V (cell, Islet) = Vv (cell/Islet) x V (Islet, Pan) 
A: area; Vv: volume density; V: total volume; cell: refers to either ?-, ?-, δ- or pp-cells 
3.3.4.1 Immunohistochemical procedures 
The indirect immunoperoxidase technique was used for the detection of insulin, 
glucagon, somatostatin and pancreatic polypeptide while the indirect alkaline 
phosphatase (AP) method was used for the detection of insulin and cleaved 
caspase-3. For immunostaining of GIPR and GLP-1R the horseradish 
peroxidase (HRP) -labeled streptavidin-biotin (LAB) method was used while the 
avidin-biotin-complex (ABC) technique was used for the detection of Ki67. For 
all immunohistochemical stainings, sections were deparaffinized in xylene for 15 
minutes, rehydrated in a descending alcohol series and washed in distilled 
water. Endogenous peroxidase activity was blocked by incubation of the 
sections using 1% hydrogen peroxide in TBS buffer (pH 7.4) for 15 minutes. 
After each incubation step, sections were washed in TBS buffer for 10 minutes, 
except after non-immune serum incubation. Following visualization of the 
immunoreactivity and counterstaining, sections were washed in distilled water, 
dehydrated in an ascending alcohol series, cleared in xylene and mounted 
under coverslips using Roti® Histokitt II (Roth, Karlsruhe). Antibodies, 
pretreatment, chromogens and counterstainings used for the different 
immunohistochemistries are listed in Table 3.8. All immunohistochemistries 
were performed in 11-week-old, 5-month-old and 1-1.4-year-old GIPRdn 
transgenic pigs and control animals. 
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Immunohistochemistry for GIPR and GLP-1R was carried out by Prof. Werner 
Amselgruber and coworkers, Institute of Anatomy and Physiology, Universtiy of 
Stuttgart-Hohenheim, Germany. 
3.3.4.2 Hemalaun/Eosin staining 
Hemalaun/Eosin staining was accomplished following immunohistochemistry for 
the proliferation marker Ki67(see Table 3.8) to allow identification of the islets of 
Langerhans within pancreas tissue. Sections were washed in tap water for five 
minutes after visualizing of the immunoreactivity for Ki67 using 3,3`-
diaminobenzidine tetrahydrochloride dehydrate. For nuclear staining slides were 
incubated in Meyer`s Hemalaun solution for four minutes. Subsequently, 
sections were washed with tap water for five minutes and dipped four to five 
times in eosin solution. Sections were cleared in distilled water, dehydrated in 
an ascending alcohol series, cleared in xylene and mounted under coverslips 
using Roti® Histokitt II (Roth, Karlsruhe). 
3.3.4.3 Immunofluorescence 
The indirect immunfluorescence method was used for a double 
immunohistochemical staining for the proliferation marker Ki67 and insulin. The 
sections were deparaffinized in xylene for 15 minutes, rehydrated in a 
descending alcohol series and washed in distilled water. Microwave heating for 
20 minutes in citrate buffer (pH 6.0) was accomplished for antigen demasking. 
Following a cool-down period of 20 minutes endogenous peroxidase activity 
was blocked by incubation of the sections using 1% hydrogen peroxide in TBS 
buffer (pH 7.4) for 15 minutes. After washing the sections for 10 minutes in TBS 
they were incubated with normal donkey serum (dilution 1:10) for 30 minutes to 
reduce non-specific binding. The primary antibody for Ki67 (monoclonal mouse 
anti-human Ki67; dilution 1:8) and insulin (polyclonal guinea pig anti-porcine 
insulin; dilution 1:1000) were mixed with the appropriate amount of TBS buffer, 
applied on slides and incubated for 60 minutes. Then sections were washed 
again in TBS buffer for 10 minutes and thereafter incubated for one hour 
protected from light with a mixture of the secondary antibodies for Ki67 (FITC-
conjugated donkey anti-mouse IgG; dilution 1:500) and insulin (Cy 3-conjugated 
donkey anti-guinea pig IgG; dilution 1:500) in TBS buffer containing 5% (vol/vol) 
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porcine serum. Then, sections were washed for 10 minutes in TBS for the last 
time, followed by counterstaining and mounted under coverslips using 
Vectashield Mounting Medium with DAPI for nuclear staining. Sections were 
stored at 4°C protected from light. 
. 
Table 3.8 Immunohistochemical procedures  
Antigen Pretreatment Serum Primary antibody Dilution Secondary antibody Dilution CM Chromogen Counterstaining 
GIPR X Goat Rabbit anti-human 
GIPR, polyclonal  
2 µg/ml Goat anti-rabbit IgG, 
biotinylated 
1:400 LAB DAB Hemalaun 
GLP-1R X Goat Rabbit anti-human  
GLP-1R, polyclonal  
2 µg/ml Goat anti-rabbit IgG, 
biotinylated 
1:400 LAB DAB Hemalaun 
Insulin X Rabbit Guinea pig anti-porcine 
insulin, polyclonal  
1:1000 Rabbit anti-guinea pig 
IgG, 
HRP-conjugated 
1:50 X DAB Hemalaun 
Glucagon 20 min MW 
(citrate buffer 
pH 6.0) 
Pig Rabbit anti-human 
glucagon, polyclonal  
1:50 Pig anti-rabbit IgG, 
HRP-conjugated  
1:50 X DAB Hemalaun 
Somatostatin 20 min MW 
(citrate buffer 
pH 6.0)
 
Pig Rabbit anti-human 
somatostatin, polyclonal  
1:50 Pig anti-rabbit IgG, 
HRP-conjugated 
1:50 X DAB Hemalaun 
Pancreatic 
Polypeptide 
X Pig Rabbit anti-human 
pancreatic polypeptide, 
polyclonal  
 
1:100 Pig anti-rabbit IgG, 
HRP-conjugated  
1:50 X DAB Hemalaun 
Mouse anti-human Ki67, 
monoclonal  
1:8 Goat anti-mouse IgG, 
biotinylated  
1:200 DAB 
 
Ki67 
(+ Insulin) 
 
 
20 min MW 
(citrate buffer 
pH 6.0) 
Goat 
Guinea pig anti-porcine 
insulin, polyclonal  
 
1:1000 Goat anti-guinea pig 
IgG, 
AP-conjugated 
1:100 
ABC 
BCIP/NBT 
 
Hemalaun/Eosin 
(Ki67) 
Hemalaun 
(Ki67 + Insulin) 
 
Rabbit anti-human 
cleaved caspase-3, 
polyclonal  
1:200 Donkey anti-rabbit IgG, 
AP-conjugated 
1:100 BCIP/NBT 
 
Cleaved 
Caspase-3 + 
Insulin 
 
30 min 
steamer 
(citrate buffer 
pH 6.0)
 
Horse 
Guinea pig anti-porcine 
insulin, polyclonal  
1:1000 
 
Donkey anti-guinea pig 
IgG, 
HRP-conjugated 
1:200 
X 
DAB 
Nuclear Fast 
Red 
 
 
CM: complex method; DAB: 3,3`diaminobenzidine tetrahydrochloride, BCIP/NBT: 5-bromo-4-chloro-3-indolyl phosphate/ nitroblue tetrazolium; MW: microwave
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3.3.4.4 Proliferation rate of islet cells 
Proliferating cells were detected by immunohistochemical staining for the 
proliferation marker Ki67 (see Table 3.8). Hemalaun/Eosin counterstaining 
allowed identification of the islets of Langerhans wihtin pancreatic tissue. 
Sections were screened for islet profiles. Immunostained-Ki67-positive 
(proliferating) as well as not immunostained islet cell nuclei were counted. Only 
nuclei with a clearly visible cell membrane were implied for the counting of not 
immunostained islet cell nuclear profiles. To screen for immunostained-Ki67-
positive nuclei a 20 x objective lens was used while verification was carried out 
with a 40 x objective lens. A minimum of 104 islet cells per animal was included 
in the quantification. Islet cell proliferation index was defined as the number of 
immunolabeled cell nuclei divided by the total number of cell nuclei counted, 
and expressed as the number of immunolabeled Ki67 positive cell nuclei per 
105 nuclear profiles. 
3.3.4.5 Proliferation/apoptosis rate of ?-cells 
Proliferation/apoptosis rates of ?-cells were determined by double 
immunohistochemical staining for insulin and the proliferation marker Ki67 or 
the apoptosis marker cleaved caspase-3 (see Table 3.8). To verify the 
assumption that the number of nuclear profiles per ?-cell area does not differ 
significantly from the number of nuclear profiles per islet area immunostained 
nuclear profiles of one section of 16 randomly selected animals of the three age 
groups were counted and compared to the corresponding results of the nuclear 
profile quantification using the H.E. stained sections. As no marked difference 
was detected, the counted number of nuclear profiles of this section was 
adjusted to the total ?-cell area of all sections evaluated for the determination of 
?-cell proliferation/apoptosis rate. Subsequently all insulin positive cells within 
all immunohistochemically stained sections were surveyed for Ki67-
positive/cleaved caspase-3-positive cell nuclei using a 20 x objective lens. 
Verification of Ki67-positive/cleaved caspase-3-positive cell nuclei was carried 
out with a 40 x objective lens. A minimum of 104 ?-cells per animal was included 
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in the quantification of ?-cell proliferation and apoptosis. Islet cell 
proliferating/apoptotic index was determined as described in 3.3.4.4. 
3.3.5 Statistics 
All data are presented as means ± SEM. The results of glucose tolerance tests 
as well as incretin stimulation test were statistically evaluated by analysis of 
variance (Linear Mixed Models; SAS 8.2; PROC MIXED), taking the fixed 
effects of Group (wt, tg), Time (relative to glucose or hormone application) and 
the interaction Group*Time as well as the random effect of Animal into account. 
The same model was used to compare body weight gain of GIPRdn transgenic 
and control pigs. Pancreas weight and the results of quantitative stereological 
analyses were evaluated by the General Linear Models (GLM) procedure (SAS 
8.2) taking the effects of Group (wt, tg), Age (11 wk, 5 mo, 1-1.4 yr) and the 
interaction Group*Age into account. Calculation of AUCs was performed using 
Graph Pad Prism 4 software. Statistical significance of differences between tg 
and wt pigs was tested using the Mann-Whitney-U test in combination with an 
exact test procedure (SPSS 16.0). P values less than 0.05 were considered 
significant. 
4 Results 
4.1 Identification of GIPRdn transgenic pigs by PCR and 
Southern blot analysis 
GIPRdn transgenic pigs were genotyped by PCR using DNA of ear punches. A 
marked band was visible in GIPRdn transgenic pigs, while non-transgenic 
littermates showed no band. Genomic DNA of a wild-type pig and aqua bidest. 
were used as negative controls, while genomic DNA of a previously genotyped 
GIPRdn transgenic pig served as a positive control. Concurrently, a PCR using 
?-actin specific primers was performed in order to control DNA integrity. Two 
bands were visible if DNA was intact. The upper band showed the ?-actin gene, 
while the lower one represented a pseudogene.  
720 bp
_ _M 56 58 6059 6261 646357 65 + M
tg tg tgtg wtwt wtwtwt wt
A
wt
 
501 bp
331 bp
_ _M 56 6059 6261 646357 65 + M
tg tgtg wtwt wtwtwt wt
B
wttg
58
 
Figure 4.1 Identification of GIPRdn transgenic pigs and littermate control 
animals by PCR analysis 
(A) Specific PCR analysis for the GIPRdn transgene; (B) ?-actin PCR (control of DNA 
integrity); (A/B) tg: GIPRdn transgenic pig; wt: littermate non-transgenic pig; +: positive 
control (genomic DNA of a previously genotyped GIPRdn transgenic pig); -: negative 
control (genomic DNA of a wild-type pig (wt -) and aqua bidest.(-), respectively); M: 
pUC Mix Marker 8. 
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Southern blot analyses were performed to identify the number of integration 
sites of the GIPRdn construct in transgenic pigs. The founder generation of 
GIPRdn transgenic pigs was generated previously by lentiviral gene transfer. 
Two founder boars were selected to generate two transgenic lines. Both 
founders had two integration sites of the transgenic construct. Southern blot 
analyses of the F1-generation revealed transgenic pigs with one or two 
integrants proving germ line transmission and segregation according to 
Mendelian rules. To establish F2- and F3-generations of GIPRdn transgenic pigs 
that have been used in this study male offspring of both transgenic lines were 
mated to German Landrace-Swabian-Hall crossbred wildtype sows. Southern 
blot analyses of littermates were continued to control transmission of integrants.  
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29 31 32 34 35 36 37 38 3930 40 41
tg tg tg tg tg tg tg tg wttg tg tg
 
Figure 4.2 Representative Southern blot analysis of one litter of GIPRdn 
transgenic pigs and non-transgenic littermates of the F3-generation 
Southern blot analysis of genomic DNA from EDTA blood of GIPRdn transgenic pigs 
(tg) and littermate control animal (wt); piglets show segregation of integration sites. 
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4.2 Normal body weight gain in GIPRdn transgenic pigs 
GIPRdn transgenic pigs and age-matched controls were weighed regularly to 
clarify effects of GIPRdn expression on weight gain. The body weight of GIPRdn 
transgenic pigs did not differ from control animals at any time point investigated. 
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Figure 4.3 Increase of body weight related to age 
Body weight gain of GIPRdn transgenic pigs (tg) compared to age-matched control pigs 
(wt). n: number of animals investigated. Data are means ± SEM (published in Renner 
et al. 2010). 
4.3 Examination of GIPRdn specifity and in vivo function 
To proof specific action of the GIPRdn in vivo, a stimulation test with glucose in 
combination with porcine GIP or the GLP-1R agonist Exendin-4 was performed. 
Previously, different GIP and Exendin-4 concentrations were tested to 
determine the amount of GIP/Exendin-4 needed to induce a markedly higher 
insulin secretion compared to the stimulation with only glucose (IVGTT). 
4.3.1 GIP concentration test 
Different GIP concentrations were tested in 11-week-old non-transgenic pigs 
(n=2). During the GIP concentration test a GIP bolus of 40, 80 or 160 pmol/kg 
BW was administered immediately after an intravenous glucose load (0.5 g/kg 
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BW). Prior, to receive reference values for serum glucose and insulin levels 
after an intravenous glucose load without bolus injection of GIP, an intravenous 
glucose tolerance test (IVGTT) was performed. Following a bolus injection of 
40 pmol/kg BW GIP, insulin levels were almost equal compared to insulin levels 
after stimulation with glucose only, while the decrease of glucose levels was 
even slower. Bolus injection of 80 pmol/kg BW GIP caused a marked increase 
of insulin levels compared to an intravenous glucose load without GIP. Also, 
serum glucose levels were lowered nearly similar to values of the IVGTT. A 
160 pmol/kg BW bolus injection of GIP had slightly less effect on insulin levels 
compared to the effects of an 80 pmol/kg BW bolus but markedly higher effects 
compared to a 40 pmol/kg BW GIP bolus. Serum glucose levels decreased 
most rapidly after administration of a 160 pmol/kg BW GIP bolus. As a GIP 
bolus of 80 pmol/kg BW resulted in markedly higher insulin levels compared to 
a bolus of only glucose this concentration was used for the GIP stimulation 
tests. 
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Figure 4.4 GIP concentration test 
Intravenous glucose tolerance test (IVGTT) and IVGTT in combination with bolus 
application of different concentrations of synthetic porcine GIP in 11-week-old non-
transgenic pigs. (A) serum insulin levels; (B) serum glucose levels. Data are means ± 
SEM. 
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4.3.2 Exendin-4 concentration test 
Exendin-4 is a GLP-1 mimetic with equal binding affinity to the GLP-1 receptor 
as GLP-1 itself (Eng et al. 1992). GLP-1 has a short half-life (<2min) because of 
its fast degradation by the enzyme dipeptidyl peptidase IV (DPP-IV) (Deacon et 
al. 1995). In contrast to GLP-1, Exendin-4 is not degraded by DPP-IV involving 
a longer half-life, and thus provides the opportunity of a better monitoring of 
insulin level changes during a bolus challenge. The Exendin-4 concentration 
test was performed in 11-week-old non-transgenic pigs (n=2). Similar to the GIP 
concentration test an IVGTT was carried out to receive standard values. 
Exendin-4 was administrated as a bolus of 20, 40, and 60 pmol/kg BW. After a 
bolus injection of 20 pmol/kg BW no distinct changes in serum glucose and 
insulin levels were observed compared to glucose administration only, so that 
this concentration was excluded for further investigations. A clear increase in 
insulin levels was induced by Exendin-4 concentrations of 40 and 60 pmol/kg 
BW with insulin levels being higher following a 60 pmol/kg BW Exendin-4 bolus. 
Furthermore, both concentrations lowered serum glucose levels, whereas 
serum glucose levels after a 60 pmol/kg BW bolus injection decreased 
considerably below the levels of the IVGTT without Exendin-4 bolus injection 
while blood glucose levels following a 40 pmol/kg BW bolus were little below 
levels of the IVGTT. Due to the fact that the bolus administration of 40 pmol/kg 
BW of Exendin-4 resulted in a distinct elevation of insulin levels compared to 
the insulin levels during an IVGTT this concentration was selected for the 
Exendin-4 stimulation tests. 
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Figure 4.5 Exendin-4 concentration test 
Intravenous glucose tolerance test (IVGTT) and IVGTT in combination with bolus 
application of different synthetic Exendin-4 concentrations in 11-week-old non-
transgenic pigs. (A) serum insulin levels; (B) serum glucose levels. Data are means ± 
SEM. 
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4.3.3 Reduced insulinotropic effect of GIP in GIPRdn transgenic pigs 
The GIPRdn is characterized by exhibiting equal binding affinity to GIP 
compared to the endogenous GIPR but prohibiting further signal transduction 
pathways (Herbach et al. 2005). In GIPRdn transgenic pigs both the 
endogenous GIPR and the GIPRdn are expressed. To evaluate whether 
expression of a GIPRdn impairs the insulinotropic action of GIP in vivo a 
stimulation test with exogenous administered GIP in combination with glucose 
was performed in 11-week-old GIPRdn transgenic pigs and control animals (n=4 
per group). Additionally, an intravenous glucose tolerance test was carried out 
to receive baseline values. GIPRdn transgenic pigs exhibited an unaltered 
intravenous glucose tolerance and insulin levels compared to controls. The 
insulinotropic effect of GIP (80 pmol/kg BW) was significantly diminished 
(p<0.01) in GIPRdn transgenic vs. control pigs (Figure 4.6 A) leading to a 
moderately, although not significant, decelerated decrease of serum glucose 
levels (Figure 4.6 B). Detection of impaired insulinotropic action of GIP in 
GIPRdn transgenic pigs confirmed integrity and in vivo function of the GIPRdn. 
4  Results 75 
-10 0 10 20 30 40 50 60
0
20
40
60
80
100
 Glc (tg; n=4)
 Glc (wt; n=4)
 Glc+GIP (tg; n=4)
 Glc+GIP (wt; n=4)
**
*
Time (minutes)
In
s
u
lin
 
(µU
/m
l)
-10 0 10 20 30 40 50 60
0
50
100
150
200
250
300
350
 Glc (wt; n=4)
 Glc (tg; n=4)
 Glc+GIP (wt; n=4)
 Glc+GIP (tg; n=4)
Time (minutes)
G
lu
c
o
s
e
 
(m
g/
dl
)
A
B
In
s
u
lin
 
(µU
/m
l)
G
lu
c
o
s
e
 
(m
g/
dl
)
 
Figure 4.6 Impaired insulinotropic action of GIP in GIPRdn transgenic pigs 
Intravenous glucose tolerance test (IVGTT) and IVGTT with application of 80 pmol/kg  
BW GIP in 11-week-old GIPRdn transgenic pigs (tg) and control animals (wt). (A) serum 
insulin levels; (B) serum glucose levels; Glc: glucose; n: number of animals 
investigated. Data are means ± SEM; *: p<0.05; **: p<0.01 vs. controls (published in 
Renner et al. 2010). 
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4.3.4 Enhanced insulinotropic effect of Exendin-4 in GIPRdn transgenic 
pigs 
The Exendin-4 stimulation tests were accomplished in 11-week-old GIPRdn 
transgenic pigs and controls (n=4 per group) to evaluate the insulinotropic effect 
mediated by the GLP-1R and to exclude possible disruptive effects of the 
GIPRdn on GLP-1R function. Same binding affinity to the GLP-1 receptor but 
longer half-life of Exendin-4 vs. GLP-1 allowed a better monitoring of effects on 
glucose metabolism during a bolus challenge. Changes in insulin/glucose levels 
after an Exendin-4 and glucose bolus injection were compared to 
insulin/glucose levels during an intravenous glucose tolerance test without 
Exendin-4 application. The insulinotropic effect of Exendin-4 intravenously 
administered as a bolus was significantly enhanced (p<0.01) in GIPRdn 
transgenic pigs compared to controls (Figure 4.7 A). Insulin levels after an 
intravenous glucose load without Exendin-4 bolus application did not differ 
between both groups. Accordingly, the decline of serum glucose after a bolus 
injection of 40 pmol/kg BW Exendin-4 combined with glucose was significantly 
lower in GIPRdn transgenic pigs compared to the administration of glucose only 
(p<0.05), while control animals exhibited lower serum glucose levels following 
Exendin-4 stimulation compared to intravenous glucose application (Figure 
4.7 B). 
In summary, the results of both stimulation tests, GIP and Exendin-4, 
demonstrate that the GIPRdn specifically reduces insulinotropic action of GIP 
and does not impair the function of the related G-protein coupled GLP-1R. 
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Figure 4.7 Enhanced insulinotropic action of Exendin-4 in GIPRdn transgenic 
pigs 
Intravenous glucose tolerance (IVGTT) and IVGTT with application of Exendin-4 in 11-
week-old GIPRdn transgenic pigs and control animals. (A) serum insulin levels; (B) 
serum glucose levels; Glc: glucose; n: number of animals investigated. Data are means 
± SEM; *: p<0.05; **: p<0.01 vs. controls (published in Renner et al. 2010). 
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4.3.5 Unaltered immunohistochemical appearance of incretin receptors 
Due to the results of the GIP/Exendin-4 stimulation tests, immunohistochemical 
stains for GIPR and GLP-1R were performed. Immunohistochemistry should 
clarify, if there were striking differences in GIPR/GLP-1R expression of GIPRdn 
transgenic pigs compared to control pigs. Immunohistochemical analysis of 
serial sections clearly showed, that both receptors (GIPR, GLP-1R) are 
selectively expressed in identical islet cells either of transgenic or wild type 
animals. Pancreatic exocrine cells, ductal cells, stroma cells and vascular cells 
were uniformly not stained with both antibodies used. Based on number and 
localization pattern the analysis of these serial sections indicated that the insulin 
producing ?-cell is the labeled cell-type. At the cellular level both receptors were 
found to be homogenously distributed in the cytoplasm in a fine granular 
manner. Regional and cellular variations in the intensity of the immunoreaction 
could be found. Enhanced GLP-1R expression or reduced GIPR expression 
was not detected in 11-week-old GIPRdn transgenic pigs compared to controls. 
Hence, no correlation between the immunohistochemical signals of both 
receptors and the results from the GIP/Exendin-4 stimulation tests showing 
impaired insulinotropic action of GIP and enhanced insulinotropic action of 
Exendin-4, respectively, could be detected. Correspondingly, evaluation of the 
sections immunohistochemically stained for GIPR and GLP-1R in the other age-
groups showed no apparent difference in the abundance and spatial distribution 
of both receptors comparing GIPRdn transgenic and control pigs (Figure 4.8 and 
Figure 4.9).  
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Figure 4.8 Expression of the GIPR in GIPRdn transgenic pigs and controls 
Immunostaining for GIP receptor (GIPR); representative pancreas sections of a GIPRdn 
transgenic pigs (tg) and a non-transgenic control animal (wt) of all three age groups; 
we: weeks, mo: months; scale bar = 100 µm (published as supplementary material to 
Renner et al. 2010). 
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Figure 4.9 Expression of the GLP-1R in GIPRdn transgenic pigs and controls 
Immunostaining for GLP-1 receptor (GLP-1R); representative pancreas sections of a 
GIPRdn transgenic pig (tg) and a non-transgenic control animal (wt) of all three age 
groups; we: weeks; mo: months; scale bar = 100 µm (published as supplementary 
material to Renner et al. 2010). 
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4.4 Results on glucose control of GIPRdn transgenic pigs 
4.4.1 Disturbed oral glucose tolerance and delayed insulin secretion in 
11-week-old GIPRdn transgenic pigs 
The oral glucose tolerance test (OGTT) is used to obtain information on the 
body’s ability in glucose metabolism and clearing excess of glucose from the 
bloodstream. The incretin hormones GIP and GLP-1 are released from the 
enteroendocrine cells into the bloodstream after ingestion and are estimated to 
account for up to 60% of the total insulin secretion (Nauck et al. 1986a). At 
5 months of age GIPRdn transgenic pigs revealed a disturbed oral glucose 
tolerance going along with a significantly reduced insulin secretion as has been 
shown previously (Renner 2008). In order to evaluate the effects of GIPRdn 
expression on oral glucose tolerance and insulin secretion in younger animals, 
OGTTs were performed in 11-week-old GIPRdn transgenic (n=5) and control 
pigs (n=5). GIPRdn transgenic pigs exhibited elevated serum glucose levels 
(p<0.05) as well as a distinct delay in insulin secretion after glucose challenge 
(Figure 4.10). The area under the insulin curve (AUC insulin) during the first 45 
minutes following glucose challenge was 31% (p<0.05) smaller in GIPRdn 
transgenic pigs than in age-matched controls. However, the total amount of 
insulin secreted during the experimental period (i.e. total AUC insulin until 120 
minutes following glucose load) load was not different between the two groups 
(5155 ± 763 vs. 5698 ± 625; p=0.351). The AUC glucose was significantly 
elevated during the entire measuring period comparing GIPRdn transgenic and 
non-transgenic pigs (p<0.05). These findings indicate that expression of a 
GIPRdn in the pancreatic islets of transgenic pigs is sufficient to interfere with 
the incretin effect, but does initially not affect the total AUC insulin. 
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Figure 4.10 Disturbed oral glucose tolerance in 11-week-old GIPRdn transgenic 
pigs 
Oral glucose tolerance and insulin secretion in 11-week-old GIPRdn transgenic pigs (tg) 
compared to non-transgenic pigs (wt). (A) serum insulin levels; (B) AUC insulin during 
the first 45 minutes; (C) serum glucose levels; (D) AUC glucose; (A/C) 0 minutes = 
point of glucose administration; n: number of animals investigated; (B/D) AUC: area 
under the curve. Data are means ± SEM; *: p<0.05; **: p<0.01 vs. controls (published 
in Renner et al. 2010). 
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4.4.2 Undisturbed intravenous glucose tolerance in 11-week-old and 5-
month-old GIPRdn transgenic pigs 
The intravenous glucose tolerance test (IVGTT) offers the possibility to evaluate 
glucose tolerance and insulin secretion by-passing the incretin effect. 
Additionally, the IVGTT is not subject to variations in glucose resorption rate like 
the oral glucose tolerance test. It has been shown previously that 11-month-old 
GIPRdn transgenic pigs have a disturbed intravenous glucose tolerance 
(p<0.05) as well as significantly diminished insulin secretion (p<0.05) (Renner 
2008). To further characterize the GIPRdn transgenic pig model an IVGTT was 
performed in 11-week-old (n=5) and 5-month-old (22.5 ± 1.5 weeks; n=4) 
GIPRdn transgenic pigs and their age-matched controls (n=6/4). Eleven-week-
old GIPRdn transgenic pigs exhibited no differences in serum glucose levels at 
each determined point of time following intravenous administration of 0.5 g/kg 
BW of concentrated 50% glucose solution compared to their controls (p<0.633) 
(Figure 4.11 C). Accordingly, the time course and amount of insulin secreted 
were not different between the two groups (p<0.644) (Figure 4.11 A). 
Determination of the area under the insulin curve (AUC insulin) revealed no 
alterations in GIPRdn transgenic pigs compared to controls (p<0.644) (Figure 
4.10 B). Correspondingly, the area under the glucose curve (AUC glucose) did 
not differ between the two groups (p<0.633) (Figure 4.11 D). Serum glucose 
levels of 5-month-old GIPRdn transgenic pigs were only little elevated but 
significant differences could not be observed in comparison to glucose levels of 
control animals (Figure 4.12 C). Determination of the AUC glucose reflected this 
observation (p<0.165) (Figure 4.12 D). Although insulin secretion of 5-month-
old GIPRdn transgenic pigs following an intravenous glucose load was lower 
compared to controls (Figure 4.12 A) no significance was reached. Likewise the 
AUC insulin showed no significant difference (p<0.106) comparing GIPRdn 
transgenic pigs and controls (Figure 4.12 B). However, a tendency towards 
reduced intravenous glucose tolerance and reduced insulin secretion in 
5-month-old transgenic pigs was visible. 
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Figure 4.11 Undisturbed intravenous glucose tolerance in 11-week-old GIPRdn 
transgenic pigs 
Intravenous glucose tolerance and insulin secretion in 11-week-old GIPRdn transgenic 
pigs (tg) compared to age-matched controls (wt). (A) serum insulin levels; (B) AUC 
insulin; (C) serum glucose levels; (D) AUC glucose; (A/C) 0 minutes = point of glucose 
administration; n: number of animals investigated; (B/D) AUC: area under the curve. 
Data are means ± SEM (published in Renner et al. 2010).  
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Figure 4.12 Tendency towards reduced insulin secretion and disturbed IVGT in 
5-month-old GIPRdn transgenic pigs 
Intravenous glucose tolerance test of 5-month-old GIPRdn transgenic pigs (tg) 
compared to age-matched controls (wt): (A) serum insulin levels; (B) AUC insulin; (C) 
serum glucose levels; (D) AUC glucose; (A/C) 0 minutes = point of glucose 
administration; n: number of animals investigated; (B/D) AUC: area under the curve. 
Data are means ± SEM (published in Renner et al. 2010). 
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4.5 Results of morphological analyses 
4.5.1 Impaired age-related expansion of pancreatic ?-cell mass in 
GIPRdn transgenic pigs 
To clarify short-term as well as long-term effects of GIPRdn expression on the 
islets of Langerhans, quantitative stereological analyses of pancreata from 11-
week-old, 5-month-old and 1-1.4-year-old GIPRdn transgenic pigs and controls 
were performed, whereby the parameters volume density of ?-cells in the 
pancreas (Vv (?-cell/Pan)) and total ?-cell volume (V (?-cell, Pan)) were determined. 
Additionally, volume density and total volume of isolated ?-cells (Vv (iso?-cell/Pan) 
and V (iso?-cell, Pan)) as a parameter for islet neogenesis were evaluated (Petrik et 
al. 1999; Xu et al. 1999). In 11-week-old GIPRdn transgenic pigs (n=5) neither 
the total volume of ?-cells (p<0.843) nor the volume density of ?-cells in the 
pancreas (p<0.430) differed from controls (n=5). At the age of 5 months the 
total ?-cell volume (V (?-cell, Pan)) in the pancreas was diminished by 35% 
(p<0.05) in the group of GIPRdn transgenic pigs (n=4) compared to controls 
(n=4). Also, the volume density of ?-cells in the pancreas (Vv (?-cell/Pan)) was 
reduced significantly (p<0.05) by 41%. Total ?-cell volume as well as the 
volume density of ?-cells in the pancreas of 1-1.4-year-old GIPRdn transgenic 
pigs and their controls (n=3 per group) has been previously examined by 
quantitative stereological analyses (Renner 2008). Here, total ?-cell volume as 
well as the volume density of ?-cells in the pancreas was found to be 
significantly reduced by 71% respectively (p<0.05). To raise the validity of these 
analyses two more animals per group were investigated. Including these 
additionally analyzed animals, GIPRdn transgenic pigs exhibited a significantly 
reduced total ?-cell volume (V (?-cell, Pan)) by 56% (p<0.01) as well as a 
significantly diminished volume density of ?-cells (Vv (?-cell/Pan)) in the pancreas 
by 61% (p<0.01) (Figure 4.13 A/B). Notably, total ?-cell volume of non-
transgenic pigs expanded markedly with increasing age (6-fold from 11 weeks 
to 5 months of age; 1.5-fold from 5 months to 1-1.4 years of age). In contrast, 
total ?-cell volume of GIPRdn transgenic pigs rose between 11 weeks and 
5 months of age (4-fold) but almost no further increase could be detected 
between 5-month-old and 1-1.4-year-old GIPRdn transgenic pigs (Figure 
4.13 A). Volume density of ?-cells in the pancreas increased from 11 weeks of 
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age up to 5 months of age by 1.5-fold in control animals while 5-month-old 
GIPRdn transgenic pigs showed no increase compared to 11-week-old 
transgenic pigs. 1-1.4-year-old GIPRdn transgenic pigs revealed a decreased 
volume density of ?-cells in the pancreas (62%) compared to the other two age-
groups while volume density of ?-cells in the pancreas of 1-1.4-year-old control 
pigs was almost equal compared to 5-month-old-pigs (Figure 4.13 B). Volume 
density as well as the total volume of isolated ?-cells (single insulin positive 
cells and small ?-cell clusters) were not different between GIPRdn transgenic 
pigs and age-matched non-transgenic controls neither at 11 weeks of age 
(p=0.840/p=0.695) and 5 month of age (p=0.686/p=0.883) nor at 1-1.4 years of 
age (p=0.225/p=0.844). The volume density of isolated ?-cells in the pancreas 
was highest in 11-week-old GIPRdn transgenic pigs and controls (tg=0.16%; 
wt=0.15%) compared to that of 5-month-old (tg=0.10%; wt=0.11) and 1-1.4-
year-old (tg=0.07%; wt=0.08%) GIPRdn transgenic pigs and controls (Figure 
4.13 D). The total volume of isolated ?-cells was lowest in 11-week-old and 
highest in 5-month-old GIPRdn transgenic and control pigs (Figure 4.13 C). 
Correspondingly to quantitative-stereological analyses, qualitative histological 
assessment of pancreas sections revealed that pancreatic islet profiles of 5-
month-old and 1-1.4-year-old GIPRdn transgenic pigs appeared smaller in size 
and reduced in number while there was no difference in 11-week-old transgenic 
pigs compared to controls. Representative pancreas sections from GIPRdn 
transgenic pigs and non-transgenic control animals are shown in Figure 4.14. In 
summary, these analyses revealed an impaired age-related expansion of ?-cell 
mass leading to a significant reduction of ?-cell mass 5-month-old and 1-1.4-
year-old GIPRdn transgenic pigs. 
4  Results 88 
11 weeks 5 months 1-1.4 years
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
*
**
p=0.843
wt
tg
n=5 n=4 n=5
V 
( ββ ββ-
ce
ll,
 
Pa
n
) (m
m
3 )
A
11 weeks 5 months 1-1.4 years
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
wt
tg
p=0.430
*
**
n=5 n=4 n=5
Vv
( ββ ββ-
c
e
ll/
Pa
n
) (%
)
B
11 weeks 5 months 1-1.4 years
0
20
40
60
80
100
120
140
160
p=0.695
p=0.883
p=0.844
wt
tg
n=5 n=4 n=5
V 
(is
o
ββ ββ-c
e
ll,
 
Pa
n
) (m
m
3 )
11 weeks 5 months 1-1.4 years
0.00
0.02
0.04
0.06
0.08
0.10
0.12
0.14
0.16
0.18
0.20
wt
tg
p=0.840
p=0.686
p=0.225
n=5 n=4 n=5
Vv
(is
o
ββ ββ-c
e
ll/
Pa
n
) (%
)
C D
V 
( ββ ββ-
ce
ll,
 
Pa
n
) (m
m
3 )
Vv
( ββ ββ-
c
e
ll/
Pa
n
) (%
)
V 
(is
o
ββ ββ-c
e
ll,
 
Pa
n
) (m
m
3 )
Vv
(is
o
ββ ββ-c
e
ll/
Pa
n
) (%
)
 
Figure 4.13 Quantitative stereological analyses of GIPRdn transgenic pigs 
(A/B) Volume density (Vv (?-cell/Pan)) and total volume (V (?-cell, Pan)) of the ?-cells in the 
pancreas; (C/D) volume density (Vv (iso?-cell/Pan)) and total volume (V (iso?-cell, Pan)) of 
isolated ?-cells in the pancreas; tg: GIPRdn transgenic pigs; wt: non-transgenic control 
pigs; n: number of animals investigated per age group. Data are means ± SEM; 
*: p<0.05; **: p<0.01 (published in Renner et al. 2010). 
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Figure 4.14 Age-related reduction of ?-cell mass in GIPRdn transgenic pigs 
Representative histological sections of pancreatic tissue immunohistochemically 
stained for insulin of a control (wt) and a GIPRdn transgenic pig (tg); (A/B) 11-week-old 
pigs; (C/D) 5-month-old pigs (E/F) 1-1.4-year-old pigs; scale bar = 200 µm (published 
in Renner et al. 2010). 
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4.5.2 Altered cellular composition of islets in GIPRdn transgenic pigs 
Due to the knowledge of reduced total ?-cell volume in GIPRdn transgenic pigs 
with increasing age, fractions of ?-, ?- and pp-cells in the islets were 
investigated by quantitative stereological analyses. Additionally, the distribution 
of the different endocrine cells within the islets was evaluated qualitatively. 
Islets were defined as the cumulative volume of the various endocrine islet 
cells, thus excluding capillaries and other interstitial tissues in the islets. 
Immunohistochemistry was accomplished for each endocrine islet fraction. A 
similar age-dependent increase in total volumes of ?-, ?- and pp-cells in 
established islets was seen in GIPRdn transgenic pigs and their age-matched 
controls. However, in comparison to controls, the increase of total ?-cell volume 
of GIPRdn transgenic pigs was less pronounced from 11 weeks to 5 months of 
age. Importantly, there was no further augmentation of total ?-cell volume in 1-
1.4-year-old GIPRdn transgenic pigs compared to 5 months of age, 
demonstrating that impaired GIPR function interferes with the physiological 
expansion of pancreatic ?-cells. In addition, the fractional volume of ?-cells in 
the islets (V (?-cell, Islet)) was decreased, while that of ?- and ?-cells was increased 
in 1-1.4-year-old GIPRdn transgenic pigs. However, the total volumes of these 
non-?-cell populations were not different from those of age-matched control 
pigs. Qualitative evaluation of the distribution of endocrine cells within the islets 
revealed insulin positive cells as the major fraction of the different endocrine cell 
types. Insulin positive cells were located in the central area of the islets. 
Glucagon positive cells (?-cells) represented the second most numerous 
endocrine fraction within the islet encircling them peripherally with some single 
cells being localized in the center of the islet. Commonly, somatostatin 
immunoreactive cells (δ-cells) were distributed in the periphery of the islet with a 
few isolated cells being spread over the islet. The appearance of pancreatic 
polypeptide positive cells (pp-cells) varied between the sections of each animal 
revealing no pp-cells in some sections up to even clusters of pp-cells in other 
sections. In general pp-cells were localized in the periphery of the islet or as 
single cells in the exocrine pancreas representing the least numerous fraction of 
the endocrine cell types. Representative immunohistochemical pictures are 
shown in Figure 4.15, Figure 4.16 and Figure 4.17. 
Table 4.1 Quantitative stereological analyses of the endocrine pancreas of GIPRdn transgenic pigs (tg) and wild-type control pigs (wt) 
Parameter Group 11 wk (n = 5 wt, 5 tg) 5 mo (n=4 wt, 4 tg) 1-1.4 yr (n = 5 wt, 5 tg) Analysis of Variance 
  mean SEM mean SEM mean SEM Group Age Group*Age 
           
           
wt 34.5 4.2 115.3 5.6 183.4 13.8 n.s. <0.0001 n.s. Pancreas 
weight [g] tg 32.7 3.1 125.7 6.1 206.1 4.9    
 
          
wt 69.8 2.2 89.0 1.5 90.2 1.2 0.0066 <0.0001 0.0024 VV(β-cell/Islet) [%] 
tg 70.8 1.3 87.0 1.2 76.4** 3.2    
           
wt 14.1 1.2 5.0 0.8 5.0 0.7 0.0122 <0.0001 0.0008 VV(α-cell/Islet) [%] 
tg 12.2 0.7 6.5 0.7 13.8** 2.3    
           
wt 13.5 2.8 4.3 0.8 2.2 0.6 n.s. <0.0001 n.s. VV(δ-cell/Islet) [%] 
tg 13.0 1.0 5.5 0.9 5.8* 0.9    
           
wt 2.7 0.7 1.8 0.3 2.8 0.8 n.s. 0.0355 n.s. VV(pp-cell/Islet) 
[%] tg 3.9 0.5 1.3 0.3 3.8 1.1    
           
wt 168.7 29.5 1088.2 82.0 1694.6 251.7 0.0002 <0.0001 0.0024 V(β-cell, Islet) 
[mm³] tg 152.1 17.1 664.1* 74.5 663.7** 130.5    
           
wt 32.6 8.7 58.4 6.3 95.7 17.4 n.s. <0.0001 n.s. V(α-cell, Islet) 
[mm³] tg 24.5 1.7 47.7 4.5 112.8 14.5    
           
wt 26.6 3.9 49.5 6.1 36.8 6.3 n.s. 0.0014 n.s. V(δ-cell, Islet) 
[mm³] tg 25.9 1.8 39.6 3.5 47.5 5.2    
           
wt 6.0 1.8 20.7 2.9 52.4 12.6 n.s. <0.0001 n.s. V(pp-cell, Islet) 
[mm³] tg 8.2 1.7 9.3 2.1 30.3 7.9    
           
(published in Renner et al. 2010) 
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Figure 4.15 Immunostaining of insulin, glucagon, somatostatin and pancreatic 
polypeptide (PP) containing cells 
Representative consecutive pancreas sections from an 11-week-old GIPRdn transgenic 
pig (tg) and a non-transgenic control pig (wt); scale bar = 20 µm (published as 
supplementary material to Renner et al. 2010). 
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Figure 4.16 Immunostaining of insulin, glucagon, somatostatin and pancreatic 
polypeptide (PP) containing cells 
Representative consecutive pancreas sections from a 5-month-old GIPRdn transgenic 
pig (tg) and a non-transgenic control pig (wt); scale bar = 20 µm (published as 
supplementary material to Renner et al. 2010). 
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Figure 4.17 Immunostaining of insulin, glucagon, somatostatin and pancreatic 
polypeptide (PP) containing cells 
Representative consecutive pancreas sections from an 1-1.4-year-old GIPRdn 
transgenic pig (tg) and a non-transgenic control pig (wt); scale bar = 20 µm (published 
as supplementary material to Renner et al. 2010). 
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4.5.3 Reduced proliferation rate of ?-cells in GIPRdn transgenic pigs 
In order to clarify the mechanism of impaired ?-cell expansion in GIPRdn 
transgenic pigs, ?-cell proliferation was determined by immunohistochemical 
staining for the proliferation marker Ki67. The Ki67 antigen is preferentially 
expressed during all active phases of the cell cycle (G1, S, G2 and M-phases), 
but it is absent in resting cells (G0-phase) (Gerdes et al. 1984). The antigen is 
rapidly degraded as the cell enters the non-proliferative states (Scholzen et al. 
2000). For double immunohistochemical staining of insulin and the proliferation 
marker Ki67 different variations of chromogens were tested: 
3,3`diaminobenzidine (DAB) for insulin combined with Fuchsin for Ki67, Fuchsin 
for insulin combined with DAB for Ki67 and 5-bromo-4-chloro-3-
indolylphosphate/nitroblue tetrazolium (BCIP/NBT) for insulin combined with 
DAB for Ki67. Furthermore, immunofluorescence was carried out using a FITC-
conjugated secondary antibody for Ki67 and a Cy 3-conjugated secondary 
antibody for the detection of insulin containing cells. Combination of Fuchsin 
and DAB resulted in difficult identification of double positive cells for insulin and 
Ki67 independent which of both chromogens was chosen for the detection of 
Ki67 and insulin because of the high similarity between the red and the brown 
shade. Best results were obtained by staining insulin positive cells with 
BCIP/NBT and Ki67 positive nuclei with DAB. Staining by immunofluorescence 
revealed approximately equivalent results compared to combination of 
BCIP/NBT and DAB, but as technical efforts required for data analyses were 
considerably higher immunohistochemical staining was chosen. The 
proliferation rate of ?-cells in double immunohistochemically stained sections 
was significantly reduced by 60% (p<0.05) in 11-week-old GIPRdn transgenic 
pigs (n=5 per group), while ?-cell proliferation in 5-month-old (n=4 per group; 
p<0.549) and 1-1.4-year-old (n=5 per group; p<0.352) GIPRdn transgenic pigs 
was unaltered compared to age-matched controls. Comparing the age groups 
the total amount of proliferation rate of ?-cells decreased with increasing age 
(Figure 4.19 A). In conclusion, analysis of ?-cell proliferation rate points towards 
a diminished proliferation rate of ?-cells as reason for reduced ?-cell mass in 
GIPRdn transgenic pigs. 
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Figure 4.18 Chromogen variations of double immunohistochemistry for insulin 
and the proliferation marker Ki67 
(A) DAB for insulin staining combined with Fuchsin for Ki67 staining; (B) Fuchsin for 
insulin staining combined with DAB for Ki67 staining; (C) Immunofluorescence 
(Insulin=green; Ki67=pink); (D) BCIP/NBT for insulin staining combined with DAB for 
Ki67 staining; pancreas sections from 11-week-old wild-type pigs served for this 
experiment; scale bar = 20 µm (Figure D published in Renner et al. 2010). 
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4.5.4 Reduced proliferation of islet cells in 11-week-old GIPRdn 
transgenic pigs 
Single staining for the proliferation marker Ki67 in combination with a 
Hemalaun/Eosin counterstaining to localize islets of Langerhans allowed 
determination of proliferating islet cells. In 11-week-old GIPRdn transgenic pigs 
proliferation of islet cells was significantly reduced by 38% (p<0.05) compared 
to controls (n=5 per group). No differences in islet proliferation could be 
determined in GIPRdn transgenic pigs at the age of 5 months (n=4 per group; 
p=0.549) and at the age of 1-1.4 years (n=5 per group; p=0.276) compared to 
age-matched non-transgenic controls. 
4.5.5 Tendency of more cleaved caspase-3 positive ?-cells in 1-1.4-year-
old GIPRdn transgenic pig 
Changes in apoptosis rate were investigated by quantitative stereological 
analyses of immunohistochemically stained sections for cleaved caspase-3. 
Caspase-3 is one of the key factors of apoptosis, as it is either partially or totally 
responsible for the proteolytic cleavage of many key proteins (Fernandes-
Alnemri et al. 1994). Activation of caspase-3 requires proteolytic processing of 
its inactive zymogen into activated fragments. Cleavage of caspase-3 requires 
aspartic acid at the P1 position (Nicholson et al. 1995). The used cleaved 
caspase-3 (Asp175) antibody detects endogenous levels of the large fragment 
of activated caspase-3 resulting from cleavage adjacent to Asp175. Double 
immunohistochemistriy for cleaved caspase-3 and insulin was performed in all 
three age groups to evaluate a potential impact of GIPRdn expression on cell 
death in the ?-cell compartment. Overall the proportion of cleaved caspase-3 
positive cells was very low, with no significant difference between GIPRdn 
transgenic pigs and controls of all age classes. However, there was a trend 
(p=0.075) of more cleaved caspase-3 positive cells in 1-1.4-year-old GIPRdn 
transgenic pigs as compared to age-matched controls. 
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Figure 4.19 Reduced proliferation rate of ?-/islet cells in 11-week-old GIPRdn 
transgenic pigs and trend of elevated apoptosis rate of ?-cells in 
1-1.4-year-old GIPRdn transgenic pigs  
(A) Proliferation rate of ?-cells; representative pancreas section of double 
immunohistochemical staining for insulin and the proliferation marker Ki67;  
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(B) proliferation rate of islet cells; representative pancreas section of immunohisto-
chemistry for the proliferation marker Ki67 in combination with Hemalaun/Eosin 
counterstaining for localization of the islets of Langerhans; (C) apoptosis rates of ?-
cells; representative pancreas section of double immunohistochemical staining for 
insulin and cleaved caspase-3; (A/B/C) tg: GIPRdn transgenic pigs; wt: non-transgenic 
control pigs; n: number of animals investigated per group; scale bar = 20 µm. Data are 
means ± SEM; *: p<0.05 (published in Renner et al. 2010). 
 
 
 
 
 
 
 
 
5 Discussion 
5.1 GIP/Exendin-4 concentration test 
A dose-response study with three different concentrations of GIP (40, 80 and 
160 pmol/kg BW) and Exendin-4 (20, 40 and 60 pmol/kg BW) was carried out to 
determine the amount of GIP/Exendin-4 needed to induce a markedly higher 
insulin secretion compared to the stimulation with only glucose. A bolus 
injection has the advantage to potentiate the insulin secretion more than a 
continuous intravenous infusion (Meier et al. 2004; Vilsboll et al. 2002) providing 
a better monitoring on glucose-lowering and insulin-enhancing effects of the 
different doses. 
A dose of 40 pmol/kg BW GIP failed to distinctly enhance insulin levels 
compared to insulin levels following an intravenous glucose load. A distinct 
increase of insulin secretion was observed after a bolus injection of 80 and 
160 pmol/kg BW GIP, although, unexpectedly, peak insulin levels after 
80 pmol/kg BW GIP bolus injection were higher compared to a dose of 
160 pmol/kg BW GIP. 160 pmol/kg BW GIP represent a very high dose 
compared to a GIP bolus of 80 pmol/kg BW GIP that was used in humans 
studies as a high dose (Meier et al. 2004) so that a receptor saturation at a 
concentration of 160 pmol/kg BW GIP is definitely conceivable. Furthermore, 
only two pigs were used to estimate the dose-dependent increase of insulin 
secretion wherefore one must also be aware of inaccuracy due to the small 
animal number. Glucose decrease after each GIP bolus concentration did not 
differ markedly from IVGTT without GIP bolus injection. The only slight glucose-
lowering effects of GIP observed in this experiment might be due to the short 
half-life of GIP as GIP is rapidly degraded by the enzyme DPP-4 (Deacon et al. 
2000). As the dose of 80 pmol/kg BW GIP showed a markedly increase in 
insulin response and the use of the two-fold amount of GIP provided no 
advantages, 80 pmol/kg BW was chosen for the GIP stimulation tests.  
The Exendin-4 concentration test demonstrated clear dose-dependent 
increases of insulin secretion after bolus injection of 20, 40 and 60 pmo/kg BW 
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Exendin-4 compared to an intravenous glucose load without Exendin-4 bolus 
application. Correspondingly, serum glucose decreased more rapidly with rising 
Exendin-4 concentration. Although the insulin secretion after the administration 
of 60 pmol/kg BW Exendin-4 was higher than after 40 pmol/kg BW Exendin-4, 
40 pmol/kg BW Exendin-4 was selected for the Exendin-4 stimulation tests as 
this concentration but not 20 pmol/kg BW resulted in a markedly elevated 
insulin secretion compared to an intravenous glucose load without Exendin-4 
bolus. Additionally, the probability of the appearance of known side effects like 
vomiting and nausea were lower using 40 pmol/kg BW Exendin-4 as the 
appearance of side-effects is dose-dependent (Poon et al. 2005). 
5.2 Examination of GIPRdn specifity 
GIP/Exendin-4 stimulation tests were performed in 11-week-old GIPRdn 
transgenic pigs and control animals to clarify whether GIP signaling is reduced 
and GLP-1 signaling is sustained in transgenic pigs due to the expression of the 
GIPRdn. GIPRdn transgenic pigs exhibited significantly diminished insulin levels 
indicating an impaired insulinotropic effect of GIP. Importantly, insulin levels 
after an intravenous glucose load without GIP revealed no differences between 
the two groups arguing against the suspicion that toxic effects due to GIPRdn 
expression are responsible for the impaired insulinotropic action of GIP in 
GIPRdn transgenic pigs. A residual function of GIPR signaling was expected 
because the GIPRdn is expressed in addition to the endogenous GIPR. Both 
receptors compete for GIP binding showing nearly the same binding affinity 
(Herbach et al. 2005; Volz 1997). In contrast, in vitro stimulation of isolated 
islets of GIPR-/- mice did not induce residual GIP function indicating a complete 
loss of GIPR signaling (Miyawaki et al. 1999). Furthermore, GIPR and GLP-1R 
belong to the same receptor family explaining that a supraphysiological dose of 
GIP might lead to an additional binding of GIP to the intact GLP-1R of GIPRdn 
transgenic pigs mediating a further increase in insulin secretion after 
intravenous administration of GIP and glucose (Brubaker et al. 2002; Wheeler 
et al. 1993). 
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Exendin-4 is a potent GLP-1R agonist used to demonstrate sustained GLP-1R 
activity in GIPRdn transgenic pigs. After stimulation with glucose and Exendin-4 
11-week-old GIPRdn transgenic pigs exhibited significantly enhanced insulin 
secretion levels compared to controls. These results are consistent with findings 
in perfused pancreas and isolated islets of GIPR-/- mice and GLP-1R-/- mice 
where insulin responses to GLP-1 and GIP, respectively, were significantly 
greater in the knockout mice compared to controls (Pamir et al. 2003; Pederson 
et al. 1998). Hence, the enhanced insulin secretion after Exendin-4 bolus 
injection suggested the presence of compensatory mechanisms. 
To clarify whether compensatory mechanisms comprise alterations in receptor 
expression immunohistochemical staining for GIPR and GLP-1R was 
performed. No apparent difference in the abundance and spatial distribution of 
both receptors were detected comparing GIPRdn transgenic pigs and controls. 
Notably, these results reflect only an impression but no quantification. The 
validity of quantification of immunohistology is disputable due to variables 
during fixation and processing and should be regarded as approximations only 
(Leong 2004). However, striking differences in the amount and intensity of 
staining can be detected by immunohistochemistry (Herbach et al. 2007). 
5.3 Disturbed oral glucose tolerance in 11-week-old GIPRdn 
transgenic pigs 
GIP and GLP-1 are responsible for up to 60% of the total amount of insulin 
secretion (related to C-peptide levels) after an oral glucose load whereby the 
degree of the incretin effect depends on the amount of glucose ingested (Nauck 
et al. 1986a; Nauck et al. 1986b). This observation demonstrates an important 
role of the incretins in glucose metabolism. Eleven-week-old GIPRdn transgenic 
pigs showed an impaired insulinotropic action of GIP due to a prohibited signal 
transduction after binding of GIP to the GIPRdn (Herbach et al. 2005; Volz 
1997). A first functional consequence of the GIPRdn expression in the pancreas 
of 11-week-old GIPRdn transgenic pigs was a reduced oral glucose tolerance 
going along with significant higher serum glucose levels and delayed insulin 
secretion associated with a significant smaller area under the insulin curve 
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during the first 45 minutes compared to controls. The impaired insulinotropic 
action of GIP in GIPRdn transgenic pigs can explain the initially delayed insulin 
secretion. However, in 11-week-old GIPRdn transgenic pigs ?-cell response to 
glucose is not diminished as the total amount of secreted insulin did not differ 
between transgenic pigs and controls. GIPRdn transgenic pigs showed an 
enhanced insulinotropic action of Exendin-4, a GLP-1 mimetic, in the stimulation 
test. An enhanced insulinotropic action of GLP-1 in GIPRdn transgenic pigs may 
compensate for the initially reduced insulin secretion and contribute in a 
balancing manner. In GIPR-/- and GLP-1R-/- mice such a compensatory action of 
the functional incretin hormone could also be observed (Flamez et al. 1999; 
Pamir et al. 2003; Pederson et al. 1998). No differences in the total ?-cell 
volume and ?-cell integrity of 11-week-old GIPRdn transgenic pigs were 
detected confirming that the disturbed oral glucose tolerance is the 
consequence of the impaired insulinotropic action of GIP. Normal fasting blood 
glucose and insulin levels, but altered glucose excursions that came along with 
significantly elevated blood glucose and reduced insulin levels after an OGTT 
were also observed in GIPR-/- mice (Miyawaki et al. 1999). Furthermore, early 
insulin secretion after oral glucose ingestion was impaired in GIPR-/- mice 
showing parallels to the findings in the GIPRdn transgenic pigs (Miyawaki et al. 
1999). Insulin release after nutrient ingestion is biphasic and a defect within the 
first 30 minutes (as a marker for early insulin secretion) was detected to occur 
long before the development of diabetes (Del Prato 2003; Gerich 1997; Leahy 
2005). Changes in the early insulin secretion result in an elevated postprandial 
rise of glucose levels (Leahy 2005) suggesting that the first phase of insulin 
secretion seems to be important to prime the tissues for the incoming nutrients. 
Moreover, GIP appeared to be the more potent incretin hormone contributing 
approximately 80% of the incretin induced insulin secretion (Gault et al. 2003b; 
Nauck et al. 1993a) wherefore an impaired action of GIP caused by GIPRdn 
expression in the islets of Langerhans can be responsible for a disturbed oral 
glucose tolerance as observed in 11-week-old GIPRdn transgenic pigs. 
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5.4 Undisturbed intravenous glucose tolerance in 11-week-
old and 5-month-old GIPRdn transgenic pigs. 
For further physiological characterization an intravenous glucose tolerance test 
was performed in 11-week-old and 5-month-old GIPRdn transgenic pigs. As 
previously described, 11-month-old GIPRdn transgenic pigs showed a disturbed 
intravenous glucose tolerance as well as a significantly diminished insulin 
secretion (Renner 2008). Eleven-week-old GIPRdn transgenic pigs exhibited an 
unaltered intravenous glucose tolerance and insulin secretion compared to 
controls. Five-month-old GIPRdn transgenic pigs also showed no significant 
differences in insulin secretion and serum glucose levels compared to non-
transgenic pigs. However, insulin secretion tended to be lower and glucose 
decline was delayed in 5-month-old GIPRdn transgenic pigs. When glucose is 
administered intravenously the incretin effect is bypassed meaning that an 
impaired incretin effect alone cannot cause the development of a disturbed 
intravenous glucose tolerance in GIPRdn transgenic pigs. Quantitative 
stereological analyses revealed a significant reduction of the total ?-cell volume 
in 5-month-old (35%) and 1-1.4-year-old (58%) GIPRdn transgenic pigs while 
total ?-cell volume of 11-week-old GIPRdn transgenic pigs was unaltered 
compared to controls. These observations demonstrate that the progressive 
deterioration of intravenous glucose tolerance correlates with the progressive 
reduced expansion of ?-cell mass in GIPRdn transgenic pigs. 
In contrast, GIPR-/- mice showed no differences in blood glucose levels after an 
intraperitoneal glucose tolerance test that is comparable to an IVGTT (Miyawaki 
et al. 1999). However, it has to kept in mind that the incretin hormones can be 
released to some degree by enhanced glucose levels in the hepatoportal region 
following an intraperitoneal glucose load (Gallwitz et al. 1997). 
5.5 Impaired age-related expansion of pancreatic ?-cell mass 
in GIPRdn transgenic pigs 
Determination of quantitative stereological parameters for ?-cells were carried 
out using unbiased model-independent stereological methods (Gundersen et al. 
5  Discussion 105 
1987; Gundersen et al. 1988; Kroustrup et al. 1983). In 5-month-old GIPRdn 
transgenic pigs the total ?-cell volume and volume density of ?-cells were 
significantly diminished compared to non-transgenic controls. Moreover, the 
growth of ?-cell mass appeared to stagnate as no further increase of the total ?-
cell volume of 1-1.4-year-old GIPRdn transgenic pigs compared to the 
transgenic animals at 5 months of age was detected. Due to this fact this 
situation is described as an impaired expansion of ?-cell mass. Total volume 
and volume density of isolated ?-cells as a parameter for islet neogenesis 
(Petrik et al. 1999; Xu et al. 1999) were determined in all three age groups. It 
has been shown that besides the replication of already existing cells new ?-cells 
or small new islets are formed by neogenesis from progenitor cells or by 
transdifferentiation from acinar cells (Bonner-Weir 2000; Montanya et al. 2009). 
GIPRdn transgenic pigs showed neither at the age of 11 weeks and 5 months 
nor at the age of 1-1.4 years differences in the total volume and volume density 
of isolated ?-cells in the pancreas. Pigs at 5 months of age exhibited the highest 
total volume of isolated ?-cell compared to the transgenic and non-transgenic 
pigs of the other two age groups. However, the total ?-cell volume consists of all 
insulin positive cells including the single insulin positive cells and small clusters 
of insulin positive cells (isolated ?-cells). With respect to this, the mean 
percentage of the total volume of isolated ?-cells referring to the total ?-cell 
volume is the highest in 11-week-old transgenic (tg) pigs and controls (wt) 
(tg=24.5%; wt=22.4%) and decreases with age (5 months: tg=16%; wt=10%; 
1-1.4 years: tg=8.8%, wt=4.2%). These observations are in line with the age-
related decrease of the volume density of the isolated ?-cells in the pancreas. It 
has to be kept in mind to what extent isolated ?-cells are a valid marker for islet 
neogenesis. The upper threshold to define insulin positive cells either as islets 
or as isolated ?-cells, and therefore as markers for islet neogenesis, is not 
definitely determined whereas the interpretation of islet neogenesis data must 
be evaluated with caution. However, all analyses in GIPRdn transgenic pigs 
were carried out under the same conditions so that possible inaccuracies apply 
to all age groups. As the used parameters for the quantification of islet 
neogenesis in GIPRdn transgenic pigs did not differ from controls at any age 
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group other mechanisms like alterations in proliferation or apoptosis rate of ?-
cells might be responsible for the impaired expansion of ?-cells in GIPRdn 
transgenic pigs (see below). Studies on the pancreatic development in rodents 
indicated that ?-cell mass rather expands by replication than by neogenesis 
after the first weeks of life (Bouwens et al. 2005). Less information is available 
about the postnatal growth of the ?-cell mass in pigs. Constant increases in ?-
cell mass after birth into adulthood associated by waves of apoptosis and 
mitosis were detected examining pancreata from pigs (Bock et al. 2003). 
Qualitative histological assessment of pancreas sections of all three age groups 
confirmed the results of the quantitative stereological analyses. Pancreatic islet 
profiles of 5-month-old and 1-1.4-year-old GIPRdn transgenic pigs appeared to 
be smaller in size and reduced in number indicating changes in ?-cell 
remodeling due to GIPRdn expression. 
5.6 Altered cellular composition of islets in GIPRdn 
transgenic pigs 
Quantitative stereological analyses of the total ?-cell volume and volume 
density revealed markedly reduced expansion of ?-cells in GIPRdn transgenic 
pigs with increasing age. To control changes in the islet composition 
immunohistochemistry for ?-, δ- and pp-cells were performed. The fraction of ?- 
and δ- cells was increased in 1-1.4-year-old GIPRdn transgenic pigs. Notably, 
only the volume densities of ?- and δ- cells were altered in 1-1.4-year-old 
GIPRdn transgenic pigs whereas the total volumes of the non-?-cells were 
unaltered compared to controls. This observation could be explained 
considering that concomitantly to the diminished ?-cell fraction the total islet cell 
volume was reduced. Accordingly, studies in type 2 diabetic patients discovered 
changes in the cellular composition of the islets of Langerhans in the pancreas. 
Diabetic people exhibited an enhanced relative volume of ?-cells going along 
with a reduced relative volume of ?-cells (Deng et al. 2004; Yoon et al. 2003). 
GIPRdn transgenic mice showed a marked increase of the total volume of non-
?-cells and a decrease of total ?-cell volume compared to controls (Herbach et 
al. 2005). Qualitative histological assessment of randomly selected pancreas 
5  Discussion 107 
sections of transgenic and control animals of each age group were performed to 
get more information about endocrine cell distribution within the islet. According 
to immunohistochemical studies of minipig pancreata insulin positive cells 
represented the major fraction of endocrine cells located in the central area of 
the islets while glucagon, somatostatin and pp-positive cells were primarily 
localized in the periphery of the islet of GIPRdn transgenic pigs (Wieczorek et al. 
1998). 
5.7 Reduced proliferation rate of ?- and islet cells in GIPRdn 
transgenic pigs 
The marked reduction of the total ?-cell volume in 5-month-old and 1-1.4-year-
old GIPRdn transgenic pigs but unaltered total volume of isolated ?-cells as a 
marker for islet neogenesis required investigations related to proliferation and 
apoptosis (see 5.8) rates of ?-cells. Immunohistochemical staining for the 
proliferation marker Ki67 revealed significantly reduced proliferation rates of 
?-cells as well as of islet cells in 11-week-old GIPRdn transgenic pigs compared 
to controls. Determination of proliferating islet cells included all endocrine cell 
types whereas proliferating endothelial as well as connective tissue cells were 
not counted. In GIPRdn transgenic pigs at 5 months of age and 1-1.4 years of 
age proliferation rate of both islet and ?-cells reached no significant difference, 
but a tendency towards diminished proliferation was observed comparing 1-1.4-
year-old transgenic animals and controls (p<0.276). The total ?-cell volume in 
11-week-old non-transgenic pigs showed a 6-fold increase up to the age of 
5 months while the total ?-cell volume from 5 months to 1-1.4 years of age not 
even doubled. According to these results, the proliferation rate of the young (11-
week-old) non-transgenic pigs was 3-fold higher than in 5-month-old control 
pigs indicating that proliferation is important for ?-cell mass expansion. The 
increase of the total ?-cell volume is only modest (1.5-fold) from 5 months to 1-
1.4 years of age going along with a markedly lower proliferation rate in these 
groups compared to the 11-week-old pigs which are in a developmental stage 
of massive ?-cell expansion (Bock et al. 2003). Recently, experiments in mice 
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showed that ?-cell proliferation and the ability of ?-cells to regenerate decline 
with increasing age (Tschen et al. 2009). 
Additionally, Hemalaun/Eosin (HE) staining in combination with 
immunodetection of Ki67 was carried out to obtain information about islet cell 
proliferation. The endocrine fraction in the pig pancreas is not clearly separated 
from the exocrine fraction by a reticular capsule as in rodents (Wieczorek et al. 
1998) wherefore counterstaining with HE was utilized to make the islets of 
Langerhans visible. The course of islet cell proliferation showed the same age-
related decrease pattern as was detected for ?-cell proliferation. By absolute 
numbers, more proliferating cells occurred in 11-week-old non-transgenic pigs 
comparing the double immunohistochemistry (insulin Ki67) and 
immunohistochemistry for Ki67 combined with HE counterstaining. ?-Cells 
represent the major fraction of endocrine cells in the islets of Langerhans with a 
content of 60-80% in pigs (Larsen et al. 2004). Even if in immunohistochemistry 
for Ki67 combined with HE counterstaining proliferating non-?-cells (?-, δ- and 
pp-cells) are included these cells represent only a minor fraction. Therefore it is 
possible that in double immunohistochemistry an almost similar number of 
proliferating cells is related to a lower number of nuclei as ?-cell area is smaller 
than islet area. Another explanation for the higher proliferation rate of ?-cells 
compared to islet cells could be that young (11 weeks) GIPRdn transgenic pigs 
showed primarily small islets and a lot of single ?-cells compared to the other 
age groups. It has to kept in mind that small HE stained islets are more difficult 
to identify than single cells stained for insulin, possibly resulting in inaccuracies 
in determining proliferating islet cells due to overlooked cells. The reason 
carrying out two variants of analyzing the proliferation rate was that it might be 
possible that a proliferating ?-cell dedifferentiates and transiently loses function 
as it replicates (Bonner-Weir 2000) and therefore might not be insulin positive 
during that period of time. As the results of both analyses were similar this 
assumption appeared not to play an important role for determination of the 
proliferation rate. Both analyses for the proliferation rate showed a significant 
reduction of proliferating ?-/islet cells in 11-week-old GIPRdn transgenic pigs 
compared to controls and a tendency towards reduction in 1-1.4-year-old 
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GIPRdn transgenic pigs. These results are in line with previous in vitro studies 
showing that GIP has trophic effects on ?-cells (Ehses et al. 2002; Trumper et 
al. 2001; Trumper et al. 2002). In contrast, GIPR-/- mice revealed a paradoxical 
increase in relative ?-cell area (Pamir et al. 2003) providing no evidence that the 
trophic action of GIP is required for the maintenance of islet and ?-cell integrity 
in vivo (Brubaker et al. 2004; Hansotia et al. 2004; Pamir et al. 2003). Both 
GIPR-/- and GLP-1R-/- mice exhibited compensatory mechanisms involving a 
higher action of the other incretin (Flamez et al. 1999; Pamir et al. 2003; 
Pederson et al. 1998). Furthermore, number and size of islets in DIRKO mice 
lacking functional expression of both the GIPR and the GLP-1R did not differ 
from controls assuming that unidentified compensatory mechanisms might 
balance the absence of both incretin receptors (Hansotia et al. 2004). In 
contrast, GIPRdn transgenic mice exhibited striking abnormalities in the 
endocrine pancreas concluding the importance of GIP signaling for postnatal 
islet and ?-cell development as well as neogenesis of islets (Herbach et al. 
2005). As a functional endogenous GIPR is present in transgenic mice the 
various compensatory mechanisms occurring in GIPR-/-, GLP-1R-/- and DIRKO 
mice might not be triggered (Herbach et al. 2005). This conclusion might also 
apply to GIPRdn transgenic pigs. 
There are different proliferation markers that can be used to determine the 
proliferation rate. Bromodeoxyuridine (BrdU), proliferating cell nuclear antigen 
(PCNA) and Ki67 are often utilized for this purpose. BrdU is a thymidine 
analogue incorporated during DNA synthesis. An uptake of BrdU labeling is 
restricted to cells in the S-phase of the cell cycle (Gratzner 1982). PCNA 
represents a subunit of the DNA-Polymerase-delta being essential for both DNA 
replication and DNA repair (Bravo et al. 1987; Prelich et al. 1987; Toschi et al. 
1988). Even if its maximal expression occurs in the G1 and S-phases PCNA is 
also present in the G0-phase because of its long half life (8-20h) (Scott et al. 
1991). In contrast, Ki67 is also visible in all phases of the cell cycle but is only 
rarely detectable in cells in the G0-phase due to its short half life of about one 
hour (Bruno et al. 1992; Gerdes et al. 1984). Despite the accuracy of the BrdU 
method, this chemical must be administered to living animals including the 
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disadvantage to render previously collected pancreas samples useless. A study 
about the correlation of the labeling indices of the proliferation markers PCNA 
and Ki67 to the BrdU labeling index in rat renewing tissues supported 
immunohistochemistry for Ki67 as the preferable technique to assess 
proliferative activity compared to PCNA immunohistochemistry (Muskhelishvili 
et al. 2003). Due to this fact the proliferation marker Ki67 was selected being 
the best possible method for determination of the proliferation rate. 
5.8 Tendency towards more cleaved caspase-3 positive ?-
cells in 1-1.4-year-old GIPRdn transgenic pigs 
GIPRdn transgenic pigs revealed significantly reduced total ?-cell volume at 
5 months and 1-1.4 years of age while total ?-cell volume in 11-week-old 
transgenic pigs was unaltered compared to controls. The regulation of the ?-cell 
mass is dynamic due to a balance between cell renewal (replication, 
neogenesis) and cell loss (necrosis, apoptosis) (Finegood et al. 1995). To find 
out whether this balance is altered in GIPRdn transgenic pigs investigations for 
proliferation (as described in 5.7) and apoptosis rates of ?-cells were carried 
out. Apoptosis rates in GIPRdn transgenic pigs did not differ significantly from 
non-transgenic pigs at any age group using immunohistochemistry for cleaved 
caspase-3 and insulin. However, a tendency towards more cleaved caspase-3 
positive cells in 1-1.4-year-old GIPRdn transgenic pigs vs. controls was visible. 
An antiapoptotic effect has been proposed for GIP in several in vitro studies. 
Ehses et al. (2003) showed GIP as an inhibitor of cell death associated p38 
MAPK pathway in ?-INS-1 cells. Furthermore, it was demonstrated that GIP 
protects ?-cells during glucolipotoxicity-induced apoptosis (Kim et al. 2005). 
Recently, it was discovered that GIP is involved in a pathway preventing the 
proapoptotic actions of p38 MAPK and JNK (Widenmaier et al. 2009). In type 2 
diabetes patients apoptosis appeared to play an important role in ?-cell 
reduction (Butler et al. 2003) and the insulinotropic action of the antiapoptotic 
factor GIP has been proven to be impaired both in humans affected by diabetes 
as well as in GIPRdn transgenic pigs.  
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Chronic elevation of blood glucose concentration is characteristic of the 
diabetes state and was discovered to derogate ?-cell function and trigger ?-cell 
apoptosis (Zhang et al. 2009), a phenomenon referred to as glucotoxicity 
(Kaiser et al. 2003). Hyperglycemia also accounts for oxidative stress that is 
potentiated by low expression and activity of anti-oxidative enzymes in the 
pancreas and documented to increase ?-cell apoptosis (Del Guerra et al. 2005; 
Robertson et al. 2004). Likewise, endoplasmic reticulum stress activated by 
chronic hyperglycemia initiates apoptosis (Marchetti et al. 2007). Obesity, a 
main risk factor of diabetes, is accompanied with increased levels of leptin and 
free fatty acids exerting proapoptotic effects on ?-cells due to lipotoxicity (Lupi 
et al. 2002). Furthermore, elevated islet amyloid content in the pancreas of 
diabetic patients was discovered to contribute to the loss of ?-cells (Lorenzo et 
al. 1994) representing another factor for increased apoptotic processes. 
However, GIPRdn transgenic pigs did not develop diabetes up to an age of at 
least two years and showed normal body weight providing an explanation for 
the only slightly enhanced apoptosis rates of 1-1.4-year-old GIPRdn transgenic 
pigs compared to controls. Nevertheless, the tendency towards an increased 
apoptosis rate in 1-1.4-year-old GIPRdn transgenic pigs may have contributed to 
the reduced expansion of ?-cell mass in GIPRdn transgenic pigs. It must also be 
mentioned that in vivo apoptotic cells are rapidly cleared by macrophages 
(O'Brien et al. 2002), making apoptosis a rapid process that can only be 
detected during a restricted time window (Donath et al. 2004) and might explain 
the small number of cleaved caspase-3 positive nuclei in the pancreatic 
sections.  
Immunohistochemistry for cleaved caspase-3 is not the only method to detect 
apoptosis in tissue sections, wherefore the advantages of this technique 
compared to other apoptosis detection assays like the terminal transferase 
dUTP nick-end labeling (TUNEL) and the labeling of a cleavage product of 
cytokeratin 18 (CK18) are discussed. The TUNEL method is carried out as a 
standard method for the detection of apoptosis but one must be aware of the 
inaccuracy with this technique. Besides apoptotic nuclei also non-apoptotic 
nuclei are labeled (Kockx et al. 1998) as the TUNEL technique is not able to 
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distinguish between apoptosis, necrosis and autolysis (Grasl-Kraupp et al. 
1995) indicating that the detection of DNA fragmentation is not specific for 
apoptosis. Furthermore, a well defined fixation and pretreatment of the samples 
is needed to obtain reliable results (Kockx et al. 1998; Negoescu et al. 1998). 
Caspases play an essential role in initiation, regulation and execution of 
downstream proteolytic events occurring during apoptosis whereby caspase-3 
is on of the key factors (Fernandes-Alnemri et al. 1994; Slee et al. 2001). 
Detection of activated caspase-3 allows identification of apoptosis before the 
morphological features of apoptosis occur. However, apoptosis may also be 
triggered to caspase-independent pathways (Borner et al. 1999; Sperandio et 
al. 2000). Another possibility to detect apoptosis in tissue sections is the 
labeling of an apoptosis specific neo-epitope of CK18, a substrate of caspases 
3, 6 and 7 cleaved during apoptosis (Caulin et al. 1997). The cleaved CK18 can 
be recognized by binding of the monoclonal antibody M30 to its specific epitope 
(Leers et al. 1999). Duan et al. (2003) compared the immunohistochemical 
stains for TUNEL, activated caspase-3 and cleaved CK18 to quantificate 
apoptosis in histological sections. Activated caspase-3 and cleaved CK18 
labeling showed the best correlations to morphological analysis of apoptosis. 
Cleaved CK18 staining was associated with some background staining and 
therefore the signal to noise ratio with M30 was inferior to that obtained with 
activated caspase-3 immunohistochemistry (Duan et al. 2003). Hence, using 
cleaved caspase-3 labeling for determination of apoptotic ?-cells in GIPRdn 
transgenic pigs and controls pointed towards being a reliable tool for the early 
identification and quantification of apoptotic cells in histological sections. 
5.9 Concluding remarks 
The analyses of the metabolic and morphological investigations revealed clear 
similarities of the GIPRdn transgenic pig to type 2 diabetes patients. First, the 
impaired insulinotropic action of GIP represents an important characteristic of 
both GIPRdn transgenic pigs and type 2 diabetes patients (Nauck et al. 1986a). 
Second, like diabetic humans GIPRdn transgenic pigs have a reduced ?-cell 
mass. (Butler et al. 2003; Sakuraba et al. 2002). Third, deterioration of glucose 
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tolerance as observed in type 2 diabetes patients was also detected in GIPRdn 
transgenic pigs. However, GIPRdn transgenic pigs have normal fasting blood 
glucose and serum fructosamine levels indicating no diabetic phenotype until at 
least two years of age (Renner 2008). In contrast, GIPRdn transgenic mice 
developed already at three weeks of age a severe diabetic phenotype 
characterized by a marked hyperglycemia and striking abnormalities within the 
pancreas (Herbach et al. 2005). Different methods of transgenesis (lentiviral 
gene transfer vs. microinjection) as well as different copy numbers and/or 
integration sites might lead to different expression levels of the transgene 
involving different outcomes. Interestingly, a third line of GIPRdn transgenic mice 
showed similar physiological and morphological characteristics as the GIPRdn 
transgenic pig. The absence of chronic hyperglycemia is advantageous for 
evaluation of the GIP function in vivo. Therefore the results of the physiological 
and morphological analyses can be related to the impaired insulinotropic action 
of GIP disregarding effects due to hyperglycemia. The findings in GIPRdn 
transgenic pigs suggest that the function of GIP is not only restricted to that of 
an incretin but also plays an important role for the expansion of ?-cell mass and 
that its partial loss cannot be fully compensated by hyperactivation of the 
GLP-1/GLP-1R system. Due to similarities to humans GIPRdn transgenic pigs 
offer a valuable tool to elucidate a possible role of GIP in the pathogenesis of 
type 2 diabetes mellitus. 
6 Perspectives 
GIPRdn transgenic pigs represent a valuable model to obtain more information 
about the function and effects of GIP within the glucose metabolism. Insulin 
resistance is a typical pathophysiological characteristic of type 2 diabetes 
mellitus (DeFronzo et al. 1991). Thus, it would be interesting to define the role 
of GIP with respect to insulin sensitivity. Hyperinsulinemic euglycemic glucose 
clamp techniques are used as a standard method to analyze insulin sensitivity. 
This test allows to gain more detailed information on the components of insulin 
sensitivity and insulin secretion overcoming the limitations of an OGTT due to 
variability of gastric emptying and glucose absorption from the gastrointestinal 
tract (Muniyappa et al. 2008; Trout et al. 2007). Striking differences in the 
proliferation rate of GIPRdn transgenic pigs were detected. Studying the 
proliferative signaling pathways of GIP might give new impetus how to stimulate 
?-cell proliferation or whether defects in proliferation signal cascades might 
contribute to the reduction of ?-cell mass in type 2 diabetic patients. Holistic 
transcriptome and proteome analyses might be useful in this context. Obesity is 
known to be a major risk factor for the development of diabetes. GIPR-/- mice 
were resistant to obesity when fed a high-fat diet (Hansotia et al. 2007; 
Miyawaki et al. 2002). In this context, it would be interesting to perform diet 
studies using a high-fat diet to find out whether GIPRdn transgenic pigs are 
protected from obesity or whether it is possible to induce a diabetic phenotype 
feeding a high-fat/high-carbohydrate diet. Furthermore, GIPRdn transgenic pigs 
can be used for therapy studies, especially with respect to incretin-based 
therapies (GLP-1 receptor agonists like liraglutide or exenatide; DPP-4 
inhibitors like vildagliptin or sitagliptin). Preclinical evidence suggested that 
GLP-1 receptor agonists may have stimulative effects on ?-cell proliferation and 
neogenesis and prohibiting effects on apoptosis (Vilsboll 2009). However, there 
are still a lot of unresolved issues with respect to the effects of incretin-based 
therapies on ?-cell mass. Therefore, GIPRdn transgenic pigs might be an 
excellent tool. Another use of GIPRdn transgenic pigs might be to test or develop 
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in vivo imaging techniques to assess the total ?-cell mass (Moore 2009; 
Schneider 2008). In combination with therapy studies the effects of incretin-
based therapies on ?-cell mass could be determined in chronological sequence. 
Due to their similarity to humans new findings in the pigs might be translated to 
humans providing new advances in monitoring therapeutic trials. 
In summary GIPRdn transgenic pigs seem to be a valuable animal model in 
various areas of diabetes research. 
7 Summary 
Physiological and morphological characterization of transgenic pigs 
expressing a dominant-negative glucose-dependent insulinotropic 
polypeptide receptor (GIPRdn) – a large animal model for diabetes 
research 
 
The incretin hormones GIP (glucose-dependent insulinotropic polypeptide) and 
glucagon-like peptide-1 (GLP-1) mediate the so-called incretin effect, which 
describes the phenomenon that glucose given orally causes a higher insulin 
response compared to an isoglycemic intravenous glucose load. The 
insulinotropic action of GIP is reduced to almost absent in type 2 diabetes 
patients, while the action of GLP-1 is vastly preserved. GIPRdn transgenic pigs 
were generated by lentiviral genetransfer to establish a large animal model to 
investigate the effects of an impaired insulinotropic action of GIP on glucose 
homeostasis. At the age of 5 months GIPRdn transgenic pigs showed a 
disturbed oral glucose tolerance going along with reduced insulin secretion. 
Eleven-month-old GIPRdn transgenic pigs exhibited an impaired intravenous 
glucose tolerance and reduced insulin secretion as well as a significantly 
reduced total ?-cell volume compared to controls. 
In this work different age classes (11 weeks, 5 months, 1-1.4 years) of GIPRdn 
transgenic were investigated to obtain detailed data about physiological and 
morphological characteristics. To proof specifity of the GIPRdn GIP/Exendin-4 
stimulation tests were carried out in 11-week-old GIPRdn transgenic pigs. The 
insulinotropic action of intravenously injected porcine GIP was impaired, while 
this of Exendin-4, a GLP-1 mimetic, was enhanced in GIPRdn transgenic pigs 
compared to controls. Marked alterations in the expression profile of the GIPR 
and the GLP-1R were excluded as no apparent differences of 
immunohistochemically stained pancreas sections for GIPR and GLP-1R were 
detectable between GIPRdn transgenic pigs and controls at any age group. The 
effects of the impaired insulinotropic action of GIP on glucose metabolism were 
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investigated by oral and intravenous glucose tolerance tests. Eleven-week-old 
GIPRdn transgenic pigs exhibited significantly reduced oral glucose tolerance 
with a delay in insulin secretion compared to controls. The area under the 
insulin curve (AUC insulin) during the first 45 minutes following glucose load 
was 31% smaller in transgenic pigs compared to controls. The total amount of 
insulin secretion was not different between the two groups indicating that 
GIPRdn expression initially only interferes with the incretin effect. This was 
supported by the fact that intravenous glucose tolerance and insulin secretion in 
transgenic pigs were not different from controls. Five-month-old GIPRdn 
transgenic pigs exhibited a tendency towards reduced intravenous glucose 
tolerance and reduced insulin secretion in response to an intravenous glucose 
challenge. 
To determine the reason for the alterations in glucose metabolism quantitative 
stereological analyses of the pancreas were performed. In 11-week-old pigs, 
transgenic and control groups showed similar ?-cell mass. However, pancreatic 
β-cell mass was reduced by almost 40% in 5-month-old and by 60% in adult 
(1-1.4 years) GIPRdn transgenic pigs compared to controls. Furthermore, the 
cellular composition of the islets was analyzed by quantitative stereological 
investigations. The relative volumes of ?- and δ-cells in the islets were 
increased in 1-1.4-year-old GIPRdn transgenic pigs but the absolute volumes of 
these non-?-cell populations were not different from those of age-matched 
controls. 
To investigate the reason for the reduced pancreatic ?-cell mass in GIPRdn 
transgenic pigs, ?-cell proliferation and apoptosis rate was determined 
performing a double-immunohistochemistry for insulin and the proliferation 
marker Ki67 and cleaved caspase-3, respectively. Eleven-week-old GIPRdn 
transgenic pigs showed significantly less Ki67 positive cell nuclei compared to 
controls, whereas proliferation rates in 5-month-old and 1-1.4-year-old GIPRdn 
transgenic pigs reached no statistical significance. No differences were shown 
in the apoptosis rates of GIPRdn transgenic pigs compared to controls at any 
age, although a trend of higher numbers of cleaved caspase-3 positive ?-cells 
was visible in 1-1.4-year-old GIPRdn transgenic pigs. 
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In conclusion, GIPRdn transgenic pigs exhibit a comparable situation as in type 
2 diabetes mellitus patients like impaired insulinotropic action of GIP, disturbed 
glucose tolerance and reduced ?-cell mass. Moreover, the results of this work 
demonstrate an essential role of GIP for the physiological expansion of ?-cell 
mass. In this context GIPRdn transgenic pigs represent a valuable model for 
further investigations on type 2 diabetes mellitus including diet studies and 
therapeutic trials. 
 
 
 
 
 
 
8 Zusammenfassung 
Physiologische und morphologische Charakterisierung von transgenen 
Schweinen, die einen dominant-negativen Glukose-abhängigen 
insulinotropen Polypeptid Rezeptor (GIPRdn ) exprimieren – ein 
Großtiermodel für die Diabetesforschung 
 
Die Inkretinhormone glucose-dependent insulinotropic polypeptide (GIP) und 
glucagon-like peptide-1 (GLP-1) werden nach Nahrungsaufnahme aus den 
enteroendokrinen Zellen des Darms sezerniert und bewirken eine Steigerung 
der Insulinsekretion, den sogenannten Inkretineffekt. Bei Typ 2 Diabetes 
Patienten ist die insulinotrope Wirkung von GIP deutlich vermindert, während 
die insulinotrope Wirkung von GLP-1 weitgehend erhalten bleibt. Mittels 
lentiviralem Gentransfer wurden Schweine erstellt, die einen dominant-
negativen GIP Rezeptor (GIPRdn) exprimieren, um die Folgen einer 
verminderten insulinotropen Wirkung von GIP auf den Glukosemetabolismus 
näher zu erforschen. Im Alter von fünf Monaten zeigten GIPRdn transgene 
Schweine eine gestörte orale Glukosetoleranz, die mit einer reduzierten 
Insulinsekretion einherging. Bei 11 Monate alten GIPRdn transgenen Schweinen 
wurde eine gestörte intravenöse Glukosetoleranz und verminderte 
Insulinsekretion festgestellt sowie eine deutliche Reduktion des Gesamt-?-
Zellvolumens.  
Ziel dieser Arbeit war es GIPRdn transgene Schweine verschiedener 
Altersklassen (11 Wochen, 5 Monate, 1-1,4 Jahre) zu charakterisieren, um die 
Dynamik und den Verlauf der metabolischen und morphologischen 
Veränderungen zu erforschen. Zunächst wurde bei 11 Wochen alten GIPRdn 
transgenen Schweinen mittels GIP/Exendin-4 Stimulationstests die Spezifität 
des GIPRdn überprüft. Die insulinotrope Wirkung von intravenös verabreichten 
porcinem GIP war bei GIPRdn transgenen Schweinen signifikant vermindert, 
wohingegen die insulinotrope Wirkung von Exendin-4, einem GLP-1 Mimetikum, 
erhöht war. Deutliche Veränderungen in der Expressionshöhe des GIPR oder 
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GLP-1R konnten mittels immunhistochemischer Nachweise beider Rezeptoren 
in allen drei untersuchten Altersklassen ausgeschlossen werden. Die 
Auswirkungen der verminderten insulinotropen Wirkung von GIP auf den 
Glukosestoffwechsel wurden mitttels oraler und intravenöser 
Glukosetoleranztests charakterisiert. Elf Wochen alte GIPRdn transgene 
Schweine zeigten eine gestörte orale Glukosetoleranz sowie eine verzögerte 
Insulinsekretion. Im Zeitraum von null bis 45 Minuten nach Glukosegabe war 
die Fläche unter der Insulinkurve (AUC Inulin) bei den transgenen Tieren im 
Vergleich zu den Kontrolltieren 31% kleiner. Die gesamte Insulinsekretion (AUC 
Insulin bis 120 Minuten nach Glukosegabe) hingegen war nicht vermindert und 
auch die intravenöse Glukosetoleranz wies keine Veränderungen im Vergleich 
zu Kontrolltieren auf. Diese Ergebnisse deuten darauf hin, dass zunächst nur 
der Inkretineffekt durch die GIPRdn Expression beeinflusst wird. Bei fünf Monate 
alten Tieren war ebenfalls eine gestörte orale Glukosetoleranz zu erkennen. Die 
Insulinsekretion war nicht nur verzögert, sondern signifikant vermindert im 
Vergleich zur Kontrollgruppe. Neben den metabolischen Tests wurden 
quantitativ-stereologische Untersuchungen des Pankreas durchgeführt, um 
Auswirkungen der Expression des GIPRdn auf die Morphologie und/oder die 
Integrität der Langerhansschen Inseln detektieren zu können. Die Bestimmung 
des Gesamt-?-Zellvolumens bei elf Wochen alten Tieren ergab keinen 
Unterschied zwischen den beiden Gruppen. Fünf Monate alte GIPRdn transgene 
Schweine wiesen gegenüber den Kontrolltieren eine beinahe 40%ige Reduktion 
im Gesamt-?-Zellvolumen auf. Das Gesamt-?-Zellvolumen von 1-1,4 Jahre 
alten GIPRdn transgenen Tieren war um fast 60% vermindert. Die Reduktion 
des Gesamt-?-Zellvolumens von GIPRdn transgenen Tieren kann eine 
Erklärung für die Entwicklungen im Glukosestoffwechsel sein. Zusätzlich wurde 
die zelluläre Zusammensetzung der Inseln anhand quantitativ-stereologischer 
Untersuchungen der ?-, δ- und PP-Zellen analysiert. Das relative Volumen der 
?- und δ-Zellen war bei 1-1,4 Jahre alten GIPRdn transgenen Schweinen erhöht, 
wohingegen das Gesamtvolumen dieser beiden endokrinen Fraktionen sich 
nicht von denen der Kontrollgruppe unterschied. 
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Untersuchungen der Proliferations- sowie der Apoptoserate von ?-Zellen sollten 
Aufschluss über mögliche Ursachen für die Reduktion der ?-Zellmasse 
ergeben. Die Auswertung der doppelimmunhistochemischen Färbung mit dem 
Proliferationsmarker Ki67 und Insulin ergab eine signifikant verminderte 
Proliferationsrate bei elf Wochen alten GIPRdn transgenen Schweinen im 
Vergleich zur Kontrollgruppe, wobei 5 Monate und 1-1,4 Jahre alte GIPRdn 
transgene Schweinen keinen signifikanten Unterschied zu ihren Kontrolltieren 
aufwiesen. Doppelimmunhistochemische Färbungen mit cleaved caspase-3 und 
Insulin dienten zur Bestimmung der Apoptoserate. Es konnten keine statistisch 
signifikanten Unterschiede der Apoptoserate zwischen transgenen Tieren und 
Kontrolltieren detektiert werden, obwohl 1-1,4 Jahre alte GIPRdn transgene 
Schweine einen Trend zu vermehrter Apoptose zeigten. Die verminderte 
Proliferation von ?-Zellen deutet auf eine reduzierte Expansion von ?-Zellen bei 
GIPRdn transgenen Schweinen hin. 
GIPRdn transgene Schweine stellen ein interessantes Großtiermodell dar, da sie 
wichtige Parallelen zum Typ 2 Diabetes mellitus Patienten aufweisen: 
verminderte insulinotrope Wirkung von GIP, gestörte orale und intravenöse 
Glukosetoleranz sowie ein vermindertes Gesamt-?-Zellvolumen. Weiter lassen 
diese Daten eine bedeutende Rolle von GIP für die physiologische Expansion 
von ?-Zellen erkennen. In diesem Zusammenhang wäre es interessant, das 
GIPRdn transgene Schweinemodell in Zukunft auch für Therapiestudien und 
Diätstudien heranzuziehen. 
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GIPRdn dominant-negative glucose-dependent insulinotropic  
 polypeptide receptor 
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GIPR GIP receptor 
GIPR-/- GIPR knockout 
GLP-1 glucagon-like peptide-1 
GLP-1R GLP-1 receptor 
GLP-1R-/- GLP-1R knockout 
GLP-2 glucagon-like peptide-2 
HD Huntingon disease 
HE hematoxylin and eosin 
HF high-fat 
HNF hepatic nuclear factor 
H2O2 hydrogen peroxide 
HP horseradish peroxidase 
IAPP islet amyloid peptide 
ICSI intracytoplasmic sperm injection 
IEQ islet equivalents 
IGF insulin-like growth factor 
ILK interleukin 
IPTT intraperitoneal glucose tolerance test 
IVGTT intravenous glucose tolerance test 
JNK Jun N-terminal kinase 
MAPK mitogen-activated protein kinase 
mg milligram 
ml milliliter 
mRNA messenger RNA 
NIA nicotinamide 
OGTT oral glucose tolerance test 
OVX ovariectomized 
PBS phosphate buffered saline 
PCiA phenol-chloroform isoamylalcohol 
PCNA proliferating cell nuclear antigen 
PCR polymerase chain reaction 
PI3K phosphatidylinositol 3-kinase 
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PKA protein kinase A 
PKB protein kinase B 
PLA pospholipase A 
PSEN presinilin genes 
RIA radioimmunoassay 
RIP2 rat insulin 2 promoter 
RNA ribonucleic acid 
RNase ribonuclease 
RP retinitis pigmentosa 
RT room temperature 
RT-PCR reverse transcription PCR 
SCNT somatic cell nuclear transfer 
SDS sodium dodecyl sulphate 
SIRKO single incretin knockout 
SMA spinal muscle atrophy 
SMN survival motor neuron 
STS staurosporine 
STZ streptozotocin 
TAE tris-acetate buffer 
TBS tris-buffered saline 
Tris tris-(hydroxymethyl)-aminomethan 
TNF ?/? tumor necrosis factor ?/? 
TUNEL terminal transferase dUTP nick-end-labeling 
UV ultraviolet 
VDF Vancouver diabetic fatty 
ZDF Zucker diabetic fatty 
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